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Scientific environment 
The Bergen Gynecologic Cancer Research Group is a part of the Department of 
Clinical Science, University of Bergen. Offices and lab facilities are located in the 
Department of Obstetrics and Gynecology at Haukeland University Hospital. The 
group is led by Professor Camilla Krakstad and includes PhD students, postdoc fellows, 
research fellows as well as lab and study personnel. Professor Jone Trovik is PI for the 
ongoing Molecular Markers in the Treatment of Endometrial Cancer 2 (MoMaTEC2) 
international clinical study that emanates from this group. 
The group maintains a comprehensive biobank with samples from gynecological 
cancer patients to be used in research, ongoing endometrial cancer organoid lines and 
animal model facilities to enable top-level translational research. Nearness to the clinic, 
including outpatient facilities and surgical theatre facilitates collection of biologic 
material and lays the foundation for new research ideas and collaborations with Helse 
Bergen in the cross-section of pre-clinical and clinical sciences. 
The research group is a part of the Centre for Cancer Biomarkers (CCBIO), a 
Norwegian Center of Excellence, led by Professor Lars A. Akslen, which hosts state of 
the art research facilities and organizes activities and collaborations. The overall aim 
of CCBIO is to develop biomarkers to promote individualized cancer treatment. 
The Bergen Gynecologic Cancer Research Group has close ties to the Mohn Medical 
Imaging and Visualization center (MMIV) and Bergen Abdominal Imaging research 
group led by Professor Ingfrid S. Haldorsen, which specializes in development and 
evaluation of radiological biomarkers for gynecological cancers. 
Apart from MoMaTEC 2, a clinical multicenter study which involves centers from 
Norway, the Netherlands and Poland, there is ongoing participation in the European 
Network for Individualized Treatment in Endometrial Cancer (ENITEC) group, 
resulting in numerous collaborations. Other international partners include the Broad 
institute (Boston, USA) and the MD Anderson Cancer Centre. 
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The research group, the department and the university provide an unlimited source of 
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AMPK 5' - adenosine monophosphate-activated protein kinase 
ANOVA Analysis of variance 
AR Androgen receptor 
ARID1A AT-rich interaction domain 1A 
BSO Bilateral salpingo-oophorectomy 
CA-125  Cancer antigen 125 
CI Cervical stroma invasion  
CT  Computed tomography  
CTNNB1 Catenin beta 1 
D&C Dilatation and curettage 
DJ-1 Parkinson disease protein 7, protein deglycase 
DNA Deoxyribonucleic acid 
DSS Disease-specific survival 
EDTA Ethylenediaminetetraacetic acid 
EORTC European organization for research and treatment in cancer  
ER Estrogen receptor 
ERBB2 Erb-B2 receptor tyrosine kinase 2 
FACT-G Functional assessment of cancer therapy - General 
FDA Food and drug administration 
FDG Fluorodeoxyglucose 
FIGO International federation of gynecology and obstetrics  
GDF-15 Growth/differentiation factor 15 
GR Glucocorticoid receptor 
GSEA Gene set expression analysis 
HE4 Human epididymis protein 4 
HER2/Neu Human epidermal growth factor receptor 
IARC International agency for research on cancer 
IGF-1 Insulin-like growth factor-1  
IGF1R Insulin-like growth factor 1 receptor 
IR Insulin receptor 
JGOG Japanese gynecologic oncology group 
KRAS K-Ras proto-oncogene, GTPase 
LC-MS/MS  Liquid chromatography -tandem mass spectrometry 
MI Myometrial invasion 
MMR-D/P Mismatch repair deficient/proficient 
MoMaTEC2 Molecular markers in the treatment of endometrial cancer 2 (study) 
MRI Magnetic resonance imaging  
MSI-H  Microsatellite instability high  
mTOR Mammalian target of rapamycin 
OS Overall survival 
PARP Poly (ADP-ribose) polymerase 
PD-1 Programmed cell death protein 1 
PET Positron emission tomography 
PI3K Phosphoinositide-3-kinase 
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POLE Polymerase ε 
PORTEC Postoperative radiation therapy for endometrial carcinoma (study) 
PPP2R1A Serine/threonine-protein phosphatase 2A regulatory subunit A 
PR Progesterone receptor 
PRO Patient-reported outcome 
PTEN Phosphatase and tensin homolog 
QLQ Quality of life questionnaire 
RAINBO Refining adjuvant treatment in endometrial cancer based on molecular profile 
(study) 
RCT Randomized clinical trial 
RFS Recurrence-free survival 
RNA Ribonucleic acid 
SAM Significance analysis of microarrays  
SEPAL Survival effect of para-aortic lymphadenectomy in endometrial cancer (study) 
SISAQOL Setting international standards in analyzing patient-reported outcomes and 
quality of life endpoints (group) 
TCGA The cancer genome atlas program 
TMA Tissue microarray 
TP53 Encodes p53 (tumor suppressor) 
VEGF Vascular endothelial growth factor  




Background: Endometrial cancer is the most common gynecological cancer among 
women in countries with a high developmental index, and the incidence is expected to 
rise. Major controversies in the treatment of endometrial cancer revolve around the 
identification of women at risk of recurrence and optimal modes of treatment to 
minimize this risk. In addition, optimizing treatment-related quality of life is gaining 
attention. In recent years, several biomarkers have been identified and gradually 
implemented through changes in treatment algorithms, but further refinement is 
needed. Also, continuous evaluation of the resulting treatment changes is vital to 
improve survival and quality of life for endometrial cancer patients. 
Aims: The overall aim was to improve endometrial cancer treatment through better 
preoperative stratification and evaluation of the effects of different treatment 
modalities on survival and morbidity. 
Methods: In Paper I, 100 postmenopausal patients were selected from a population-
based cohort, reflecting the clinical characteristics of the whole cohort. Preoperative 
blood samples were analyzed by liquid chromatography-tandem mass spectrometry, 
using a clinically implemented steroid hormone panel. Steroid levels were related to 
survival, tumor characteristics, radiologic assessment of fat distribution and gene 
expression. 
In Paper II, all consenting endometrial cancer patients receiving primary treatment at 
Haukeland University Hospital over the period 2001-2019 were reviewed with a focus 
on comparing outcomes before and after implementing major treatment changes. These 
treatment changes were 1) a discontinuation of radiotherapy as an adjuvant treatment 
from 2009 (due to changes in national guidelines) and 2) a local initiative to implement 
a biomarker- and imaging-based selective lymphadenectomy policy in 2012-2013 to 
reduce the rate of patients undergoing lymphadenectomy. We assessed recurrence and 
survival and performed a trend analysis of changes in clinical and pathological factors 
over the time period. 
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In Paper III, we determined the effects of treatment modalities on quality of life and 
treatment-related symptoms in Norwegian patients enrolled in the ongoing Molecular 
Markers in the Treatment of Endometrial Cancer 2 (MoMaTEC2). Patients were 
grouped by received treatment modalities. Patient-reported outcomes at baseline and 
one and two years postoperatively were analyzed and compared to a Norwegian 
reference population. We used linear mixed models to assess the individual 
contribution of different treatment modalities.  
Results: Low preoperative levels of 17-hydroxyprogesterone, 11-deoxycortisol and 
androstenedione were associated with aggressive tumor characteristics and poor 
disease-specific survival. 17-hydroxyprogesterone and 11-deoxycortisol were 
associated with prognosis independently of preoperative histological type and grade. 
Gene expression analysis revealed that tumors in patients with lower levels of these 
hormones expressed gene sets related to proliferation and cell cycle progression to a 
higher degree, whereas tumors in patients with higher levels expressed more 
inflammation-related genes. Higher levels of estrone and estradiol were associated with 
higher levels of body fat, expression of hormonal receptors and estrogen signaling-
related gene expression, but not with survival (Paper I). 
After omitting radiotherapy as an adjuvant modality, 5-year overall survival increased 
in FIGO stage III (0.49 to 0.61, p=0.04) and recurrence-free survival increased from 
0.51 to 0.71 (p=0.03). In other stages, survival outcome was maintained. For patients 
with stage I high-risk disease, the rate receiving adjuvant chemotherapy increased from 
40% to 79%, but was not associated with any gain in survival (Paper II). 
The proportion of patients undergoing lymphadenectomy was reduced from 78% in 
2001-2012 to 53% in 2013-2019 (p<0.001), with a maintained proportion of all patients 
with lymph node metastasis (9% versus 8%, p = 0.58). Patients not undergoing 
lymphadenectomy after 2012 were signified by low-intermediate risk based on MRI 
and histology of preoperative samples, negative PET/CT imaging and ER/PR 
positivity. Stage I patients, not undergoing lymphadenectomy, had maintained 
recurrence-free survival when comparing the time periods (Paper II).  
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We found quality of life and functioning in endometrial cancer survivors comparable 
to a healthy age- and sex-matched cohort but significantly lower at baseline and 
increasing at year one and two post-operatively. Patients treated with adjuvant 
chemotherapy reported more tingling/numbness, lymphedema, and muscular pain at 
follow-up. There were no observable differences between patients in the groups not 
receiving chemotherapy (with or without lymph node staging). In multivariable mixed 
models, adjuvant chemotherapy was associated with tingling/numbness, lymphedema, 
fatigue and reduced physical functioning (Paper III). 
Conclusions: Blood steroids have prognostic value, can be assessed from a 
preoperative blood sample with existing routine methods and may provide additive 
value to established preoperative biomarkers (Paper I).  
Replacing adjuvant radiotherapy with adjuvant chemotherapy had no negative impact 
on survival and showed improved survival for stage III patients (Paper II). However, 
a marked increase in chemotherapy to stage I high-risk patients was not accompanied 
by an improved survival or recurrence rate, indicating an important area for further 
stratification of patients by biomarkers (Paper II). A selective lymphadenectomy 
algorithm based on hormonal and imaging biomarkers allowed for a substantial 
reduction of patients undergoing lymphadenectomy. The rate of patients with 
diagnosed lymph node metastasis and recurrence-free survival was maintained (Paper 
II). 
Overall quality of life is good for endometrial cancer patients. The group receiving 
adjuvant chemotherapy, however, reported increases in several symptoms, whereas 
patients undergoing lymphadenectomy without receiving chemotherapy did not. 
Removal of lymph nodes to select patients for adjuvant therapy therefore seems 
justified from the patient’s viewpoint (Paper III). In addition, the combination of 
unchanged survival and worse symptoms for early-stage patients receiving adjuvant 
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1. Introduction 
1.1 Epidemiology of endometrial cancer 
1.1.1 Incidence 
Endometrial cancer, arising in the epithelial lining of the uterus, is the most common 
of the gynecological cancers in countries with high developmental index, and is the 4th 
most common cancer among women in Europe and Northern America1. In Norway, 
approximately 750 new cases are diagnosed annually, resulting in a lifetime incidence 
around 2%, similar to other countries with high developmental index2 (Figure 1). Over 
the last decades, many countries have reported increased rates of endometrial cancer, 
also when adjusting for increasing age and rates of hysterectomy3, 4, and a further 
increase is expected due to increasing obesity5. Endometrial cancer is mainly a disease 
of postmenopausal women, with a median age at diagnosis of 68 years in Norway2. A 
substantial portion of the population has comorbidity and disability that needs to be 
considered when planning treatment6.  
 
Figure 1. Estimated cumulative risk of endometrial cancer in 2020, up to age 74 in different 
continents. Source: IARC, Globocan 2020, https://gco.iarc.fr/ (with permission) 
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1.1.2 Risk factors 
The Bohkman classification of endometrial cancer from 1983 describes two main 
types, and is still important for understanding the principal clinical division of 
endometrial cancer7. Type I, representing 80% of tumors, is estrogen dependent, has a 
lower median age of diagnosis and carries a better prognosis, whereas Type II tumors 
are more aggressive and are generally less dependent on estrogen exposure. The 
Bohkman classification has been replaced by more precise histological morphology in 
research and clinically, with endometrioid endometrial cancer roughly representing 
type I and non-endometrioid endometrial cancer representing type II tumors. The 
distinction can be unclear in endometrioid tumors with low differentiation and some 
non-endometrioid subtypes, but ongoing research into molecular subtypes is gradually 
providing a better understanding of connections between risk factors, histological 
morphology, and clinical characteristics. Still, influence of the female reproductive 
hormones is the most important mechanism through which risk factors of endometrial 
cancers can be understood (Table 1). Most epidemiological research on endometrial 
cancer risk factors has not discriminated between histological types, and there is reason 
to assume that endometrioid tumors are better represented in these statistics than non-
endometrioid, as they are more common. There is evidence of some hormonal 
influence also on non-endometrioid tumors, albeit not to the same extent as for 
endometrioid endometrial cancer8. 
1.1.2.1 Unopposed estrogen 
Healthy endometrium is an active tissue that responds to endocrine signals to 
accommodate reproduction during the fertile years. Estrogens and gestagens are 
endogenous sex hormones produced by the ovaries to control the cyclic endometrial 
transformation, with estrogen acting as a mitogen, inducing endometrial proliferation, 
whereas progesterone induces differentiation and maturation9. Withdrawal of 
progesterone after a period of exposure leads to shedding of the endometrium to 
prepare for a new reproductive cycle. This provides a natural protective mechanism 
against endometrial cells thriving long enough to accumulate oncogenic mutations. It 
has long been known that estrogenic exposure without balancing progesterone 
increases the risk of hyperplasia with increasing cellular atypia and finally cancer10. 
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Table 1. Clinical Risk Factors for endometrial cancer grouped by main (hypothetical) 
pathogenic mechanism. 
Factors increasing risk Factors decreasing risk 
Genetic risk 
- Lynch syndrome11, Cowden syndrome12 
- First-degree relative with endometrial 
cancer13 
Endogenous hyperestrogenic balance 
- Obesity14, 15 
- Years of menstruation16 
- Nulliparity17-19 
- High concentrations of estrogens post-
menopause20, 21 
Exogenous estrogen 
- Long-term use of tamoxifen22 
- Hormone-replacement therapy with less 
than 12–14 days of gestagens23  
Decreasing estrogen/promoting 
gestagen: 
- Grand multiparity17-19 
- Smoking24 
- Oral-contraceptive use25, 26 
- Older age at last birth27 
- Breastfeeding28 
- Physical activity29 
- Diet of some phyto-estrogens30 
 
 
Higher levels of endogenous circulating estrogens and their precursors increase the risk 
of endometrial cancer20, 21, 31-33. Exposure to exogenous estrogen or related compounds, 
(e.g. Tamoxifen) further increases the risk, while gestagen supplement can protect from 
or even resolve early cancer34-36.  
1.1.2.2 Obesity and endometrial cancer 
Endometrial cancer risk increases with around 60% per 5 unit increase in body mass 
index, unparalleled by any other cancer type15. The strong link between obesity and 
endometrial cancer is multifaceted (Figure 2). Human adipocytes contain aromatase 
which can metabolize circulating androgen to estrogen leading to inhibition of normal 
endocrine cyclicity and anovulation, the unopposed estrogen mechanism. In addition, 
endogenous steroid levels could be further boosted by lack of sex-hormone binding 
globulins in obese individuals, and increased action of insulin-like growth factor and 
insulin resistance increase risk of endometrial cancer independently of estrogen37, 38. 
The relationship between obesity and endometrial cancer is likely even more complex 
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with adipokine-mediated influence and adipose-tissue mesenchymal stem cells that can 
be recruited to support the tumor39, 40.  
 
Figure 2. The oncogenic mechanisms of obesity in endometrial cancer. Adipocytes provide 
increased estrogen levels through androgen aromatization and alter the inflammatory 
environment through release of cytokines. Increased levels of estrogen, glucose, insulin, and 
insulin-like growth factor-1(IGF1) stimulate tumor growth through activation of mitogenic 
pathways. Furthermore, mesenchymal fibroblasts with stem cell properties can be recruited 
from adipose tissue to provide support in the tumor microenvironment. AMPK,5’-adenosine 
monophosphate-activated protein kinase; ER, estrogen receptor; IGF1R, insulin-like growth 
factor 1 receptor; IR, insulin receptor; IRS, insulin receptor substrate; mTOR, mammalian 
target of rapamycin. Illustration created by Suety Kwan, reprinted from Onstad et al. (2016) 
with permission39.  
1.1.2.3 Hereditary risk factors 
Lynch syndrome, or Hereditary Non-Polyposis Colorectal Cancer syndrome, results 
from germline inactivating mutations in genes coding for specific DNA repair proteins. 
The function of these mismatch-repair (MMR) proteins (MLH1, MSH2, MSH6 and 
PMS2) is to resolve errors that arise in DNA replication, and deficiency results in a 
high number of mutations arising in a specific pattern; microsatellite instability 
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(MSI)41. Lynch syndrome is one of the most common inheritable causes of cancer, 
affecting cancer risk in diverse organs42, 43. In women with Lynch syndrome, 
endometrial cancer is the most prevalent initial site of manifestation, not rarely 
presenting at an early age. It is estimated that around 3% of endometrial cancer in 
unselected populations is attributable to Lynch syndrome, with higher prevalence in 
younger women11, 44. Diagnosing Lynch syndrome allows for proper surveillance and 
likely improves survival45. Prophylactic surgery has been shown to reduce endometrial 
cancer risk and is cost-effective46, 47.  
Hereditary inactivating mutations of the Phosphatase and tensin homolog (PTEN) 
suppressor gene are rare and give rise to the PTEN hamartous tumor syndrome 
(including Cowden syndrome). Patients with this disorder have an increased risk of 
several cancer types, among these a risk of endometrial cancer at 21-28%12. 
1.1.3 Survival 
Long-term survival is excellent in early-stage endometrial cancer as the disease can be 
surgically removed by hysterectomy in about 85% of patients, yielding 5-year relative 
survival rates at 97 % for localized disease, and 87% for all patients2 (Norwegian data, 
adjusted for expected mortality from other causes). Despite good prognosis, in some 
early-stage patients, the disease will recur, and make up a significant proportion of 
patients requiring non-surgical treatment. For patients with locally advanced or 
metastasized disease, prognosis is more dismal with 5-year relative survival rates of 68 
% and 44 %, respectively (Figure 3). 
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Figure 3. Five-year relative survival rates for Norwegian endometrial cancer patients, adjusted 
for expected mortality. Grouping is based on Surveillance Epidemiology and End Results 
Program (SEER) stage. Approximate corresponding International Federation of Gynecology 



























Total Localized (I) Regional (II-III) Distant metastasis (IV)
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1.2 Symptoms and diagnosis 
1.2.1 Presenting symptoms 
As endometrial cancer grows in the uterine cavity it may cause vaginal bleeding, and 
postmenopausal bleeding is estimated to be the presenting symptom in 90% of 
patients48. In women presenting with postmenopausal bleeding, approximately 10% 
will have endometrial cancer49. Thus, all postmenopausal women with vaginal bleeding 
should have an examination to rule out cancer, generally by vaginal ultrasound and a 
biopsy. Endometrial thickness, as assessed by vaginal ultrasound, has been used as a 
stratification to allocate patients with postmenopausal bleeding to endometrial 
sampling, but sampling should be performed liberally, at least in women > 60 years50. 
In pre- and perimenopausal women, bleeding irregularity can be a symptom of 
endometrial cancer. A minority of patients will present with symptoms from metastasis 
without vaginal bleeding, in those cases, bowel symptoms, abdominal distension and 
pelvic pain may be present. Finally, a portion of endometrial cancer patients are 
diagnosed without symptoms, either through follow-up of abnormal cervical screening 
tests, suspect imaging findings or after pathological examination of a presumed benign 
hysterectomy specimen. There are no routine screening programs for endometrial 
cancer, and studies have failed to show a better prognosis for patients diagnosed 
without symptoms than for those with bleeding51, 52, implying that detection at debut of 
symptoms is adequate as a population strategy. 
1.2.2 Diagnosis 
The endometrial cancer diagnosis is based on a histological assessment of an 
endometrial tissue sample. Traditionally, the gold standard for endometrial assessment 
is a dilatation of the cervix and curettage of the entire endometrial lining (D&C), 
requiring anesthesia. During the last 20-30 years, devices for endometrial sampling in 
outpatient settings have been developed and gained popularity (pipelle, tao brush, etc.) 
with performance statistics comparable to D&C for the detection of endometrial 
cancer53, 54. The amount of tissue retrieved by sampling is generally small, and 
histopathological diagnosis can be limited or unclear. A full D&C can be performed in 
these cases to retrieve enough material for typing, grading and biomarker analysis and 
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should be performed in symptomatic patients with negative or inconclusive 
endometrial biopsies where there is clinical suspicion of cancer. A stenotic cervix can 
also mandate a dilatation under anesthesia to retrieve endometrial tissue. Hysteroscopy 
for the diagnosis of endometrial cancer has been studied and is shown to diagnose focal 
(pre)cancer in up to 6% of sampling-negative patients55, but the simplicity and 
reliability of a clinical evaluation with ultrasound and endometrial biopsy makes it 
unnecessary in most situations. Although hysteroscopy may increase the dissemination 
of tumor cells to the peritoneum, this does not worsen prognosis56, 57. 
1.2.3 Pre-treatment risk assessment 
1.2.3.1. Histological assessment 
Currently, the main value of the endometrial biopsy is in diagnosing the disease and 
stratifying the tumor according to histological appearance (Figure 4). The World 
Health Organization (WHO) Classification of tumors is generally recommended for 
classification58. The histological type of the tumor derives from its morphology and is 
associated with prognosis. Endometrioid endometrial cancer is the most common type, 
constituting roughly 80% of cases. Endometrioid cancers are traditionally graded 
according to the three-tier FIGO grading system, where higher grade signifies less 
glandular differentiation (and/or more nuclear atypia) and poorer prognosis. A binary 
grading system, grouping grades 1-2 as low risk and grade 3 as high risk, is more 
clinically relevant as distinguishing between grade 1 and 2 endometrioid tumors rarely 
affect treatment planning59. Among non-endometrioid subtypes, serous endometrial 
cancer is the most frequent, followed by clear cell cancers and carcinosarcomas. The 
non-endometrioid histological types are all considered high risk and are associated with 
a higher rate of extrauterine spread at diagnosis, carry poorer prognosis and require 
more aggressive treatment. More rare histological types exist such as dedifferentiated, 
undifferentiated and mixed carcinomas, and are generally classified high risk. Low 
interobserver reproducibility in distinguishing serous and high-grade endometrioid 
tumors is an important issue in endometrial cancer pathology with disagreement 
present in around 30%60-62, and further refinement is needed to approach the 
histological reproducibility attained in ovarian or breast cancer63. Another problem is 
the lack of correlation between preoperative and final histopathological diagnosis, with 
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agreement as low as 67%, likely due to limited sampling preoperatively and tumor 
heterogeneity64. Assessment of biomarkers in the preoperative sample will be discussed 
in the chapter on precision medicine. 
 
Figure 4. Histopathological subtypes of endometrial carcinoma. A) Endometrioid carcinoma 
grade 1. B) Endometrioid carcinoma grade 3. C) Serous carcinoma. D) Clear cell carcinoma. 
All images in 400x magnification, courtesy of Karen Mauland. 
1.2.3.2 Preoperative imaging 
Imaging modalities are used to assess the extent of endometrial cancer preoperatively 
to plan treatment or to assign stage to patients in whom surgery is not an option. 
Findings reported from preoperative imaging correspond to the surgico-pathological 
FIGO 2009 staging system, where important parameters are degree of myometrial 
invasion (MI), cervical stroma invasion (CI) and metastatic spread to adjacent organs, 
lymph nodes or distant organs65.  
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Transvaginal ultrasound is integral in the gynecological exam used in the primary 
assessment of endometrial cancer patients. Apart from being used to diagnose the 
disease, it can be used to assess MI, CI and surgical mobility of the uterus. Magnetic 
resonance imaging (MRI) has emerged as a state-of -the-art imaging modality for 
pelvic tumors, as it avoids bony artefacts seen with computed tomography (CT) and 
provides high resolution in assessing MI and CI in uterine tumors66. Performance of 
transvaginal ultrasound to diagnose MI or CI, in the hands of expert operators 
(subspecialized gynecologists >6 years of experience), is comparable to MRI, but is 
poorer when handled by general gynecologists67. For diagnosis of extra-pelvic 
metastases, a preoperative CT is commonly used. 18F-FDG-Positron Emission 
Tomography combined with CT (PET/CT) has better sensitivity and specificity for 
detection of retroperitoneal lymphadenopathy and distant metastases, but is more 
expensive, and less available globally68. Ongoing research strives to identify novel 
radiologic biomarkers to improve prognostication and treatment for endometrial cancer 
patients. 18F-FDG uptake intensity is related to aggressive traits and may provide 
clinically useful information69. Other promising areas are artificial intelligence-derived 
radiological parameters and combinations with genetic tumor information; 
radiogenomics. 
1.2.3.3 Blood samples 
Clinical blood samples are obtained to assess the patient’s health status preoperatively. 
Several blood biomarkers have been investigated in endometrial cancer, but none have 
reached wide acceptance as clinically useful. CA-125 is shown to have prognostic 
value and identifies advanced disease and lymph node metastasis to some degree, and 
HE4 is associated with an endometrial cancer diagnosis and higher stage70-72. Other 
blood-based biomarkers such as GDF-15 and DJ-1 have also been found promising73, 
74, but lack validation and clear clinical meaningfulness. Blood-based protein 
biomarkers may add value to multifactor models where they are combined with several 
other risk factors75, 76. Another area of intensive research is the detection of tumor 
material in blood, such as circulating tumor cells, tumor DNA or extracellular vesicles.  
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1.3 Treatment of endometrial cancer 
1.3.1 Hysterectomy 
In a majority of patients, the endometrial tumor is confined to the uterus and can be 
completely removed by surgically excising the uterus - a hysterectomy. Total 
hysterectomy, as opposed to amputating at the level of the cervix, is recommended for 
complete staging66, 77, 78. A radical hysterectomy, removing parametrial tissue and a 2 
cm vaginal margin has not been shown to increase survival79 and is not recommended 
in modern guidelines. A bilateral removal of salpinx and ovaries (BSO) is traditionally 
mandatory, but ovaries can be spared in selected premenopausal women without 
significantly affecting prognosis80, 81. In patients with advanced disease, when complete 
tumor removal is not attainable, debulking surgery is often performed, where removal 
of tumor tissue is performed to the limit of feasibility, including resection of abdominal 
organs, and affected peritoneum. In selected patients, a palliative hysterectomy can 
provide a solution to bleeding problems in the final stages of life. 
1.3.2 Staging procedures 
Surgical staging procedures, such as lymphadenectomy and omentectomy, do not on 
their own improve the prognosis for the patient. Instead, they serve to categorize 
patients into disease stages (Figure 5) according to the spread of the disease. In some 
cases, the results of staging will also affect adjuvant therapy, such as identifying lymph 
node metastases in a patient with presumed uterus-confined low-risk disease. 
Importantly, staging procedures increase operating time and risk of iatrogenic 
morbidity and should generally be restricted to where necessary.   
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Figure 5. International Federation of Gynecology and Obstetrics (FIGO) Staging system for 




Lymphadenectomy is the removal of lymph nodes along the lymphatic pathways 
draining the uterus. In practice it is limited to the pelvic basin or extended to include 
para-aortic lymph nodes to the level of the inferior mesenteric artery or the renal 
vessels. The role of lymphadenectomy in endometrial cancer is controversial. Two 
large randomized clinical trials have concluded with no survival benefits of 
lymphadenectomy in endometrial cancer82, 83. However, important criticism has been 
raised, in part concerning low node counts for lymphadenectomies and unstandardized 
adjuvant regimes, that draw the conclusions into question. Interestingly, Naumann and 
colleagues performed a decision analysis suggesting that the studies were flawed by 
design and would not have been able to show benefits of lymphadenectomy even if 
these existed84. Other studies have documented survival benefits that correlate to the 
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number of lymph nodes removed85, 86. In the Survival effect of para-aortic 
lymphadenectomy in endometrial cancer (SEPAL) study, which was retrospective and 
with center bias, patients who went through pelvic and para-aortic lymphadenectomy 
had better survival than patients receiving only pelvic lymphadenectomy87. These 
findings are now being tested prospectively in the randomized JCOG1412- study 
(UMIN clinical trials registry id: UMIN000025399). 
Lymphadenectomy increases the risk of perioperative complications such as blood loss, 
and postoperative lymphedema and lymphocyst formation, which can give long-term 
problems and affect quality of life88, 89. To weigh the importance of correct staging and 
tailoring of adjuvant treatment against the risk of inducing morbidity, preoperative 
algorithms have been developed to select patients at higher risk for lymphatic spread 
for lymphadenectomy while omitting it in those with lower risk. 
1.4.2.2 Sentinel node biopsy 
Sentinel node biopsy is rapidly gaining popularity in endometrial cancer as a 
replacement for lymphadenectomy for surgical staging90. Briefly, injection of a tracer 
in the uterine cervix allows for mapping of draining lymphatic pathways and the 
identification of the first encountered (sentinel) lymph nodes91. A sentinel node biopsy 
algorithm (including ipsilateral lymphadenectomy in case of failed mapping) is shown 
to have excellent performance in the detection of lymph node metastasis, with a 
sensitivity and negative predictive value reaching 98% and 99.8%92. Sentinel node 
biopsy does not affect oncological outcome compared to a comprehensive 
lymphadenectomy policy in retrospective studies93. Its strength lies in a reduction of 
peri- and post-operative complications89, and it has been shown to be associated with 
lower cost and higher gain in quality of life adjusted years compared to systematic or 
selective lymphadenectomy in one study94. Although very promising, effective sentinel 
node biopsy relies on procedure experience and availability of equipment91, and as of 
yet, no randomized trials comparing sentinel node biopsy to standard 
lymphadenectomy have reported results.   
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1.4.2.3 Omentectomy 
Infracolic omentectomy is recommended for serous cancers and carcinosarcomas, as 
these are associated with a high rate of micrometastases to the omentum95. The risk of 
omental spread in presumed early-stage endometrioid endometrial cancer is very low 
and does not justify routine omentectomy96. There is some guideline divergence 
regarding the procedure for clear cell tumors66, 77.  
1.4.2.4 Other staging procedures 
Peritoneal washings have traditionally been secured at the start of surgery to identify 
malignant cells outside the uterus. Positive washings led to an advanced stage diagnosis 
according to the FIGO system up until the 2009 revision, where it was removed, as 
data did not support an independent prognostic value97. Perioperative frozen section of 
the uterus, with evaluation of for example myometrial invasion, has been used to 
ascertain the need for further staging. It is deemed as obsolete by the latest European 
Society of Gynæcological Oncology guideline and is not mentioned as a staging 
technique in the National Comprehensive Cancer Network (USA) guidelines66, 77.  
1.3.3 Adjuvant treatment 
Adjuvant treatment refers to non-surgical treatment given in addition to primary 
surgery to reduce the risk of relapse (or prolong progression-free interval). In 
endometrial cancer, the main modalities have been chemotherapy, radiotherapy and 
hormonal therapy. Because many patients are cured by surgery alone, and adjuvant 
therapies generally are associated with toxicity and reduced quality of life, there is 
consensus that adjuvant therapy should be restricted to groups of patients that likely 
benefit. Standard regimens are presented in table 2. 
Adjuvant therapy policies have varied greatly between institutions, generally motivated 
by tradition and interpretation of available data. In Norway, adjuvant radiotherapy was 
generally discontinued after a randomized controlled trial (RCT) demonstrating better 
survival for adjuvant chemotherapy-treated patients than those receiving whole 
abdomen irradiation98. Two other RCTs have compared these modalities, finding no 
survival difference99, 100. Heterogeneity in the composition of chemotherapy and 
irradiation technology make comparisons challenging and interpretations uncertain. 
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Table 2. Standard adjuvant therapy regimens for endometrial cancer. Examples of 
regimens from PORTEC-2, PORTEC-3 and GOG-258101-103. In Norway, chemotherapy is 
the preferred adjuvant modality. 




paclitaxel 175mg/m2 + 
carboplatinum AUC 5-6   




1.8 Gy fractions directed to 
pelvic area, aortal field can be 
included, brachtherapy boost 





Dose delivering isotope inserted 
in vaginal vault for long (LDR) 
or short (HDR) duration  
2-6 3 weeks 
Chemoradiotherapy 
EBRT + concomitant cisplatin 
50mg/m2 x 2 + post-radiation 
paclitaxel 175mg/m2 +  
carboplatin AUC 5-6 x 4  
25-27 + 4 18 weeks 
Hormonal therapy 
Gestagen or anti-estrogen until 
failure 
- - 
AUC, Area under curve 
 
There is however data to show that local recurrence rates are reduced by radiotherapy, 
also compared to chemotherapy98, 101, 104, 105. This effect can be achieved also by 
brachytherapy, thereby reducing the radiation load delivered to healthy tissue103. 
Institutions avoiding upfront adjuvant radiotherapy may still benefit from its effect on 
local recurrences by offering it when the recurrence arises (salvage therapy), and there 
are no definitive data to support either of these radiotherapeutic strategies above the 
other. Recently, The PORTEC group demonstrated the combination of radiotherapy 
and chemotherapy to be more effective than radiotherapy alone for high-risk 
patients102. A comparable study conducted by Matei and colleagues did not find any 
difference between the same radiochemo regimen versus chemotherapy alone101. 
Hormonal therapy is not regarded as a first-line adjuvant treatment66. 
The application of molecular subgroups is likely to affect adjuvant therapy guidelines. 
Stratification to improve identification of those patients that most benefit from the 
treatment, and prospective trials to explore this are in progress, such as the RAINBO 
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(Refining Adjuvant treatment IN endometrial cancer Based On molecular profile) 
umbrella program and PORTEC-4a.106   
1.3.4 Advanced or recurrent endometrial cancer 
In patients with metastatic spread of endometrial cancer, treatment can consist of tumor 
reducing surgery, chemotherapy or radiotherapy, or combinations thereof. A 
comprehensive debulking is recommended if deemed feasible, combined with 
chemotherapy, radiotherapy or both66. The 5-year recurrence-free survival in this group 
is similar for patients treated with adjuvant chemotherapy and radiochemotherapy, but 
slightly poorer for radiotherapy alone101, 102. Carboplatin is preferred to cisplatin due to 
milder adverse effects, and the combination with paclitaxel is shown to be non-inferior 
to a triplet with doxorubicine, cisplatin and paclitaxel107. In cases where local spread 
makes resection impossible, neoadjuvant chemotherapy followed by surgery or 
definitive radiotherapy are options66, 77.  
Local recurrences can be excised if feasible and/or targeted with radiotherapy. 
Systemic treatment options for recurrent disease are limited to single agent or 
combination chemotherapy in patients with good performance status, or hormonal 
therapy. For the combination of carboplatin and paclitaxel in the recurrence setting, 
overall survival and progression-free survival is 37 and 13 months, respectively107.  The 
response rate to hormonal treatment in around 25%, with up to 35% in hormone 
receptor positive patients108, 109. For retreatment with chemotherapy (where adjuvant 
chemotherapy was given after primary surgery), a small retrospective series showed 
partial response in 50%, with no complete responses and progression-free survival and 
overall survival of 10 months and 27 months respectively110.  
As new mechanisms of tumor biology are unraveled, novel targets for treatment can be 
identified. Thus, there is hope for improving treatment and subsequently prognosis for 




1.4 Endometrial cancer biology 
1.4.1 Important genetic alterations in endometrial cancer 
Increasing understanding of the mechanisms that drive the development of malignant 
tumors have identified crucial properties that cells must acquire to prosper as cancer 
(for general reviews on key features of tumor biology, see 111, 112). Genetic alterations 
are required to obtain these properties, and may follow distinct patterns based on 
germline features, mutagen exposure, qualities of the original somatic cell, and its 
environment113, 114. The development of tools to assess mutations genome-wide, such 
as massive parallel sequencing, has led to the identification of multitudes of possible 
tumorigenic genomic alterations and research is ongoing to clarify how these may be 
exploited in the treatment of cancer113.  
In endometrial cancer, specific recurring mutations have the potential to affect 
treatment decisions, with many promising applications115, 116. Of the most notable are 
alterations in the phosphatase and tensin homolog (PTEN) suppressor gene (present in 
60-90% of endometrioid tumors), or in Phosphoinositide -3-Kinase (PI3K) proteins, 
that induce an uninhibited PI3K-Akt-mTOR signaling116. PTEN-mutations are 
frequently seen in endometrial hyperplasia, suggesting a role in early development, 
albeit not sufficient for malignant transgression117, 118. Other targetable mutations 
include TP53, CTNNB1, ERBB2, FGFR2, ARID1A, and KRAS, where alterations can 
be found in different histologic subtypes to varying degree119. For example, mutations 
in CTNNB1 commonly occur in low-grade endometrioid tumors and signify adverse 
prognosis, but are uncommon in non-endometrioid subtypes. TP53 mutation on the 
other hand is highly recurrent in serous endometrial cancer, and ERBB2 amplifications 
are rarely seen in other subtypes than serous119.  
Next generation sequencing and bioinformatic analysis of 373 endometrial cancer 
samples by the Cancer Genome Atlas (TCGA) research network identified four 
molecular subgroups with distinct prognosis120 (figure 6). The first group, constituting 
7% of tumors in the TCGA-study, were characterized by mutations in the exonuclease 
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domain of polymerase ε (POLE). This results in a defect DNA-synthesis proof-reading 
mechanism, and an ultra-high mutational rate. These tumors have an excellent  
 
Figure 6. The Cancer Genome Atlas molecular subgrouping for endometrial cancer a) 
Tumors were stratified into four groups by nucleotide substitution frequencies and patterns, 
MSI status, and copy-number cluster. SNV, single nucleotide variant. b) POLE-mutant 
tumors have significantly better progression-free survival, whereas copy-number high 
tumors have the poorest outcome. c) Commonly mutated genes differ between the four 
subgroups. The mutation frequencies of all genes that were significantly mutated in at least 
one of the four subgroups are shown (asterisk denotes false discovery rate < 0.05). Adapted 
with permission from Levine at al 2013120, under the CC-by-NC-SA 3.0 license. 
 
prognosis, even in high grade endometrial cancer. Next, MSI-high (MSI-H) or MMR 
deficient (MMR-D) tumors have deactivating mutations in one of the MMR genes, 
resulting in a high mutation rate (but lower than POLE). Interestingly, this genetic 
alteration has important treatment consequences, as tumors may respond to immune 
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checkpoint inhibitors121. The remaining tumors were divided into two groups based 
on copy number alterations, with the copy number high group containing almost all 
serous tumors, in addition to some grade 3 endometrioid. This “serous-like” group is 
generally TP53-mutated and has the poorest prognosis of the groups. The final group, 
copy-number low, has an intermediate prognosis, akin to the MSI-H/MMR-D group, 
seems to contain a mix of the classical histological subtypes and lacks obvious 
identifying protein features. The TCGA classification is currently being adopted into 
clinical guidelines, with the aim to guide treatment66, 77.   
1.4.2 Estrogen signaling and hormonal receptors 
The presence or absence of estrogen and progesterone receptors (ER/PR) are 
particularly important in endometrial cancer. In the normal active endometrium, 
estrogenic signaling drives the initial proliferative phase. Circulating estrogens 
produced by the leading ovarian follicle bind to cytoplasmic estrogen receptors that 
dimerize, enter the nucleus and act as transcription factors122. In addition, non-
transcriptional effects are mediated via G-protein coupled membrane-bound 
receptors123. Increased expression of PR, also a member of the nuclear family of 
receptors, prepares the cells to relay progesterone signaling in the luteal phase. The 
expression of PR is induced by estrogen signaling. Progesterone inhibits the 
proliferative effects of estrogen and induces differentiation and maturation of tissues 
leading to decidualization of the endometrium124. Both ER and PR have subclasses with 
functional differences (ERɑ/ERβ and PR-A/PR-B), but the importance of these for 
endometrial cancer biology is not fully elucidated. 
Epithelial expression of ER and PR is maintained in endometrial hyperplasia, the 
precursor of endometrial cancer, signifying maintained estrogen signaling. Generally, 
ER and PR are expressed in highly and moderately differentiated endometrioid 
subtypes (grade 1-2), whereas they are often lost in more aggressive tumors, such as 
grade 3 endometrioid, and non-endometrioid subtypes125. Although hormone receptors 
are absent, there may still be significant estrogenic activity8. 
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1.4.3 The role of steroid hormones 
The majority of endometrial cancer patients are post-menopausal with ceased ovarian 
hormone production. Nevertheless, residual endogenous estrogen levels vary 
(depending on phenotype) and can be affected by exogenous hormonal compounds. 
The metabolism of steroid hormones is complicated with many intermediate forms that 
may have effects on tumorigenesis20, 31, 32 (Figure 7). Studies have shown that apart 
from highly active estrogenic compounds, other steroid hormones (such as the 
androgens testosterone and androstenedione) may increase the risk of endometrial 
cancer21, 33, 38, 126. Thus, the phenotypic steroid profile may contain more information 
on risk than that imparted by estrogen levels alone. Our group previously demonstrated 
differences in levels of several steroids in blood samples in a matched sample of long 
vs short surviving endometrial cancer patients127. This finding raises the question if 
circulating steroid hormones can be exploited for prognostic information or even 
predictive value in the treatment of endometrial cancer. 
1.4.4 The hormonal microenvironment 
Although a majority of endometrial cancers are hormone receptor positive and thought 
to be estrogen-driven through activation of tumor cell nuclear receptors, little attention 
has been given to the hormonal microenvironment surrounding the tumor. There is 
however data pointing to important hormone-stroma interaction effects that may 
further our understanding of the relationship between hormonal signaling and 
endometrial cancer and how to exploit this for therapy:  
1. Stromal cells are directly involved in hormone signaling: A PTEN knockout 
endometrial cancer mouse model showed that loss of PR signaling in stromal 
fibroblasts was a mechanism of resistance to treatment with progestins. PR 
expression in the stroma could induce sensitivity to progestins in spite of 
epithelial (tumor) PR negativity128.  
2. Low stromal PR expression is associated with resistance to progestin treatment 
in complex atypical hyperplasia where epithelial PR expression is 
preserved129. Alteration of stromal hormone signaling may be an early 
component of tumorigenesis in hormone-driven endometrial cancer. 
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Figure 7. Metabolism of the major classes of steroid hormones with active enzymes. 
Background color signifies hormone action (partly overlapping). HSD, hydroxysteroid 
dehydrogenase. Reprinted with permission under CC BY-SA 3.0.130  
3. Expression of hormone-altering enzymes is associated with aggressive tumor 
characteristics and prognosis in endometrial cancer131. Induction of stromal 
hormone-converting enzymes may be an important mechanism by which to 
increase mitogenic signaling132. 
Thus, circulating hormones may affect tumor cells indirectly and independently of 
epithelial receptor expression. There is hope that a deeper understanding of the stroma-
hormone-tumor axis interactions may yield new insights to increase efficiency of 




1.5 Precision treatment in endometrial cancer 
Precision treatment in cancer refers to tailoring treatment to properties of the patient or 
the disease133. This can be achieved either by identifying the patients that benefit from 
a given treatment or by designing treatment that targets specific molecules, signaling 
pathways, or functional alterations that arise in subgroups of a cancer. 
1.5.1 Biomarkers for precision medicine 
Identification of biomarkers is closely related to development of precision treatment. 
A cancer biomarker may be any measurable biologic entity that provides information 
on cancer parameters134. Biomarkers are generally classified according to their utility 
as either prognostic or predictive, meaning they are either useful for sorting patients 
according to survival or according to response to a predefined treatment. As prognostic 
biomarkers can be identified from observational studies without controlling allocation 
to treatment, these are more abundant in the literature135.   
1.5.2 Prediction of lymph node metastasis 
Although endometrial cancer provides a unique possibility for retrieving tissue from 
the tumor prior to definitive treatment, few preoperative biomarkers have gained 
widespread use. A main reason for this is that most patients will undergo primary 
hysterectomy irrespective of risk assessment. Post-operatively, the complete primary 
tumor is available for analysis of histological risk factors which provides the gold 
standard. Possible applications for preoperative biomarkers are the selection of patients 
for non-surgical treatment or omitting staging procedures to minimize morbidity. In 
endometrial cancer research, identifying biomarkers to aid in the selection of patients 
to undergo lymphadenectomy has been a prioritized goal. For a biomarker to be 
effective in this setting, it needs to have a high sensitivity for lymph node metastasis 
and produce a low negative predictive value, minimizing the number of patients that 
are understaged, as this has important implications for adjuvant treatment and 
subsequently survival.  
Although preoperative imaging has improved the ability to diagnose lymph node 
metastasis, it is limited by the size (and metabolic activity) of the metastasis136. 
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Lymphovascular space invasion is a strong histological prognostic biomarker but is not 
assessable in preoperative biopsies137. L1CAM, ER, PR, and p53 are examples of easily 
assessed histological biomarkers that provide information on the risk of lymph node 
metastasis125, 138, 139. The ongoing Molecular Markers in the Treatment of Endometrial 
Cancer phase 4 multicenter study (MoMaTEC2) is investigating the effects of limiting 
lymphadenectomy to cases at increased risk of lymph node metastasis based on ER/PR-
expression in a preoperative sample. It is plausible that combining multiple biomarkers 
in panels will improve their prognostic value, and that this may increase the clinical 
usefulness75. Molecular classification, for example as proposed by the Proactive 
Molecular Risk Classifier for Endometrial Cancer (ProMisE) initiative, has the 
potential to alter the preoperative assessment of endometrial cancer, and preoperative 
biopsy classification correlates well with the hysterectomy specimen140, 141. 
1.5.3 Targeted treatment in endometrial cancer 
Immune checkpoint inhibitors are one of the true oncological precision medicine 
breakthroughs. These antibodies target interaction between cells of the immune system 
and the tumor and can reverse immune evasion properties in cancer cells.  
Pembrolizumab inhibits contact between PD-1 and its ligand in T-cell-tumor 
interaction, and has been approved in the USA for solid MSI-H tumors, endometrial 
cancer included142. These tumors exhibit mismatch repair deficiency (MMR-
D)/microsatellite instability (MSI), resulting in a high mutational burden and high 
neoantigen load, which makes them susceptible to the T-cell immune defense. In 
addition, recently, the combination of levatinib (a VEGF inhibitor) with 
pembrolizumab (PD-1 inhibitor) has been approved by the FDA following the results 
of Keynote-146 for treating MMR-proficient endometrial cancer patients143, 144.  
Based on overexpression of HER2 in 30% of serous cancers, and their efficacy in breast 
cancer, the effect of HER2-targeting antibodies has been explored in endometrial 
cancer. A phase II study with carboplatin/paclitaxel with or without trastuzumab in 
advanced or recurrent serous carcinomas overexpressing Her2/Neu showed increased 
PFS and OS. Median overall survival was not yet reached in the trastuzumab arm after 
a median follow-up of 26 months145. It should be stressed that none of the above-
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mentioned treatments have been validated at phase III level. No modern targeted 
therapies are in general use in Norway, but can be approved by a national “expert 
panel” evaluation system. 
There is hope for novel approaches following the logic of the TCGA classification, 
apart from the link between MMR-D and Immune checkpoint inhibitors. POLE tumors 
have an ultra-high mutational load and are likely susceptible to immune checkpoint 
inhibition, but have inherently good prognosis, and less treatment is more likely to be 
the goal for this group146. For the copy number high (serous-like) subgroup, the TCGA 
study and pathology studies reveal a high grade of similarity to high grade serous 
ovarian cancer and basal-like breast cancer, also expressing homologous repair 
deficiency in many cases; this raises the question of a potential effect of Poly (ADP-
ribose) polymerase (PARP) inhibitors for this subgroup. PARP inhibitors have shown 
in vitro effects, especially in sensitizing cells to chemotherapy, and several agents are 
being tested out in Phase I/II clinical trials147. The copy number low group contains a 
majority of endometrioid, ER/PR positive tumors, and while the molecular profile does 
not give obvious grounds for a specific targeted treatment, these tumors may be 
susceptible to hormonal treatment in the palliative setting. Also, this group had the 
highest occurrence of CTNNB1 mutations in the TCGA data (>40%), providing a 
promising target should an effective drug be discovered.  
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1.6 Quality of life 
1.6.1 Living with cancer 
After receiving primary treatment for endometrial cancer, most patients will be cured. 
Treatment-related morbidity and functional decline is highly important as it will affect 
quality of life for many years. Clinical follow-up is motivated by the possibility of 
discovering asymptomatic recurrences eligible for treatment, but the effect on survival 
is uncertain148. In contrast, follow-up is potentially an opportunity to assess post-
treatment morbidity and improve quality of life for patients. To achieve this, data on 
what parameters to measure and how to interpret responses is needed. Follow-up 
schemes vary between healthcare systems and are usually tailored to the patient’s 
wishes and available healthcare resources. In Norway, follow-up is normally planned 
for every 3-4 months during the first two years followed by every 6 months until 5 
years post diagnosis149.  
For patients presenting with uncurable disease, the time-frame post treatment is shorter. 
Palliative treatment is intended to minimize discomfort during the final stages of the 
disease. Treatment should be carefully tailored to the patient’s wishes and expectations 
in these situations. To achieve this, there must be available information on potential 
outcome related to different treatment modalities150. 
1.6.2 Treatment-related morbidity 
As nearly all patients go through primary surgery including hysterectomy and BSO, 
reducing morbidity resulting from this procedure has been in focus. Surgical 
approaches, minimally invasive laparoscopy and traditional laparotomy, have been 
compared in large trials, and suggest better short-term quality of life for laparoscopy 
but with no obvious long-term differences151, 152. Lymphadenectomy is associated with 
lower-extremity lymphedema88, 153-158. Sentinel node biopsy seems a promising 
alternative, however, there is a lack of studies assessing differences in survival, quality 
of life, or morbidity when comparing sentinel node biopsy with selective 
lymphadenectomy. Estimates of lymphedema are hard to interpret due to lack of 
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standard criteria, influence of comorbidities, and possible dynamics in the course of 
the disease159. 
Longitudinal data on long-term effects of adjuvant radiotherapy is available and show 
persisting gastrointestinal problems up to 10-15 years160-162. For adjuvant 
chemotherapy, health-related quality of life outcomes have been used to ascertain 
advantage of using carboplatin plus paclitaxel over a cisplatin-doxorubicin-paclitaxel 
triplet107, and comparisons have been made between chemotherapy, 
chemoradiotherapy and radiotherapy in treatment of advanced stage patients101, 163. 
Generally, these secondary endpoints address the short-term effects of the treatments 
and are used to find a preferred treatment when the survival outcome is equal. Less is 
known about long-term effects of adjuvant chemotherapy on endometrial cancer 
survivors. 
1.6.3 Assessing morbidity and quality of life 
In the assessment of health-related quality of life and morbidity, patient-reported 
outcome (PRO) is now regarded to constitute a highly valid endpoint, representing the 
patient’s own assessment of the problem164. Alternative outcome parameters may be 
physician’s opinion or objective measurements (e.g. leg circumference or 
pletysmography in the case of lymphedema), and although these have traditionally 
been seen as more objective, they are increasingly replaced by PRO assessments, 
transferring the power of definition to the patients. Specific assessments of for example 
lymphedema have been shown to correlate highly between patient-reported symptoms 
and objective measurement165, 166. The assessment of patient PROs such as perceived 
symptoms or functioning is useful in cancer research for several reasons: 
• Exploring patient groups to address specific problems that are not 
acknowledged, e.g. sexuality in endometrial cancer patients. 
• Developing methods for surveillance of patients with the aim to detect health 
issues that may be treated. 
• Comparing treatment-related adverse effects in randomized trials, especially 
when survival gain is similar.  
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PRO assessment is generally based on questionnaires where the respondent is prompted 
to evaluate quality of life, functioning, and symptoms on Likert scales. These scores 
can then be summed or grouped to represent different entities of interest. Figure 8 
shows an example of dimensions of a quality-of-life assessment from the European 




Figure 8. Radar plot of endometrial cancer patient means of EORTC-QLQ C30 and EN24 
scales at baseline, year 1 and year 2. General population means are plotted as lines. Increasing 
score signifies better function. * p <0.05, **p<0.001. EORTC-QLQ, European Organisation 
for research and treatment of cancer-quality of life questionnaire. Adapted from Forsse et al. 




2. Aims of the study 
2.1 Background 
Endometrial cancer is a common female malignancy that requires prompt treatment 
for best prognosis. Most patients survive their diagnosis but may struggle with 
problems related to treatment. Aggressive disease requires more and tougher 
treatment, but precise methods to tailor treatment are unavailable. More targeted use 
of available treatment modalities that potentially affect morbidity is likely the most 
efficient way to improve survival and reduce morbidity for endometrial cancer 
patients. To improve endometrial cancer treatment, implementation of biomarkers in 
treatment algorithms as well as thorough investigation of treatment effects on 
survival and quality of life is vital. 
2.2 Overall Aim 
To improve endometrial cancer treatment through better preoperative stratification and 
evaluation of the effects of different treatment modalities on survival and morbidity. 
2.3 Specific aims 
Paper I: Determine the prognostic value of circulating steroids in endometrial cancer 
patients, and explore their additive value as a preoperative test to the current work-up.  
Paper II: Assess the effects of 1) discontinuing adjuvant radiotherapy, and 2) 
reducing the rate of patients undergoing lymphadenectomy on recurrence and 
survival. In addition, we explored trends in clinical and pathological variables that 
could affect patient outcome during the observed period.  
Paper III: Determine the effect of treatment modalities on differences in quality of 
life and patient-reported outcomes in patients subjected to hysterectomy alone, lymph 
node staging procedures and/or adjuvant chemotherapy. 
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3. Materials and methods 
3.1 Patient series 
3.1.1 The Haukeland cohort 
Patients treated for endometrial cancer at Haukeland University Hospital have been 
prospectively included in a well annotated study cohort since 2001, primarily designed 
for identification of biomarkers in tumor tissue. The cohort is approved according to 
Norwegian legislation by the western regional committee for medical and health 
research ethics (REK 2014/1907, 2019/1020). Informed written consent has been 
obtained preoperatively from all included patients.  
Haukeland University Hospital serves as a tertiary hospital for gynecologic oncology 
for the Vestland region, encompassing ~10% of the Norwegian patient population. The 
cohort is considered population-based as patient and disease characteristics reflect the 
nationally reported endometrial cancer statistics2. Tumor tissue samples, blood and 
urine are stored in the Bergen Biobank for Gynecological Cancer. A database with 
clinicopathological variables has been continuously updated based on patient file 
review and routine pathology reports. Prospective registration of recurrences and 
survival has been performed.  
3.1.2 MoMaTEC2 
Molecular Markers for Treatment of Endometrial Cancer 2 (ClinicalTrials.gov 
Identifier: NCT02543710) is an ongoing multicenter phase 4 implementation study, 
designed to evaluate the implementation of hormonal receptors as preoperative 
biomarkers to guide treatment. The study emanates from Haukeland University 
Hospital and includes several Norwegian hospitals (Figure 9). International 
participating sites are Nijmegen and Eindhoven (Netherlands) and Lublin (Poland) but 
included patients from these centers are not part of this thesis. Inclusion started in 
October 2015 and the study is still enrolling, aiming to include n = 1000 patients. 
Including centers submit information on clinicopathological variables, including local 
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pathology reports. Patient-reported outcomes and follow-up are self-registered by 
consenting patients and validated by study personnel.  
 
Figure 9. Patient series included in this thesis. MoMaTEC, Molecular markers in the 
treatment of endometrial cancer (study). 
3.2 Analysis of biological tissue  
3.2.1 Liquid chromatography/Tandem mass spectrometry (LC-
MS/MS) of plasma hormone levels 
For paper I we employed an LC-MS/MS panel already in clinical use, and therefore 
validated and available for easy implementation. The panel included progesterone, 17-
hydroxyprogesterone, 11-deoxycortisol, cortisol, androstenedione and testosterone167. 
We also measured estrone and estradiol, using a novel sensitive LC-MS/MS protocol 
designed for quantification of these hormones in post-menopausal women168 (Table 3). 
The referenced method-articles above describe the development of the methods in 
detail. 
Preoperative blood samples were collected in Ethylenediaminetetraacetic acid 
(EDTA)-tubes, centrifuged at 1600 g for 15 minutes. Plasma was pipetted and stored 
at -80 °C. The hormone analyses were performed by the Hormone laboratory at 




Table 3. Limits of detection for the included LC-MS/MS analyses. Source: 




Lower limit of 
quantification* 
17-hydroxyprogesterone (nmol/L) < 0.06 0.24 
11-deoxycortisol (nmol/L) <0.03 0.10 
Testosterone (nmol/L) <0.01 0.02 
Androstenedione (nmol/L) <0.02 0.12 
Progesterone (nmol/L) <0.06 0.12 
   
Estradiol (pmol/L) <0.28 0.58 
Estrone (pmol/L) <0.15 0.25 
* Lowest value where coefficient of variance ≤ 20% 
 
 
LC-MS/MS is a technique for quantification of different chemical compounds within 
a sample. The sample is prepared in a liquid phase which passes through a 
chromatographic column under ultra-high pressure leading to a separation of the 
analytes based on their affinity to the respective phases (mobile/stationary). The 
temporarily resolved liquid phase compounds are ionized in an interface and separated 
according to mass to charge ratio in a mass spectrometer (Figure 10). In tandem mass 
spectrometer setups, additional steps of mass spectrometry allow for filtering out 
compounds and fragmenting the targeted compounds to increase the resolution.  
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Figure 10. Resolution of compounds in LC-MS/MS related to retention time in 
chromatography column and mass to charge ratio. By Daniel Norena-Caro. Permission under 
CC0 1.0 Universal public domain dedication. 
 
3.2.2 Immunohistochemistry 
In paper I, immunohistochemical staining assessments from tissue micro-arrays (TMA) 
were available for expression of ER, PR, androgen receptor (AR) and glucocorticoid 
receptor (GR) from previous research projects and were used to explore associations 
to steroid levels 169-172. In paper II, ER and PR expression in preoperative biopsies was 
assessed routinely in full sections at the Department of pathology, Haukeland 
University Hospital. Data on ER/PR expression was retrieved from the clinical 
pathology report.  
Briefly the method employed at our lab for immunohistochemistry follows. Formalin-
fixed paraffin-embedded tissue was sectioned in 5μm slides. Slides were dewaxed in 
xylene and hydrated in a stepwise ethanol gradient of decreasing concentration. 
Antigen retrieval was performed by microwave heating for 15 minutes in pH6 or pH9 
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buffer, followed by silencing of endogenous peroxidase with a blocking anti-
peroxidase. Primary antibodies were added in specific dilutions and for a defined 
duration. The corresponding species-specific secondary antibody and the enVision 
DAB+ system (DAKO, Carpinteria, CA) were used to develop staining. Slides were 
dehydrated and mounted prior to microscopic evaluation. For specifics for each 
staining procedure, refer to the above referenced publications. 
Slides were evaluated blinded for patient and tumor characteristics. A staining index 
was calculated as the product of staining intensity (0-3) and area of positive tumor cells 
(1: <10%, 2: 10%-50%, 3:>50%). Interobserver variability was assessed by two 
independent observers scoring random slides. Finally, the staining scores were 
dichotomized with consideration to survival characteristics, group sizes and number of 
events. 
3.2.3 RNA microarray studies 
In paper I, available microarray mRNA expression data from for 77 included patients 
with endometrioid histology was retrieved to assess patterns in gene expression in 
relation to levels of circulating sex hormones. A brief description of the method 
employed follows. 
Samples for mRNA studies were collected during surgery, snap-frozen in liquid 
nitrogen and stored at -80 °C. Hematoxylin-stained frozen sections were assessed by 
light microscopy to determine tumor cell content prior to RNA extraction. Lesions with 
at least 50% and preferably 80% tumor cell content were selected. Total RNA was 
extracted using the RNeasy Mini Kit (Qiagen, Germany) and quantified by the 
Nanodrop 1000 (Thermo Fischer Scientific, Waltham, USA). Integrity and quality 
were measured by the Bioanalyzer 2100 (Agilent, St Clara, USA). RNA was hybridized 
on Agilent Whole Genome Microarray 44k (Cat. No. G4112F, Agilent, St Clara, USA). 
Scanning was performed using the Agilent Microarray Scanner Bundle (Agilent, St 
Clara, USA). Expression data was quantile normalized and log2 transformed before 
gene expression analysis. J-express (Molmine, Bergen, Norway) was used to analyze 
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data, and significance analysis of microarrays (SAM) and gene set expression analysis 
(GSEA) were performed (Figure 11).  
 
Figure 11. Gene set enrichment Analysis. A) Ranked heatmap of gene expression by 
phenotype, providing the ranked gene list. B) Gene set S providing the genes of interest. The 
algorithm “walks” down the ranked gene list increasing the enrichment score (ES) when 
encountering a gene in S and decreasing when no gene in S is encountered. Figure from 
Subramanian et al. 2005173 with permission. Copyright (2005) National Academy of 
Sciences, U.S.A.     
3.3 Imaging 
3.3.1 Computer tomography and body fat distribution 
Fat-segmentation data from CT scans, previously reported174, was available for 83 
patients in paper I. 
Contrast-enhanced CT scans including thorax, abdomen and pelvis were obtained from 
the routine workup of the patients. The CT scans were assessed for abdominal fat 
distribution using iNtuition (TeraRecon Inc., San Mateo, CA, USA). The software 
provides a semi-automated volumetric segmentation in subcutaneous and visceral 
compartments based on Hounsfield units. The boundaries were controlled and adjusted 
by the operator when necessary. 
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3.3.2 Magnetic resonance imaging 
MRI findings reported in the standard radiological report including myometrial 
invasion, cervical stroma invasion, and extrauterine disease were reviewed and 
recorded for paper II.   
MRI was only sporadically used for evaluation in endometrial cancer until 2009 when 
pelvic contrast-enhanced MRI was routinely included in the preoperative work-up. The 
MRI examinations referred to in this thesis were performed at Haukeland University 
Hospital or at referring hospitals (varying brands and field strength, 1.5 or 3 Tesla). 
The imaging protocols largely adheres to European guidelines175. Protocol-adherent 
pelvic imaging included T2-weighted sagittal and axial oblique (transverse planes of 
corpus uteri) and axial T1-weighted gradient-echo images before and after intravenous 
contrast.  
3.3.3 PET/CT 
For paper II, PET/CT findings reported in the standard radiological report (FDG-avid 
lymph nodes or other sites) were reviewed and recorded.   
18F-FDG PET/CT was included in the standard work-up of endometrial cancer patients 
from 2011. All scans were performed at Haukeland University Hospital on a Siemens 
Biograph 40 True Point or a Siemens biograph Vision scanner (the latter after 
November 2018), ranging from skull base to mid-thigh. During the study period, the 
associated CT protocol was changed from diagnostic to low-dose protocol.  
3.4 Assessing quality of life and patient reported outcomes 
For Paper III, PRO measures from MoMaTEC2 were analyzed. The questionnaires 
EORTC-C30 (general) and EORTC-EN24 (endometrial cancer specific) 
questionnaires were chosen for the MoMaTEC2 protocol as they are validated and 
available in translations for all participating countries (specimens in Appendix A). The 
EORTC questionnaires were answered at baseline (preoperatively) and annually 
postoperatively. The prospective registration allowed for adjustment for baseline 
properties of importance. Age, body mass index, comorbidity, tumor stage and marital 
 50
and socioeconomic status may be important predictors of PROs in endometrial cancer 
patients176-178, and these can be approximated by including baseline PRO values.  
The EORTC questionnaires are constructed of items, where each item requires the 
respondent to evaluate the item of interest over the last week (with exception for 
“sexual activity” and “sexual interest” which is evaluated for the previous 4 weeks). 
The item responses are Likert scales ranged 1-4 from “None”, through “A little” and 
“Quite a bit” to “Very much”. The Global health score/Quality of life item responses 
are ranged 1-7. For analysis, the EORTC recommends transforming item responses to 
scales through grouping of related items and normalizing according to the EORTC 
scoring manual179, thus producing 15 scales for the EORTC-C30 and 13 Scales for the 
EORTC-EN24, ranging from 0-100 (Table 4). These scale scores are discrete, taking 
values depending on the number of items and item ranges included. 
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Table 4. Scales included in the European organization for research and treatment in cancer 
EORTC questionnaires c30 (general) and EN24 (endometrial cancer specific) 





EORTC-C30     
QL2 Global health status/QoL Function  2 x 
PF2 Physical Function Function  5 x 
RF2 Role Function Function  2  
EF Emotional Function Function  4 x 
CF Cognitive Function Function  2 x 
SF Social Function Function  2 x 
FA Fatigue Symptom 3 x 
NV Nausea / vomiting Symptom 2  
PA Pain Symptom 2  
DY Dyspnea Symptom 1  
SL Insomnia Symptom 1  
AP Appetite loss Symptom 1  
CO Constipation Symptom 1  
DI Diarrhea Symptom 1  
FI Financial problems Symptom 1  
EORTC-EN24     
ENLY Lymphoedema Symptom 2 x 
ENUR Urological symptoms Symptom 4 x 
ENGI Gastrointestinal symptoms Symptom 5 x 
ENBI Poor body image Symptom 2 x 
ENSXV Sexual/vaginal problems Symptom 3 x 
ENBP Pain in back and pelvis Symptom 1 x 
ENTN Tingling/numbness Symptom 1 x 
ENMP Muscular pain Symptom 1 x 
ENHL Hair loss Symptom 1 x 
ENTC Taste change Symptom 1 x 
ENSXI Sexual interest Function  1 x 
ENSXA Sexual activity Function  1 x 
ENSXE Sexual enjoyment Function  1 x 
* Function scales increase with increasing function (improvement), symptom scales 




3.5 Statistical methods  
All statistical analysis was performed in Statistical Program for the Social Sciences 
version 25 (SPSS, IBM inc., Chicago, IL, USA) and R version 3.6.1-4.0.2 (R Core 
Team 2020) R Foundation for Statistical Computing, Vienna Austria). For comparison 
of categorical data, the Chi-square test was preferred, but Fischer exact test performed 
when included frequencies were ≤5. No continuous data variables analyzed in these 
projects were normally distributed, and Mann-Whitney U test was used to compare 
distributions between 2 groups and Kruskal-Wallis test between 3 or more. 
 
Trends in changes of clinicopathological characteristics over time were analyzed by 
linear regression in the case of continuous variables (age, body mass index) and trends 
of proportions by the Chi square test for trend. To determine cutoffs for the prediction 
of 5-year disease-specific survival by levels of endogenous steroids, Receiver 
Operating Characteristics (ROC) curves were generated. Area under the curve was 
analyzed to establish the analytic accuracy and Youden index used to select cutoff. 
 
Overall survival was defined as time from treatment to death from any cause. Disease-
specific survival was defined as time from treatment to death from endometrial cancer. 
Recurrence-free survival was defined as time from surgery to first verified recurrence, 
and only included patients with completely resected tumors (macroscopically tumor-
free). Survival statistics were visualized in Kaplan-Meyer curves and differences 
between groups calculated by the log-rank test. Cox proportional hazard regression was 
used to perform multivariable survival analysis. 
For analysis of PROs and quality of life endpoints, linear mixed models were used. For 
each EORTC scale a model was fitted, using the scale score as outcome variable and 
treatment modalities (laparoscopy/laparotomy, lymph node staging procedure, 
adjuvant chemotherapy) as predictors (fixed effects). A patient-level random intercept 
was included as well as a baseline covariate and interactions for time and treatment.  
Two-sided P-values < 0.05 were considered significant.  
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4. Summary of results 
Paper I 
We evaluated steroid hormone levels in blood samples drawn from 100 
postmenopausal patients, selected to match histological and patient-related 
characteristics of the whole population-based cohort (Haukeland cohort). We analyzed 
a panel of sex-hormone related steroids, routinely used in the clinic to diagnose 
endocrinological conditions, in addition to a novel estrogen assay developed to 
quantify post-menopausal levels of estrogen. To assess the biomarker potential of these 
assays in endometrial cancer we explored associations with immunohistochemical 
expression, gene expression, radiologic body-composition parameters and survival. 
We found that low levels of 17-hydroxyprogesterone, 11-deoxycortisol and 
androstenedione were associated with aggressive tumor characteristics and poor 
disease-specific survival. 17-hydroxyprogesterone and 11-deoxycortisol both 
predicted outcome independently of preoperatively assessed histological type and 
grade in multivariable analysis. Tumors from patients with low levels of these 
hormones expressed gene sets correlating to mitosis and cell-cycle progression to a 
higher degree and inflammatory and estrogen-signaling gene sets to a lower degree 
than those with high levels. Levels of estrone and estradiol were associated with 
transcriptional estrogen signaling, expression of hormone receptors and higher 
measurements of body fat, but not to survival. 
Paper II 
We reviewed all endometrial cancer patients receiving primary treatment at Haukeland 
University Hospital over the period 2001-2019 with a focus on comparing outcomes 
before and after implementing treatment changes. Main treatment changes were 
discontinuation of radiotherapy as an adjuvant treatment from 2009 and a transition to 
a biomarker- and imaging-based selective lymphadenectomy policy in 2012-2013 (to 
replace a systematic lymph node sampling policy). Stage III patients treated in the post-
2009 period had better overall survival (5- year OS 0.61 vs 0.49, p = 0.04), disease-
specific survival (5-year DSS 0.68 vs 0.54, p = 0.06 and recurrence-free survival (3-
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year RFS 0.71 vs. 0.51, p = 0.03). No differences in survival were found in other stages. 
There were no significant changes in total recurrences or recurrences by site between 
patients treated before 2009 and after. A marked reduction in the total number of 
lymphadenectomies after 2012 resulted in an increase in the group of patients classified 
as early-stage disease but with unknown nodal status, and recurrence-free survival in 
this group was maintained compared to non-lymphadenectomized early-stage patients 
treated 2001-2012. Also of note, there was a substantial increase in adjuvant therapy 
given to stage I high-risk patients after 2009, without any corresponding improvement 
in survival. 
Paper III 
In this study we determined the effect of treatment modalities on patient-reported 
outcomes during the first post-operative years. We analyzed prospectively collected 
data on symptoms, function, and quality of life among Norwegian patients enrolled in 
MoMaTEC2. We found overall good quality of life and functional outcomes compared 
to reference population means at one and two years, but lower means at baseline. 
Patients treated with chemotherapy reported more peripheral neuropathy, lymphedema 
and muscular pain at follow-up. Among patients not receiving chemotherapy, lymph 
node staging procedures were not associated with worse symptoms. In multivariable 
mixed models, adjuvant chemotherapy increased peripheral neuropathy, lymphedema, 
fatigue, and reduced physical functioning. There were no independent effects of lymph 




5.1 Methodological considerations 
5.1.1 Strength and weakness of study design 
Randomized controlled trials (RCT) are considered the gold standard when settling 
clinical research questions in medicine. Properly conducted, they eliminate as much 
bias as possible, and provide evidence for cause-effect relationships.  They are however 
cumbersome in nature and place high demands on pre-trial planning, participating 
personnel, patients, and follow-up structure in order to be successful180. A problem 
when interpreting RCTs is low power leading to high risk of random sampling error, 
reflected in high variability of the outcome statistic (inaccuracy)181. There is also 
concern that in optimizing the cohort to answer a specific question, relevant subgroups 
may be excluded, since results are only valid for the group represented by the 
participants182. In contrast, observational studies are easier to perform, and can provide 
data on associations between treatment and outcome but will be biased due to non-
randomization183. In many instances a definitive RCT will be necessary, especially 
when available evidence has important implications but is conflicting. Often however, 
because of economy, unattainable power estimates, impossibility to randomize, or 
other reasons, data from observational studies will be the ultimate basis for 
conclusions. 
All of the papers included in this thesis are observational, and methodological 
considerations regarding study design and sources of bias will be briefly discussed 
below. 
For paper I, a selection of patients was performed to represent a population-based 
cohort. The advantage of using a population-based cohort is that the results are more 
robust to variability among patients and therefore are more likely to represent the 
population, thereby reducing the chance of selection bias. In paper I, the objective was 
to identify novel biomarkers, and the cohort served as a hypothesis cohort. As findings 
from such a cohort may be biased by multiple testing issues and random sampling 
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effects, any results need to be confirmed in an independent validation cohort before 
being considered for clinical use. 
Paper II was a population-based cohort study investigating the effects of changing 
therapy regimens at a large tertiary hospital. Findings related to differences in time 
periods are difficult to interpret as there are several simultaneous changes over the 
observation period that could affect outcome. To partly account for this, an analysis of 
relevant risk factors over time was performed. Bias resulting from overall changes in 
treatment approach (more therapy in total, different surgeon approach to selecting 
treatment) was however likely to be present. In contrast, a strength of Paper II is that it 
determined the effect of changing treatment under conditions that exist in the ordinary 
clinical setting. “Real world” research is valuable and necessary as it often moderates 
overly optimistic results from RCTs and can give more accurate ideas of cost-
effectiveness of implementing changes. The observations made in paper II can support 
data from relevant RCTs and raise questions that should be further explored in RCTs. 
Paper III was a cohort study derived from the ongoing MoMaTEC2 project. For Paper 
III, PRO questionnaires collected up to a specified time-point (November 2020) were 
analyzed in relation to treatment received. As patients are not randomized to treatment, 
results may be biased by grouping of patients with confounding characteristics such as 
socioeconomical or health-related factors that could have bearings on the PROs. 
Including pretreatment baseline values, that represent some of the variation caused by 
non-treatment related factors, provide some compensation184. Ideally, an RCT would 
need to be performed with randomization to treatment to settle causality. An 
observational study is however suited to uncover associations between treatment 
modalities and PROs and can pinpoint targets for further focused research.   
5.1.2 Considerations regarding biological analyzes 
In paper I multiple methods were employed to describe various properties of the patient 
and tumor. LC-MS/MS was used to quantify steroid hormones in plasma, blood 
samples were submitted to be tested by routine clinical protocols. LC-MS/MS is 
considered the gold standard for analysis of steroid hormones in human plasma and is 
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in wide-spread clinical use. High cost and low throughput may be mentioned as 
drawbacks compared to earlier methods such as immunoassays, but this is generally 
weighed up by excellent specificity, resolution, and multiplexing possibilities185. 
Issues can be raised on the representativeness of frozen samples. Previous studies 
report little degradation of steroid hormones in normal storage temperatures, and a 
generally unaltered ranking of samples over time186, 187. In addition, circadian cyclicity 
of steroid hormones is a bias that was not possible to account for due to the 
retrospective nature of the study. As the samples were collected simultaneously with 
the routine preoperative blood samples it is likely that the sample time points are evenly 
distributed between groups. This would need to be verified in a validating study with 
fixed sampling timepoints. We avoided issues with menstrual cycle variations by 
limiting the study to postmenopausal women, thereby targeting the majority of patients. 
To assess levels of these hormones in premenopausal women, samples would need to 
be taken on specific cycle days which may come in conflict with need for rapid 
treatment or at least be more demanding for included patients. This might however be 
warranted in future studies as conservative (fertility-sparing) treatment more often is 
an issue for this group, with a lack of prognostic biomarkers to guide treatment 
decisions. 
Regarding inferences with mRNA expression, there are some concerns. Firstly, use of 
microarrays may not pick up all facets, as the preformed probes will not distinguish 
between isoforms, splice variants and similar post-transcriptional alterations unless 
pre-specified. Secondly, using mRNA as a surrogate for their end-product proteins is 
not optimal as mRNA expression only explains around 40% of the protein level 
variations188, the rest being affected by post transcriptional regulation. The correlation 
may however be higher for certain groups of genes, as is suggested to be the case for 
genes differentially expressed between tumor subsets exposed to different treatment189. 
Also, translation is not the only important endpoint for mRNA, and transcriptomics 
may provide other important information on ongoing processes in the cell.  
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5.1.3 Considerations on measuring patient-reported outcome 
In paper III, PROs were investigated in relation to treatment modalities. PRO 
assessment is characterized by diverse tools, methods of analysis, and interpretation, 
and methodological choices for this paper require a deeper discussion190.  
The tools and timing of PRO assessment depends highly on the aims of the study. 
Symptoms and quality of life during treatment with different adjuvant modalities are 
important when assessing which treatment should be preferred but may be different 
from long-term outcomes. The patient may prefer worse outcomes briefly during 
treatment to gain survival or avoid other long-term side effects. In addition, different 
tools may have different aspects that are important for the pursued aims such as 
documented reference values, validated translations or may have been used in other 
research were comparison is warranted. 
In oncologic research, two tools for PRO assessment dominate: the Functional 
assessment of cancer therapy (FACT-G) and European Organisation for Research and 
Treatment of Cancer (EORTC) (table 5). Both contain numerous modules to adapt to 
different cancer settings and diagnoses and are rigorously validated. Comparisons show 
that psychometric properties are similar, there are however small differences that may 
be of interest when choosing tool for a trial or project191.  
Scales measuring quality of life and symptoms may be subjected to floor and ceiling 
effects. Floor effects are when many respondents report the lowest possible score, such 
as for a symptom that is not frequently present. Ceiling effects are when many 
respondents report the highest score, such as for functioning or quality of life, when 
these are not impaired in most patients. Both effects will result in non-normal 
distributions and standard deviations that span outside the scale limits. Floor and 
ceiling effects are shown to be present when using the EORTC-QLQ-C30 
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Despite non-normal distribution, parametric indices (mean, standard deviation) are 
commonly applied, and likely more informative than medians and percentiles. We 
opted for parametric indices for descriptive purposes and comparison with previous 
research. Non-parametric hypothesis testing was performed in paper III, although 
parametric methods are likely equally appropriate with large sample sizes.  
Another challenge when analyzing PRO is determining the clinical meaning of results. 
For example, the meaning of a 10-point increase in “social functioning” on a scale 0-
100 may not be evident. This problem may be approached in different ways. For use in 
clinical settings, defining thresholds that signify where a score becomes a potential 
health problem is a reasonable approach193. For research purposes, minimally 
important changes may be defined, optimally by comparing questionnaire output to 
independent measurements of the same entity, such as another questionnaire (anchor-
based). This has been performed for the EORTC-QLQ-C30, but not for the EN24 
questionnaire194, 195. Osoba and colleagues suggested that EORTC-QLQ-C30 changes 
between 10-20 points represented (clinically) moderate changes, by using anchoring 
questionnaires195. Another approach is to use distributions. Cohens d (effect size) is 
commonly used, which is simply calculating mean/standard deviation in the sample196. 
An effect size of 0.5 has been shown to correspond to clinically meaningful changes197. 
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It is also important to be aware that clinical meaningfulness can vary according to 
factors such as age, culture or disease status and should be qualitatively evaluated for 
each situation. 
In analysis of PROs and quality of life-endpoints, many different statistical approaches 
may be justified. The Setting International Standards in Analyzing Patient-Reported 
Outcomes and Quality of Life Endpoints (SISAQOL) consortium has attempted (in an 
ongoing effort) to systematize and recommend specific analyzes depending on the aims 
of the study190.  
For longitudinal assessment of PROs over multiple timepoints, use of linear mixed 
models are suitable, and recommended by SISAQOL190. Linear mixed models are 
essentially linear regression models that can account for different levels of dependence 
between individual datapoints (also called hierarchical structures), such as repeated 
measurements over time in the same subject198. Linear mixed models offer advantages 
over other statistical models for longitudinal data: 
1. Allows for different intercepts and/or different slopes for different hierarchical 
levels; each patient can have its own y-axis intercept for an outcome, which is 
biologically plausible in most situations. 
2. Allows for retaining cases despite missing values. As an example, ANOVA is 
restricted to complete case analysis, meaning that all data points for a subject 
will be disregarded if one point is missing. (Non-random missingness will 
naturally still bias results in mixed models) 
3. Effects of predictors on outcome can be analyzed at different time-points or 
can be averaged over the whole period according to hypothesis. 
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5.2 Discussion of results 
5.2.1 Peroperative lymph staging and adjuvant treatment are key 
factors to improve endometrial cancer treatment 
Limiting the number of patients who undergo staging procedures and/or adjuvant 
treatment is logical and effective but depends on accurate biomarkers. In this thesis, 
contributions to such an optimization have been made within different areas of 
endometrial cancer treatment.  
In Paper II, we showed that the implementation of a risk-based algorithm to reduce the 
number of lymphadenectomies maintained the rate of detected metastasis and did not 
worsen survival for patients where the procedure was omitted. This shows that 
implementation of selective lymphadenectomy strategies is likely effective, and opens 
for tailored algorithms applying available biomarkers. In Paper I, a potential 
improvement to such a strategy was explored. High plasma levels of 17-
hydroxyprogesterone and 11-deoxycortisol were found to be associated with better 
survival, independent of the prognostic information gained from histologic typing and 
grading.  
In Paper III, focus was moved from survival to patient-reported outcomes. We 
determined what parameters of treatment had the greatest impact on the health-related 
quality of life of endometrial cancer survivors. A selective lymphadenectomy policy 
and the outcome of surgical staging determined the level of treatment in these patients. 
Outcomes differed negatively for patients receiving the most treatment. These results 
further stressed the need to reduce the treatment burden where it is not overtly 
necessary to improve function, symptoms, and quality of life. Taken together, this 
thesis highlights different areas where improvements to endometrial cancer treatment 
can be achieved and how patients may be affected by these changes. 
5.2.2 Circulating sex steroid levels are associated with aggressive 
tumor traits and poor survival 
We demonstrated associations with several circulating sex steroids and prognosis in 
endometrial cancer patients (Paper I). The steroids 17-hydroxyprogesterone, 11-
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deoxycortisol and androstenedione were all negatively associated with poor outcome. 
In the synthesis pathway, these hormones are direct metabolites of each other, without 
any significant rate-limiting step (Figure 7). Although only 17- hydroxyprogesterone 
and 11-deoxycortisol were prognostic independent of histology it is not unlikely that 
the properties of these hormones are connected and in essence represent the same 
biomarker mechanism. To our knowledge, these steroids are not previously implicated 
as biomarkers in cancer (with the possible exception of rare adrenal and ovarian 
hormone-producing tumors199). Androstenedione has been shown to be elevated in 
patients with type I tumors compared to type II31 and is associated with endometrial 
cancer risk in epidemiological studies21, 33, 38, 126, but the significance of varying levels 
for prognosis has not previously been reported. 17-hydroxyprogesterone is not to a 
large degree converted into androgens in humans under normal conditions, but is 
implied to be a marker for increased ovarian production of androgens in women with 
polycystic ovary syndrome200, 201. A previous study from our group, comparing steroid 
levels in 19 patients with good survival outcome to 19 patients with poor survival 
identified other related hormones as promising biomarkers, none of which were 
available in our “clinical” panel127. However, for both 17- hydroxyprogesterone and 
11-deoxycortisol, levels were higher for the good survival group, although not to the 
level of statistical significance. 
The role of these endogenous intermediate steroids in post-menopausal women is not 
well known. In our study, higher levels of several of the steroids were associated with 
expression of progesterone receptors, implying that a higher proportion of these tumors 
exhibit active estrogen signaling. Theoretically, levels of steroids could reflect a host 
phenotype that affects what subtype of endometrial cancer is most likely to develop. In 
endometrial cancer, such a connection is established between obesity and endometrioid 
tumors, via estrogen levels39, but we could not identify any correlation between obesity 
or fat distribution and the prognostic hormones. Thus, explanations of individual 
differences in steroid levels may be sought elsewhere, such as ovarian rest function 
(preoperatively) or overall adrenal function. There is also an emerging body of 
literature to support an important role for intracrinology in endometrial cancer, where 
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hormonal precursors can be locally metabolized (in/around the tumour) into active 
compounds (e.g. estrogens) that the tumor can utilize131, 132, 202, 203. Interestingly, in 
ovarian cancer, differences in the expression of stromal steroid metabolizing enzymes 
in different histological subtypes have been found204. Together with these findings, our 
study supports that other steroid hormones than the estrogens and progesterone can 
play important roles in endometrial tumorigenesis.   
We show that biomarker data to improve stratification of patients on basis of prognosis 
may already be available in the clinic. As blood samples are already collected as part 
of the general workup, no extra invasive procedures are required. Although the 
biomarker properties of the sex steroid precursors have not previously been recognized, 
other circulating biomarkers have been proposed. Most notably, CA-125 has gained 
much attention due to its role in the diagnosis and follow-up of gynecological 
malignancies and is included in multivariable risk scores to select patients for 
lymphadenectomy75, 76. Adding additional blood sample parameters to these tools 
would not increase invasiveness and could improve stratification performance. Low 
17-hydroxyprogesterone was associated with aggressive tumor characteristics within 
the endometrioid subgroup, pointing to a role in further stratifying low-risk patients 
with regard to treatment decisions. 
In our institution, ER and PR immunohistochemistry analyzes in preoperative biopsies 
(curettage/pipelle) are utilized together with MRI and PET/CT imaging to select 
patients for lymphadenectomy, and the implementation of blood biomarkers could be 
added to refine stratification. However, further validation of these blood steroids in an 
independent cohort and an assessment of its predictive value for lymph node metastasis 
detection is needed before implementation can be considered.  
5.2.3 Lymph node staging can be limited to certain risk groups 
Reducing morbidity induced by lymphadenectomy has been a long-standing goal in 
endometrial cancer treatment. Sentinel node biopsy is a promising alternative to 
traditional lymphadenectomy but requires procedure experience for best 
performance91. In Norway, low-risk endometrial cancer has generally been treated at 
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secondary centers, with the benefit of keeping treatment and follow-up connected and 
close to home. To implement a state-of-the-art sentinel node program would require 
tertiary hospitals to accommodate more patients, and a loss of hysterectomy volume 
would ensue at local hospitals. Alternatively, sentinel node biopsy could be avoided in 
patients at low risk (determined by biomarkers) and be performed in high-risk patients 
at tertiary centers. This would possibly maintain necessary competence at the different 
levels of the health care institutions.  
As discussed earlier, comprehensive removal of lymph nodes is not considered to 
improve survival82, 83, and although it has important bearings on adjuvant treatment, 
there may be room for strategies that choose observation in node-agnostic patients and 
treat when recurrence is overt. We demonstrated that when applying a selective 
lymphadenectomy algorithm based on imaging findings and preoperative assessment 
of ER/PR expression, some recurrences will occur among non-staged patients, but with 
comparable frequency to those that were node negative (Paper II). Other groups have 
published performance data on promising selective lymphadenectomy algorithms75, 76, 
205. Our study provides data from a population-based setting showing efficient 
reduction of lymphadenectomy procedures without reduction in survival, supporting a 
selective lymphadenectomy strategy. We are not aware of any other studies that 
compare survival outcomes between patients undergoing systematic versus selective 
lymphadenectomy. 
Current literature supports equal survival outcomes for lymphadenectomy and sentinel 
node techniques93, 206, 207. Although the risk for lymphedema and related complications 
is likely lower for sentinel node biopsy than for conventional lymphadenectomy89, the 
absolute difference is not known, especially when radiotherapy is not used208. Among 
patients in our study (Paper III), lymphedema was more strongly associated with 
chemotherapy than lymph node staging. This effect remained when grouping sentinel 
node biopsy with no lymphadenectomy and comparing to more comprehensive 
lymphadenectomy techniques.  Thus, the effect of lymphadenectomy on lymphedema 
when adjuvant radiotherapy is omitted may be overrated.  
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A randomized trial comparing sentinel node biopsy to selective lymphadenectomy is 
unlikely as surgical techniques are inherently difficult to randomize (due to factors such 
as demands for surgical experience, surgeon preferences, equipment availability etc.) 
and the necessary number of participants would have to be high as complications are 
rare. When considering results from paper II and III, selective lymphadenectomy 
appears to be a viable alternative to sentinel node biopsy, and perhaps more relevant 
for the Norwegian health care system and countries with similar demographics. 
MoMaTEC2 is expected to provide important data on implementing selective 
lymphadenectomy, compared to systematic lymphadenectomy, and also compared to 
centers performing sentinel node biopsy.  
5.2.4 Optimizing adjuvant treatment is vital to improve quality of 
life for endometrial cancer patients 
The gap between preclinical progress in uncovering new potential treatment 
mechanisms and clinically implemented therapy is huge. Few endometrial cancer 
patients are offered targeted treatment. Instead, traditional adjuvant treatment, either 
chemotherapy or radiotherapy, is standard of care to reduce the risk of recurrence. As 
the majority of these patients will survive without recurrence, any treatment-specific 
complications or morbidity will weigh negatively on the treatment decision scale. Also, 
many patients in stage III will recur in spite of adjuvant treatment101, 102, with new 
treatment morbidity added to the previous in a cumulative fashion, where the utility of 
the primary adjuvant treatment may be questioned. Recently, registration of patient-
reported outcomes has come more into focus. Data collected from PRO studies is useful 
to aid patients participating in treatment planning, to make physicians aware of new 
problems during follow-up and to direct research into areas where care can be 
improved150. We demonstrated how endometrial cancer patients rate their health-
related quality of life and treatment-related symptoms (Paper III). We showed that at 
the time of diagnosis, quality of life and emotional functioning is low, but improves 
after treatment. This can be explained by the baseline data being collected at a time 
point where the patients have recently been handed a cancer diagnosis, without final 
prognostic information and with possible bleeding symptoms/pain and apprehension 
towards surgery added. Similar results are found in other longitudinal studies160, 176, 177. 
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Availability of healthy-population reference data was a strength of this study and 
allowed for better interpretation of results. In contrast, a mean increase in self-reported 
lymphedema and peripheral neuropathy (tingling/numbness) can be seen after 
treatment. We found these changes to be concentrated to the group receiving the most 
treatment, and multivariate analysis implicated adjuvant chemotherapy as the most 
relevant factor. In addition to the above-mentioned symptoms, chemotherapy was 
associated with increased fatigue and decreased physical function. In patients not 
receiving adjuvant chemotherapy, we observed no differences in reported symptoms in 
relation to lymph node staging. As rates of adjuvant radiotherapy are very low in our 
population (due to national guidelines) we could not investigate its effect on these 
outcomes. MoMaTEC2 includes patients from international sites where the use of post-
operative radiation is routine and will hopefully provide further insight.   
There is likely potential in refining algorithms for adjuvant treatment. In paper II we 
found that in spite of a substantial increase of chemotherapy in the treatment of early-
stage high-risk patients, no differences in survival could be seen. A Danish multicenter 
study (ClinicalTrials.gov Identifier: NCT1244789) is prospectively investigating the 
randomization of these patients to adjuvant chemotherapy or observation, and results 
are expected in a couple of years. The most recent European guidelines are 
incorporating molecular subtypes in addition to uterine factors to assess the need for 
adjuvant therapy66, and studies are ongoing to determine if one can refrain from 
adjuvant treatment in the presence of POLE-mutations (the RAINBO-study) or other 
risk factor combinations (the PORTEC-4a-study). These studies are mainly performed 
at centers with liberal adjuvant radiotherapy policies and need to be complemented by 
similar studies performed in regions using primarily chemotherapy.  
5.2.5 Obstacles for the clinical implementation of biomarkers 
In the search to improve patient treatment, preclinical research is a vital foundation. 
The establishment of the Bergen biobank has led to a formidable opportunity to 
discover new biomarkers such as ER/PR expression or circulating steroid hormones. 
Further development of these markers into clinical tools is however cumbersome. 
MoMaTEC2 is assessing the implementation of ER and PR immunohistochemically 
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assessed in preoperative biopsies as biomarkers into clinical practice and will provide 
important information on this process. Combining several biomarkers across 
disciplines is likely necessary to achieve good enough performance to add new value 
to clinical decisions. In the event that an optimal algorithm emerges, there are further 
challenges before implementation can be realized. Invasiveness, cost and reliability can 
and should be incorporated when nominating new biomarkers and can affect how the 
biomarker or algorithm performs in the clinic209. In addition, real-world challenges 
such as obesity or frailty can alter treatment decisions based on biomarkers210-213. In 
paper II, we found that around 50% of low-and intermediate risk patients that 
underwent lymphadenectomy did not meet algorithm criteria but were staged at the 
surgeon’s discretion. Interestingly, none of these patients had positive lymph nodes. 
This can be interpreted in two ways; either the algorithm has potential for an even more 
discriminative selection, or the clinical reality does not allow for pure algorithmic 
decision making. Likely the truth is a place in between, which highlights the 
importance of evaluation of implementation in real-world conditions.  
 68
6. Conclusions 
Paper I: Blood steroids have prognostic properties in endometrial cancer. They provide 
preoperative information independent of the histological subtype and grade and are 
easily available biomarkers. 
Paper II: A selective lymphadenectomy algorithm based on preoperative histological 
and radiological biomarkers reduced the rate of lymphadenectomy from approximately 
80% to 50%, while maintaining good survival.  
Paper II: Omitting adjuvant radiotherapy and implementing an adjuvant chemotherapy 
alone policy was followed by maintained survival for the whole cohort, with improved 
survival for FIGO stage III patients. Despite a substantial increase in administration of 
adjuvant chemotherapy in early-stage high-risk patients, there was no gain in 
recurrence-free survival for this group. 
Paper III: Overall quality of life and function is good in endometrial cancer survivors, 
however mean increases in lymphedema and neuropathy symptoms are reported. 
Patients receiving adjuvant chemotherapy perceive substantially increased neuropathy 
at years one and two, and increased lymphedema at year one. Patients that undergo 
lymph node staging but do not receive adjuvant therapy do not differ from patients that 
are unstaged regarding PRO at one and two years after treatment. 
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7. Future aspects  
Improving endometrial cancer treatment is vital, and in this pursuit two main obstacles 
can be identified. A lack of effective treatment options for advanced disease and 
recurrence, and over-treatment or too indiscriminative treatment for presumably 
localized disease. To improve survival for advanced stage endometrial cancer, it is 
likely we need new therapeutic agents and better tailoring of treatment to individual 
patients and tumors. To reduce the treatment burden for patients with early-stage 
disease we need to better identify those at risk for recurrence and stratify patients by 
effect of adjuvant treatment. Chemotherapy and/or radiotherapy is still likely to play a 
major role in endometrial cancer treatment in the years to come, and predictive 
biomarkers to assess the potential effect of these treatments are of vital importance. A 
better mapping of quality of life and PRO effects with regard to reductions in treatment 
burden is needed, as well as direct comparisons between treatment options with high-
quality PRO registration, to ensure that treatment-related morbidity is minimized. 
More specifically, to push forward from the results presented in this thesis the 
following research is needed. 
Accurate measurement of circulating sex steroids is available in the clinic and 
prognostic in endometrial cancer. The prognostic potential needs to be validated in an 
independent cohort. Secondly, the best use of this biomarker needs to be determined, 
likely through combination with other prognostic biomarkers. Also, the predictive 
capabilities of circulating steroids regarding hormonal and fertility-sparing treatment 
should be explored. 
Sentinel node biopsy is on the rise, and is likely to replace lymphadenectomy in the 
staging of endometrial cancer. High-quality evidence of improvements in long-term 
quality of life and treatment-related symptoms are needed to motivate this transition. 
Selective sentinel node algorithms can be an alternative to reduce cost, maintain 
treatment logistics and avoid transition of patient volumes from secondary to tertiary 
centers. An RCT to compare a selective sentinel node strategy to the current state-of-
the-art sentinel node (for all) strategy should be conducted. Observational studies 
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comparing these strategies between centers, such as MoMaTEC2, will provide 
important data in the absence of an RCT. 
The potential of reducing chemotherapy in early-stage high-risk patients needs to be 
further explored. Identification of new biomarkers and better staging could lead to 
better identification of patients truly at risk for recurrence. An intensified search for 
biomarkers that predict effects on recurrence by platinum-based chemotherapy could 
isolate the group that has a survival effect to balance out morbidity and indicate where 
other therapies such as immune therapy should be tried out. Most pressingly, an 
assessment of the TCGA molecular classes with regard to chemotherapy effectiveness 
needs to be conducted. 
The results of Paper III point to important adverse effects of chemotherapy present over 
years. Clinical PRO measurement can be implemented in patient follow-up and should 
be monitored and analyzed to assess how this may affect self-perceived quality-of-life 
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• A clinically available panel of steroid hormones was analyzed in 100 endometrial cancer patient plasma samples.
• Low 17OH-progesterone, 11-deoxycortisol and androstenedione associated to aggressive tumor characteristics.
• 17OH-progesterone and 11-deoxycortisol predicted poor survival independent of preoperative risk classification.
• Genes associated with estrogen signaling were enriched in tumors of patients with high steroid levels.
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Objective. Blood-based biomarkers are attractive due to ease of sampling and standardized measurement
technology, reducing obstacles to clinical implementation. The objective of this study was to evaluate a clinically
available method of steroid hormone measurement for its prognostic potential in endometrial cancer.
Methods. We quantified seven steroid hormones by liquid chromatography-tandem mass spectrometry in
100 endometrial cancer patients from a prospective cohort. Abdominal fat distribution was assessed from ab-
dominal computed tomography (CT) scans. Steroid hormone levels were compared to clinical characteristics,
fat distribution and gene expression in primary tumor samples.
Results. Low levels of 17OH-progesterone, 11-deoxycortisol and androstenedione were associated with ag-
gressive tumor characteristics and poor disease specific survival (p = .003, p = .001 and p = .02 respectively).
Adjusting for preoperative risk based on histological type and grade, low 17OH-progesterone and 11-
deoxycortisol independently predicted poor outcome with hazard ratios of 2.69 (p = .033, 95%CI: 1.09–6.68)
and 3.40 (p= .020, 1.21–9.51), respectively. Tumors frompatients with low steroid level displayed increased ex-
pression of genes related tomitosis and cell cycle progression,whereas high steroid levelwas associatedwith up-
regulated estrogen signaling and genes associated with inflammation. Estrone and estradiol correlated to
abdominal fat volume in all compartments (total, visceral, subcutaneous, p b .001 for all), but not to the visceral
fat proportion. Patients with higher levels of circulating estrogens had increased expression of estrogen signaling
related genes.
Conclusion. Low levels of certain endogenous steroids are associated with aggressive tumor traits and poor
survival and may provide preoperative information independent of histological biomarkers already in use.










Endometrial cancer is the most common gynecologic malignancy in
industrialized countries, and the incidence is rising [1,2]. Prognosis is
generally good due to early detection and predominance of low-grade
endometrioid histology, while high risk disease, comprising non-
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endometrioid tumors and grade 3 endometrioid disease, carries mark-
edly poorer prognosis [3]. However, due to the much higher incidence
of endometrioid tumors, the absolute number of recurrences is signifi-
cant also in this group [4,5]. Identification of biomarkers that can aid se-
lection of patients for optimal surgical and adjuvant treatment
independent of histological parameters is vital to improve outcome.
Several prognostic and diagnostic biomarkers have been identified
in tumor biopsies [6] but few have so far been implemented in the clinic
to improve treatment for endometrial cancer patients. In some institu-
tions, hormone receptor status is assessed as a supplement to traditional
histological evaluation, and the design and validation of combined mo-
lecular classifiers is ongoing, driven by initiatives like ProMisE and
TransPORTEC [7,8]. Compared to these tissue-based biomarkers,
blood-based biomarkers do not require a biopsy and thus represent
less invasive clinical tools to predict prognosis and to plan patient treat-
ment, and pose little technical challenge in implementation. Several
blood biomarkers have already been investigated in endometrial cancer,
e.g. Ca-125 is shown to have prognostic value and identifies advanced
disease and lymph node metastasis [9]. Other blood based biomarkers
such as HE4, GDF-15, and DJ-1 have also been found promising
[10–12], but lack validation in a prospective implementation setting.
Although the influence of hormone receptor expression on progno-
sis has been extensively researched [13–15], few studies have evaluated
the importance of endogenous steroid levels other than estrogen me-
tabolites [16–18], and to some extent androstenedione (A4) and testos-
terone (T) [19–22]. These studies have mostly focused on risk of
acquiring disease rather than biomarker properties.We have previously
demonstrated differences in levels of several steroids in blood samples
in a matched patient series of long vs short surviving endometrial can-
cer patients [23].
For clinical implementation of a blood-based test, easy and reliable
methods for detection are vital. In this study, wemeasured levels of cir-
culating steroids in endometrial cancer patients by Liquid Chromatogra-
phy Tandem Mass Spectrometry (LC-MS/MS). We selected a panel of
relevant steroids related to sex hormone synthesis, used clinically for di-
agnosing endocrinological disorders. This panel was supplemented
with measurements of estrone (E1) and estradiol (E2) using a novel
sensitive protocol, properly quantifying postmenopausal estrogen
levels in plasma. We explored the relationship to body mass, fat distri-
bution variables, associations to clinicopathologic characteristics of the
disease and patient survival. Finally, we analyzed differences in gene ex-
pression to identify links between host steroid levels and tumor biology.
The aim of the study was to evaluate the prognostic value of circulating
steroid levels in endometrial cancer patients.
2. Methods
2.1. Ethical considerations
The study has been approved according to Norwegian legislation by
the Western Regional Committee for medical and health Research
Ethics (REK 2009/2315, REK 2014/1907, REK 2018/594, REK 2019/
1020). All included patients gave written informed consent.
2.2. Patient series
A population based endometrial cancer patient series was prospec-
tively collected from 2001 to 2015 in Hordaland County (Norway). Pa-
tients were surgically staged according to the International Federation
of Gynecology and Obstetrics (FIGO) 2009 criteria. Clinical and patho-
logical variables including age at diagnosis, FIGO stage, histological sub-
type, grade, and follow up data were collected by review of medical
records as previously described [24]. From this series, 100 postmeno-
pausal patients included from2009 to 2013were selected to reflect clin-
icopathological characteristics of the whole prospective cohort
(Supplementary Table S1). Median follow-up was 67 months (range
1–116) and minimum 60 months for all survivors. During follow-up,
20 cancer specific deaths were registered, and six patients were cen-
sored due to non-cancer deaths.
Immunohistochemical staining and evaluation of hormone recep-
tors has been performed previously for this cohort [14,25–27]. Expres-
sion data for estrogen receptor (ERα), progesterone receptor (PR),
Androgen Receptor (AR) and Glucocorticoid Receptor (GR) was avail-
able for 93, 94, 87 and 76 patients, respectively.
2.3. Steroid analysis
EDTA-blood was obtained before primary surgery, and prior to ad-
ministration of any anesthetic medications, from 100 patients with en-
dometrial cancer. The blood samples were centrifuged at 1600g for
15min and the plasma was stored at −80°C. Median storage time be-
fore analysis was 66 months (range 47–104 months). Steroids were
measured at the Hormone Laboratory, Haukeland University Hospital,
Bergen Norway, using the routinely applied LC-MS/MS method for
plasma analysis of 17-hydroxyprogesterone (17-OHP), 11-
deoxycortisol (11-DOC), cortisol (CORT), androstenedione (A4) and
testosterone (T) previously described [28]. Briefly, isotope-labeled in-
ternal standards were added to 85 μL plasma and processed by liquid-
liquid extraction. The steroids were resolved by ultra-high-pressure
chromatography on a reverse phase column, and detected by triple-
quadrupole mass spectrometry. For analysis of estrone (E1) and estra-
diol (E2), a recently developed optimized protocol was used, with limits
of quantification of 0.3 pmol/L and 0.6 pmol/L respectively, thus
allowing quantificationwithin the postmenopausal ranges of these hor-
mones [29]. Both LC-MS/MS methods are accredited according to ISO
15189:2012.
17-OHP, CORT, A4 and T were measured for all 100 patients. For 11-
DOC, 98 patient samples were measured, two samples were not ana-
lyzed due to technical difficulties. For six patients plasma level of 17-
OHP was below the detectable threshold of 0.2 nmol/L. For one of
these patients A4 and T were also below the threshold (0.2 nmol/L
and 0.1 nmol/L respectively). These levels were set to the lowest detect-
able value for each steroid and included in non-parametric analyses.
Plasma level of progesterone was measured, but was below measure-
ment threshold for all patients (b0.5 nmol/L) and was subsequently
excluded.
E1 and E2 plasma levels were obtained from 96 patients. No values
were below analytic range, measurements above the analytic range
(above the highest calibrator, n=7 for E1 and n= 3 for E2) were ana-
lyzed as ranked values in non-parametric analysis.
2.4. Estimation of fat distribution from CT scans
Complete diagnostic abdominal contrast-enhanced Computer To-
mography (CT) scans were available for 83 patients and evaluated for
assessment of abdominal fat volumes as previously described [23]. The
software iNtuition (TeraRecon Inc.; San Mateo, CA, USA), was used to
analyze cross-sectional CT images from the upper right diaphragm to
L5/S1-level, segmenting pixels with values for Hounsfield units (HU)
corresponding to adipose tissue (−195 to −45 HU). If necessary, the
correct segmentation between visceral and subcutaneous fat compart-
ments was adjusted by the operator. Both the visceral abdominal fat
volume (VAV; cm3) and the subcutaneous abdominal fat volumes
(SAV; cm3) were estimated, and the sum of these was the total abdom-
inal fat volume (TAV; cm3). The percentage of visceral fat was calculated
([VAV/TAV] x 100; VAV%). In addition, waist circumference was mea-
sured in an axial image at the L3/L4 level.
2.5. Gene expression analysis
Gene expression data from tumor tissue was available for all in-
cluded patients and has been published previously [25]. Briefly, RNA
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was extracted from fresh frozen tissue using the RNeasy Mini Kit
(Qiagen, Germany), hybridized to Agilent Whole Human Genome Mi-
croarray 44 k (Cat. No. G4112F), scanned and normalized as previously
described. We limited mRNA expression analysis to the endometrioid
subgroup (n=77). Associations between blood steroid levels and acti-
vated signaling pathways in tumor tissue were investigated using J-
express 2012 software (Molmine, Bergen). Differentially expressed
genes were identified by running Significance Analysis of Microarrays
(SAM) method. Gene Set Enrichment Analysis (GSEA) was performed
in J-express with Hallmark gene-sets from MSigDB (Broad Institute,
US) [30].
2.6. Statistical analysis
Statistical analyseswere performed using the software package SPSS
25.0 (SPSS Inc., Chicago, IL). Probability of b0.05 was defined as statisti-
cally significant and all tests were two sided. Plasma concentrations
were analyzed with non-parametric tests, i. e. Mann-Whitney U test
for independent samples. Correlations were assessed by Spearman's
rank correlation (ρ = rho). Cut-off for survival analysis grouping was
set applying Receiver Operating Characteristic (ROC) analysis for dis-
ease specific death during follow-up. Area under curve (AUC) N0.6
was set as acceptable limit for further analysis and cut-off was deter-
mined using highest Youden Index (sensitivity + specificity-1) (Sup-
plementary Fig. S1). Univariate survival analyses were performed
using the Kaplan-Meier (product-limit) method. Entry date was the
date of primary surgery, and time to death due to endometrial cancer
was the endpoint (disease specific survival). Survival between groups
was compared using the log-rank test (Mantel-Cox). Multivariate sur-
vival analysis was carried out by the Cox proportional hazards method,
with single step enter.
3. Results
3.1. Low plasma levels of 17-OHP, 11-DOC and A4 associatewith aggressive
phenotype
Employing two clinically available panels of steroid hormone analy-
ses, we measured levels of seven relevant steroid hormones and inter-
mediates using LC-MS/MS (Fig. 1A). Because of the known marked
diurnal variation of CORT, it was excluded from further analysis. The re-
maining six steroid hormones had distributions as shown in Fig. 1B. An-
alyzed steroidswere generally significantly positively correlated to each
other, ranging from moderate to strong (Spearman's rho: 0.34–0.92).
11-DOC however, did not correlate significantly to any of the estrogens.
There was no correlation between storage time and level of any of the
hormones (Supplementary Table S2). The distribution of hormone
levels in our cohort was comparable to previously published data on
LC-MS/MS reference intervals of steroids in healthy postmenopausal
women [31] (Supplementary Fig. S2). Plasma levels of steroids were in-
vestigated for any associations with clinicopathological features of en-
dometrial cancer (Table 1). Overall, lower median levels of steroid
hormones associatedwithmore aggressive endometrial cancers. Specif-
ically, low 17-OHP was significantly associated with preoperative high-
risk classification (grade 3 endometrioid or non-endometrioid histol-
ogy, p = .032), post-operative non-endometrioid histology, (p =
.009) andmetastatic lymph nodes (p= .046) (Table 1). Low 11-DOC as-
sociated with advanced FIGO stage (III-IV, p = .02) and non-
endometrioid histology (p = .002). Low A4 associated with non-
endometrioid histology (p = .023). T did not associate with any of the
investigated tumor characteristics. For E1 and E2, low levels were asso-
ciated with high histologic grade (grade 3 compared to 1–2, p≤=0.015)
in the surgical specimen.
When restricting the analyses to patients with endometrioid histol-
ogy (n=77), low 17-OHP was associated with advanced FIGO stage (p
= .014), lymph node metastasis (p = .029) and deep myometrial
infiltration (p = .028). Among the other hormones, low A4 associated
with advanced FIGO stage (p = .028) and low T with lymph node me-
tastases (p = .025) (Supplementary Table S3). No significant associa-
tion was found for 11-DOC in the endometrioid endometrial cancer
subgroup.
3.2. Low levels of 17-OHP, 11-DOC and A4 predict poor survival in endome-
trial cancer
To analyze if any of the plasma steroids had prognostic value, opti-
mal plasma level cut-offs were defined by ROC-curve analysis (Supple-
mentary Fig. S1). Plasma levels of T, E1 or E2 did not predict disease
specific death (not shown). In univariate analysis, low preoperative
levels of 17-OHP, 11-DOC and A4 were associated with poor disease
specific survival (Fig. 2). In separate cox regression models for 17-
OHP, 11-DOC and A4, including the hormone and preoperative risk clas-
sification (based on histological type and grade), 17-OHP and 11-DOC
were still independent prognostic factors with hazard ratios of 2.69 (p
= .033, 95% CI: 1.09–6.68) and 3.40 (p = .020, 95% CI 1.21–9.51), re-
spectively (Table 2). The adjusted hazard ratio of A4 did not reach statis-
tical significance (p = .08).
3.3. High E1 and E2 levels are associated with overweight and high hor-
mone receptor expression in primary tumors
E1 and E2 were positively correlated with BMI, waist circumference,
TAV, SAV and VAV (ρ=0.46–0.63) (Table 3). T had aweak positive cor-
relation with BMI and subcutaneous abdominal fat volume (ρ = 0.23
and ρ=0.22, p b .05 for both). None of the other steroidswas associated
with body fat variables.
We found plasma steroid levels to be higher in hormone receptor
positive primary tumors (Supplementary Table S4). In PR positive tu-
mors, patient plasma levels of E1 and E2 were significantly higher (p
= .003 and p b .001 respectively) as well as levels of 17-OHP (p =
Fig. 1. A) Measured steroid hormones (in gray) and their positions and relations in the
steroid synthesis. B) Distribution of plasma levels of the measured steroid hormones in
the study cohort. Boxes represent median values with interquartile ranges, whiskers
represent non-outlying max and min values (b1.5 times the interquartile range). The
cutoff for survival analysis marked with x. One extreme outlier for E2 (1189 pmol/L) is
not displayed.
402 D. Forsse et al. / Gynecologic Oncology 156 (2020) 400–406
.043) and T (p= .035). Patientswith AR positive tumors also had higher
levels of E1 and E2 (p = .029 and p = .020). In line with these results,
mean values of steroid levels were higher in ER-positive tumors than
in ER-negative tumors, but not to the level of statistical significance.
3.4. Differences in plasma levels of steroids are reflected in tumormRNA ex-
pression patterns
Gene set expression analysis within the endometrioid subgroup re-
vealed gene sets related to E2F targets, Myc targets and cell cycle/mi-
totic events to be enriched in patients with low levels of 17-OHP or
11-DOC (Table 4). In patients with high levels of steroids, genes corre-
sponding to gene sets for inflammatory pathways and estrogen signal-
ing were enriched. Overall, differences in gene expression were more
pronounced when separating groups by level of 17-OHP, than for any
of the other steroids.
For patients with high plasma estrogen levels (top tertile vs bottom
tertile) several genes linked to estrogen signaling were differentially
expressed (fold change N2), including PGR (encoding progesterone re-
ceptor) (Supplementary Table S6). GSEA identified two estrogen re-
sponse gene sets indicating increased ESR1 induced signaling among
the top ranked gene sets for high levels of E1 and E2 (Table 4).
4. Discussion
Identification of new cancer biomarkers in blood samples is attrac-
tive due to ease of sampling and readily available analysis methods,
yet few blood-based biomarkers are validated and in clinical use. We
here investigate if a standard method for measuring levels of selected
steroids, implemented at our institution, can detect variations in steroid
levels in subgroups of endometrial cancer patients, and if these steroids
have prognostic value as preoperative biomarkers. This is, to our
Fig. 2.Univariate survival analysis of endometrial cancer patients grouped by level of A) 17OH-Progesterone (17-OHP) B)11-Deoxycortisol (11-DOC) C) Androstenedione (A4). Cutoffs set
by ROC-curve analysis for best prediction of survival at 5 years.
Table 1
Clinical-pathological characteristics related to median steroid hormone levels (10–90 percentile) in endometrial cancer patients. Statistically significant p-values (b.05) in bold.
17OH-Progesterone 11-Deoxycortisol Androstenedione Testosterone Estrone Estradiol
n = 100 n = 98 n = 100 n = 100 n = 96 n = 96
nmol/L p nmol/L p nmol/L p nmol/L p pmol/L p pmol/L p
Age 0.17 0.10 0.001 0.59 0.81 0.93
b66 (n = 41) 0.6 (0.2–1.9) 0.8 (0.3–1.7) 2.0 (1.0–4.1) 0.7 (0.4–1.6) 106 (43–217) 20 (5–128)
≥66 (n = 59) 0.5 (0.2–1.0) 0.6 (0.3–1.4) 1.4 (0.9–2.6) 0.7 (0.3–1.2) 89 (47–220) 22 (8–51)
Preoperative riska 0.032 0.048 0.20 0.34 0.76 0.31
Low (n = 57) 0.6 (0.2–1.3) 0.7 (0.3–1.7) 1.7 (0.9–3.6) 0.8 (0.4–1.5) 106 (44–212) 22 (8–65)
High (n = 43) 0.5 (0.2–1.0) 0.6 (0.3–1.3) 1.4 (0.9–3.1) 0.6 (0.3–1.5) 84 (44–238) 17 (5–54)
FIGO-09 stage 0.10 0.02 0.06 0.11 0.65 0.68
I-II (n = 87) 0.6 (0.3–1.2) 0.7 (0.3–1.6) 1.6 (0.9–3.6) 0.7 (0.4–1.5) 89 (44–216) 20 (8–61)
III-IV (n = 13) 0.4 (0.2–1.0) 0.6 (0.1–1.1) 1.3 (0.9–2.0) 0.5 (0.2–1.1) 108 (45–226) 22 (6–108)
Histologic typeb 0.009 0.002 0.023 0.08 0.41 0.21
EEC (n = 77) 0.6 (0.2–1.2) 0.8 (0.3–1.6) 1.6 (0.9–3.6) 0.8 (0.4–1.5) 106 (45–216) 22 (8–65)
Serous (n = 14) 0.5 (0.2–1.4) 0.6 (0.1–1.0) 1.4 (0.8–3.0) 0.8 (0.4–1.2) 97 (45–236) 20 (7–98)
Others (n = 9)c 0.4 (0.2–0.5) 0.4 (0.3–1.0) 1.2 (0.7–1.7) 0.5 (0.2–0.6) 65 (31–86) 10 (6–19)
Histologic graded 0.35 0.78 0.19 0.08 0.012 0.015
Grade 1/2 (n = 56) 0.6 (0.2–1.8) 0.8 (0.3–1.6) 1.7 (0.9–3.9) 0.8 (0.4–1.6) 108 (50–243) 24 (10–104)
Grade 3 (n = 20) 0.6 (0.2–1.1) 0.9 (0.3–1.7) 1.6 (0.8–2.8) 0.7 (0.2–1.5) 72 (41–134) 15 (5–41)
Lymph node status 0.046 0.15 0.14 0.08 0.62 0.49
Negative (n = 79) 0.5 (0.2–1.4) 0.7 (0.3–1.5) 1.6 (0.9–3.6) 0.7 (0.4–1.5) 89 (45–210) 20 (9–59)
Positive (n = 8) 0.4 (0.2–0.5) 0.6 (0.2–0.8) 1.3 (1.0–1.6) 0.5 (0.3–0.6) 81 (50–108) 19 (6–23)
Myometrial infiltr. 0.38 0.22 0.07 0.29 0.10 0.11
b50% (n = 53) 0.6 (0.2–1.1) 0.8 (0.3–1.7) 1.7 (1.0–3.8) 0.7 (0.4–1.6) 94 (54–257) 22 (10−122)
≥50% (n = 47) 0.5 (0.2–1.2) 0.7 (0.3–1.3) 1.5 (0.9–3.3) 0.7 (0.3–1.4) 83 (36–203) 17 (6–52)
Statistical comparisons are done with Mann-Whitney U test for independent samples. EEC: Endometrioid endometrial cancer.
a Based on preoperative biopsy/curettage; low if EEC grade 1–2, high if grade 3 or non-endometroid histology.
b P-values for Endometroid vs. All non-endometroid histologies.
c Clear cell (n = 2) Carcinosarcoma (n = 6) Neuroendocrine (n = 1).
d Only endometroid tumors (n = 77) (missing grade information for n = 1).
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knowledge, the first study indicating prognostic value of circulating
levels of 17-OHP, 11-DOC and A4 in endometrial cancer.
Currently, treatment decisions for endometrial cancer are based on a
preoperative histopathological evaluation of tumor biopsies in combi-
nation with available preoperative imaging. However, risk stratification
based on preoperative information is not always accurate, and can re-
sult in recurrent disease in putative low-risk patients. A recent meta-
analysis found overall pooled agreement in 67%, between preoperative
and postoperative histology [32], finding the highest disagreement for
endometrioid grade 2 tumors, where omitting lymphadenectomy at
surgery is an option. For imaging, size is generally the limiting factor,
resulting in low sensitivity when lesions are small. For lymph nodeme-
tastasis PET/CT is regarded as the optimal radiological modality, but still
with limitations in sensitivity (around 70%) [33]. Sentinel node biopsy is
emerging as clinical standard in many centres, with sensitivity for me-
tastases at 96% [34], but prolongs surgery in low-risk cases, is not avail-
able in all institutions and not applicable in cases where hysterectomy
might be avoided, for example in the morbidly obese. In this context, a
blood sample providing additional information could be valuable and
is easy to add to existing algorithms. It is not unlikely that, as in ongoing
initiatives [7,8], a panel combining severalmarkers will provide a useful
clinical tool in the future. Our findings point to a role for several steroids
as preoperative biomarkers in endometrial cancer, either alone or in
combination with other biomarkers.
In our study, low levels of 17-OHP, 11-DOC and A4 predicted poor
survival, 17-OHP and 11-DOC independently of the preoperative histo-
logical risk assessment, implying that their quantification could provide
additional information to clinical algorithms currently in use. We ob-
served an overall association between low levels of these steroids and
aggressive characteristics of endometrial cancer. Interestingly, we
found that low 17-OHP associates significantly with lymph nodemetas-
tasis and deepmyometrial infiltration in the endometrial subgroup. This
might point to a potential role for this steroid in selecting patients for
lymphadenectomy or adjuvant treatment also for patients with pre-
sumed low-risk disease, which should be addressed in future research.
17-OHP, 11-DOC and A4 are all steroid hormones with sex-steroid
related activity. 17-OHP is a weak gestagen, A4 is its derivative with an-
drogenic properties and the precursor of testosterone and estrogen
compounds. 11-DOC is another derivative of 17-OHP with glucocorti-
coid properties. As circulating hormones, they contribute to the
environment in which the tumor is evolving and may affect the tumor
through activation of the respective hormone receptors [14,26,27,35].
In addition, local intracrinological activity in the tumor or surrounding
stromamay contribute to transforming these compounds intomore po-
tent signals [23,36].
Gene expression analysis and hormone receptor status in the tumor
samples point toward more estrogen associated signaling in patients
with higher levels of 17-OHP, 11-DOC and A4. Although unopposed es-
trogen is an ascertained major risk factor for endometrial cancer, high
estrogen signaling in the tumor, reflected in PR expression in endome-
trial tumors is associated with high differentiation and less aggressive-
ness [14,37,38]. Our study contributes to this understanding by
implying a link between the host endocrine environment and
prognostically favorable gene- and protein expression patterns in the
tumor.
Although obesity is strongly connected to estrogen levels and conse-
quently to the development of endometrial cancer (recently reviewed
in [39]), we found no correlation between the levels of 17-OHP, 11-
DOC or A4 and total body fat or fat distribution. However, the observa-
tion that BMI and CT-generated fat distribution variables are linked to
estrogen levels supports the current understanding of the obesity-
estrogen pathogenesis pathway of endometrial cancer [20,40]. A recent
study showed that SAV (subcutaneous fat)was themost important con-
tributor to plasma estrogen level [41], whereas visceral fat volume per-
centage (of total fat volume) has been shown by our group to be
associated with poor prognosis in endometrial cancer [42]. In our previ-
ous study, visceral fat percentage alone correlated to high estrogen
levels in patients with non-endometrial histology [23]. This finding
was not confirmed by the present study, which we believe might be
due to differences in patient cohorts. Estrogen production is only one
of several mechanisms through which fatty tissue affects endometrial
cancer pathogenesis [39], and exploring the impact of other factors
such as inflammatory activity and insulin metabolism in relation to an-
atomical fat distribution may provide better insight.
Due to cyclic variations, assessment of hormonal levels in pre-and
perimenopausal women are challenging. In the present study, we
have focused on postmenopausal women, constituting the majority of
endometrial cancer patients. With careful planning and stratification,
future trials could explore hormonal variation, fat distribution and en-
dometrial cancer prognosis in younger women to complete the picture.
Table 2
Survival analysis by Cox proportional hazards regression model.
Variable Unadjusted HR 95% CI p Adjusted HRa 95% CI p
High preoperative riskb 5.12 1.96–13.35 0.001
Lowc 17OH-Progesterone 3.51 1.43–8.60 0.006 2.69 1.09–6.68 0.033
Lowc 11-Deoxycortisol 4.49 1.63–12.38 0.004 3.40 1.21–9.51 0.020
Lowc Androstenedione 3.86 1.13–13.16 0.031 2.98 0.87–10.26 0.080
HR: hazard ratio, CI: confidence interval.
a Adjusted for preoperative risk.
b Preoperative risk high: grade 3 endometroid and all non-endometroid histologies.
c Cutoff set by ROC-curve analysis for prediction of 5-year survival.
Table 3
Correlations (Spearmans rank coefficient, ρ) between plasma levels of steroids and measurements of body fat and fat distribution.
17OH-Progesterone 11-Deoxycortisol Androstenedione Testosterone Estrone Estradiol
Body Mass Index 0.04 0.03 0.11 0.23⁎ 0.53⁎⁎ 0.63⁎⁎
Waist circumference −0.02 −0.04 0.06 0.18 0.50⁎⁎ 0.59⁎⁎
TAV (CT) 0.12 0.08 0.12 0.19 0.52⁎⁎ 0.61⁎⁎
SAV (CT) 0.12 0.08 0.16 0.22⁎ 0.51⁎⁎ 0.60⁎⁎
VAV (CT) 0.03 0.05 0.03 0.10 0.46⁎⁎ 0.54⁎⁎
VAV% 0.08 −0.01 −0.16 −0.14 −0.01 0.01
TAV: total abdominal fat volume, SAV: subcutaneous abdominal fat volume, VAV: visceral abdominal fat volume, VAV%: VAV/TAV, CT: obtained from CT image.
⁎ Correlation significant at the 0.05 level.
⁎⁎ Correlation significant at the 0.001 level.
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In addition, the relevance of endogenous hormone levels for the re-
sponse to hormonal treatment in endometrial cancer should be ex-
plored. For young obese women with endometrial cancer, often
presenting with low grade endometrioid endometrial cancers, results
from such research could lead to important improvements in current
treatment strategies.
We have employed LC-MS/MS protocols in clinical use to evaluate
steroid hormones in endometrial cancer patients, providing reliable
and accurate estimates of plasma levels. The samples have been
stored in our biobank in −80 degrees for 4 to 9 years prior to analy-
sis, making possible degradation an issue in the interpretation of the
results. Definitive data supporting reliability of steroid levels after
long-time storage is lacking. Studies attempting to address this ques-
tion have generally found small changes in levels over time, with
close to unchanged ranking of samples [43,44]. Analysis of our data
does not demonstrate any obvious changes due to storage time, but
ultimately the retrospective nature of the study makes complete ex-
clusion of this bias difficult. To validate our results a prospective in-
clusion of patients with standardized sampling and immediate
analysis is needed.
In conclusion, our study shows that preoperative endogenous ste-
roid levels are associatedwith outcome in endometrial cancer. Ourfind-
ings imply that endogenous steroids are not merely mirroring
circulating estrogen levels or obesity, and provide additional prognostic
information to preoperative tumor histologic assessment. Measuring
circulating steroid hormones is easy and low-cost and can potentially
be included in treatment algorithms, however the proper cutoffs and
applications need to be further elucidated and validated in future trials.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2019.11.123.
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Supplementary Fig. S1. Receiver operating characteristic curve of steroid hormone for 
prediction of disease-specific death within 5 years of follow up. Optimal cutoffs (X) are 
calculated by the Youden Index
Supplementary Fig. S2. Comparison of plasma steroid levels in study cohort with a LC-
MS/MS reference cohort [31]. Boxes represent median values with interquartile ranges, 
whiskers represent non-outlying max and min values (<1.5 times the interquartile range).
AUC: 0.66 [0.53-0.80] 
X
AUC: 0.73 [0.62-0.84] 
X



























































































































17OH-Progesterone 11-Deoxycortisol Androstenedione Testosterone Cortisol










Age    0.19 (Mann-Whitney U) 
Median [range] 69[44] 66[69]  
Parity   0.98 (Chi-square) 
0 16 % 16 %  
≥1 84 % 83 %  
BMI   0.54 (t-test) 
Mean (SD) 28 (5.5) 28(6.8)  
Primary treatment   0.04 (Chi-square) 
Hysterectomy 100 % 94 %  
Curettage only 0 % 5 %  
Adjuvant treatment   0.26 (Chi-square) 
None 70 % 68 %  
Chemotherapy 26 % 20 %  
        Radiotherapy 3 % 8 %  
Chemoradiotherapy 0 % 1 %  
Hormonal therapy 1 % 2 %  
5-year survival 80 % 81 % 
0.87 (Mantel-Cox log-
rank) 
FIGO-09 stage   0.44 (Chi-square) 
I 77 % 74 %  
II 10 % 8 %  
III 10 % 12 %  
IV 3 % 7 %  
Histologic type   0.89 (Chi-square) 
Endometrioid 77 % 78 %  
Non-endometrioid 23 % 22 %  
Histologic grade   0.11 (Chi-square) 
Grade 1/2  56 % 63 %  
Grade 3 43 % 34 %  
Lymph node status   0.43 (Chi-square) 
Negative  79 % 63 %  
Positive 8 % 9 %  
No LA 13 % 28 %  
Myometrial infiltration   0.06 (Chi-square) 
<50%  53 % 59 %  
≥50% 47 % 35 %   
Percentages not accounted for represent missing values  
LA: Lymphadenectomy, EEC: Endometrioid endometrial cancer 
 
  
Supplementary Table S2. Correlations (spearmans rank coefficient, ρ) between levels of steroid hormones 








Testosterone Estrone Estradiol 
17OH-
Progesterone  0.72** 0.60** 0.54** 0.40** 0.43** 
11-Deoxycortisol   0.59** 0.34** 0.16 0.15 
Androstenedione    0.60** 0.53** 0.46** 
Testosterone     0.47** 0.51** 
Estrone      0.92** 
Storage time -0.02 -0.01 -0.05 0.08 0.03 0.06 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table S5. Gene set expression analysis: Top ranked Hallmark genesets (MSigDB) comparing 
gene expression patterns in endometroid endometrial cancer tumors, grouped by level of steroid hormones. 
Results with false detection rate (FDR) > 2% not shown. 
Rank 17OH-Progesterone high¹ FDR 17OH-Progesterone low¹ FDR 
1 TNFA_SIGNALING_VIA_NFKB <0.001 E2F_TARGETS <0.001 
2 IL6_JAK_STAT3_SIGNALING <0.001 MYC_TARGETS_V1 <0.001 
3 INFLAMMATORY_RESPONSE <0.001 G2M_CHECKPOINT <0.001 
4 IFN_ALPHA_RESPONSE <0.001 OXIDATIVE_PHOSPHORYLATION 0.01 
5 IFN_GAMMA_RESPONSE <0.001 MYC_TARGETS_V2 0.11 
6 ALLOGRAFT_REJECTION <0.001 MITOTIC_SPINDLE 0.11 
7 ESTROGEN_RESPONSE_EARLY 0.03 DNA_REPAIR 0.67 
8 ESTROGEN_RESPONSE_LATE 0.02   
9 COAGULATION 0.02   
10 APOPTOSIS 0.48   
11 COMPLEMENT 0.61   
12 IL2_STAT5_SIGNALING 0.64   
13 KRAS_SIGNALING_UP 0.62   
14 ANGIOGENESIS 0.78   
15 ANDROGEN_RESPONSE 1.25   
16 HYPOXIA 1.6   
Rank 11-Deoxycortisol high¹ FDR 11-Deoxycortisol low¹ FDR 
1 TNFA_SIGNALING_VIA_NFKB <0.001 E2F_TARGETS <0.001 
2 HYPOXIA <0.001 G2M_CHECKPOINT <0.001 
3 IL6_JAK_STAT3_SIGNALING <0.001 MYC_TARGETS_V1 <0.001 
4 EMT <0.001 MITOTIC_SPINDLE 0.14 
5 INFLAMMATORY_RESPONSE <0.001 OXIDATIVE_PHOSPHORYLATION 0.19 
6 ESTROGEN_RESPONSE_EARLY 0.05 FATTY_ACID_METABOLISM 0.82 
7 ROS_PATHWAY 0.05 PROTEIN_SECRETION 1.45 
8 ANGIOGENESIS 0.1   
9 APOPTOSIS 0.09   
10 COAGULATION 0.19   
11 INTERFERON_GAMMA_RESPONSE 0.31   
12 INTERFERON_ALPHA_RESPONSE 0.48   
13 P53_PATHWAY 0.58   
14 GLYCOLYSIS 0.88   
15 ALLOGRAFT_REJECTION 1.24   
Rank Androstenedione high¹ FDR Androstenedione low¹ FDR 
1 IFN_ALPHA_RESPONSE <0.001 MYOGENESIS 1.91 
2 IFN_GAMMA_RESPONSE <0.001  
 
3 ALLOGRAFT_REJECTION <0.001   
4 ESTROGEN_RESPONSE_EARLY 0.33   
5 IL6_JAK_STAT3_SIGNALING 0.27   
6 INFLAMMATORY_RESPONSE 0.22   
7 E2F_TARGETS 0.7   
8 ESTROGEN_RESPONSE_LATE 0.88   
9 ROS_PATHWAY 1.91   
Rank Estrone High² FDR Estrone low² FDR 
1 ESTROGEN_RESPONSE_EARLY 1.33 TNFA_SIGNALING_VIA_NFKB 0.14 
2 ESTROGEN_RESPONSE_LATE 1.99 E2F_TARGETS 0.83 
3   MYOGENESIS 1.9 
5  
 P53_PATHWAY 1.7 
Rank Estradiol high² FDR Estradiol low² FDR 
1 PROTEIN_SECRETION 0.48 TNFA_SIGNALING_VIA_NFKB 1.87 
2 UNFOLDED_PROTEIN_RESPONSE 1.55  
 
3 ESTROGEN_RESPONSE_LATE 1.03   
4 FATTY_ACID_METABOLISM 0.82   
5 GLYCOLYSIS 0.66   
5 PEROXISOME 0.81   
6 ESTROGEN_RESPONSE_EARLY 0.71     
Gray shading marks inflammation associated gene sets, encased gene sets are related to estrogen signalling. 
¹ Cutoff determined by ROC analysis for prediction of disease specific survival 
 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Maintained survival outcome after reducing lymphadenectomy
rates and optimizing adjuvant treatment in endometrial cancer
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• A cohort of 1308 endometrial cancer patients was assessed for outcome related to treatment changes over the last two decades.
• The rate of lymphadenectomy was reduced from approximately 80% to 50% without affecting survival or recurrence rates.
• Omitting adjuvant radiotherapy for a chemotherapy alone policy in high risk patients did not worsen survival or recurrence.
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Objective.Main controversies in endometrial cancer treatment include the role of lymphadenectomy and op-
timal adjuvant treatment. We assessed clinical outcome in a population-based endometrial cancer cohort in re-
lation to changes in treatment management over two decades.
Methods. All consenting endometrial cancer patients receiving primary treatment at Haukeland University
Hospital from 2001 to 2019 were included (n = 1308). Clinicopathological variables were evaluated for year-
to-year changes. Clinical outcome before and after discontinuing adjuvant radiotherapy and individualizing ex-
tent of lymphadenectomy was analyzed.
Results. The rate of lymphadenectomywas reduced from 78% in 2001–2012 to 53% in 2013–2019. The rate of
patientswith verified lymph nodemetastaseswasmaintained (9% vs 8%, p=0.58) and FIGO stage I patientswho
did not undergo lymphadenectomy had stable 3-year recurrence-free survival (88% vs 90%, p=0.67). Adjuvant
chemotherapy for completely resected FIGO stage III patients increased from 27% to 97% from 2001 to 2009 to
2010–2019, while adjuvant radiotherapy declined from 57% to 0% (p < 0.001). These patients had improved 5-
year overall- and recurrence-free survival; 0.49 [95% CI: 0.37–0.65] in 2001–2009 compared to 0.61
[0.45–0.83] in 2010–2019, p = 0.04 and 0.51 [0.39–0.68] to 0.71 [0.60–0.85], p = 0.03, respectively. For stage
I, II and IV, survival rates were unchanged.
Conclusions.Our study demonstrates that preoperative stratification by imaging and histological assessments
permits a reduction in lymphadenectomy to around 50%, and is achievable without an increase in recurrences at
3 years. In addition, our findings support that adjuvant chemotherapy alone performs equally to adjuvant radio-
therapy with regard to survival, and is likely superior in advanced stage patients.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Endometrial cancer is the most common gynecological cancer in in-
dustrialized countries,with a cumulative lifetime risk of 2–3% inwomen
[1,2]. The prognosis in endometrial cancer is generally good due to
detection at an early stage where surgery is likely curative [3]. Thus,
selecting an appropriate level of treatment that balances the risk of
recurrence with the risk of iatrogenic morbidity is a major challenge.
Gynecologic Oncology 160 (2021) 396–404
⁎ Corresponding author at: Department of Gynaecology and Obstetrics, Haukeland
University Hospital, Jonas Lies vei 72, 5020 Bergen, Norway.
E-mail address: camilla.krakstad@uib.no (C. Krakstad).
1 Current address: Department of Obstetrics and Gynecology Maastricht University
Medical Center, Maastricht, the Netherlands and GROW—School for Oncology and
Developmental Biology, Maastricht University Medical Center, Maastricht, the
Netherlands
2 Shared last author.
https://doi.org/10.1016/j.ygyno.2020.12.002
0090-8258/© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
Gynecologic Oncology
j ourna l homepage: www.e lsev ie r .com/ locate /ygyno
Currently,main controversies include themode and extent of lymph tis-
sue dissection for staging and selecting optimal adjuvant treatment reg-
imens [4,5]. As an extensive research effort is ongoing to address these
topics, oncological centers develop local, national or international
guidelines, based on their respective evaluation of scientific evidence,
available resources and clinical tradition.
During the last decade, several changes in patient treatment have
been implemented for endometrial cancer patients in our region. In
2009national guidelineswere changed; adjuvant radiotherapy (external
beam +/− brachytherapy) was no longer recommended for patients
with high-risk tumors, defined as FIGO (International Federation of Gy-
necology and Obstetrics) stage IB grade 3 endometrioid, all stage I non-
endometrioid, and completely resected stage II-III [6]. Instead adjuvant
platinum based chemotherapy was advocated for all high-risk tumors,
motivated by emerging data suggesting better survival outcome
when opting for chemotherapy in the adjuvant setting [7]. In 2009 and
2011 respectively, pelvic magnetic resonance imaging (MRI) and
fluorodeoxyglucose-positron emission tomography/computed tomogra-
phy (PET/CT) were gradually integrated in preoperative diagnostics at
Haukeland University Hospital. Finally, in October 2015, the MoMaTEC2
study (Molecular Markers in the Treatment of Endometrial Cancer,
ClinicalTrials.gov Identifier: NCT02543710) was launched, evaluating
the implementation of estrogen and progesterone receptor (ER/PR) ex-
pression in preoperative biopsies in combination with histological
subtyping and imaging, with the intent to reduce the rate of patients un-
dergoing lymphadenectomy.
The aim of this study was to assess effects and outcome when
discontinuing adjuvant radiotherapy and reducing the rate of patients
undergoing lymphadenectomy through more extensive preoperative
patient stratification. Additionally, we explored trends in clinical and




The study was approved by the Western Regional Committee for
Medical and Health Research Ethics (REK 2009/2315, 2018/594, and
2019/1020). All included patients signed an informed consent.
2.2. Patient series
HaukelandUniversity Hospital serves approximately 10% of theNor-
wegian gynecological population as a full-scale gynecological oncology
center, providing treatment for all endometrial cancer for local patients.
Additionally, the center receives high-risk/advanced stage patients from
neighboring counties, comprising approximately 15% of the cohort. The
population of Hordaland is demographically representative of the Nor-
wegian population, with similar distributions of age, gender, and body
mass index (BMI) [8].
All consentingpatients referred toHaukelandUniversity Hospital for
primary treatment of endometrial cancer from 2001 to 2019 were in-
cluded. Patients were surgically staged according to FIGO 2009 criteria;
patients treated prior to 2009 were reclassified according to the 2009
criteria as previously described [9]. Clinical and pathological variables
were collected from the medical records. Radiological findings were
recorded based on the radiology report. The surgery- and multidisci-
plinary tumor board reports were also reviewed to record how radio-
logical findings had been perceived prior to surgery and to identify
reasons for performing or not performing lymphadenectomy. The imag-
ing protocols employed at our institution are largely in linewith recom-
mended European guidelines for preoperative imaging in endometrial
cancer [10].
2.3. Treatment
Standard treatment was hysterectomy with bilateral salpingo-
oophorectomy. Indications for lymphadenectomy changed over the
study period (see below). Omentectomy was performed in patients
with serous and clear cell tumors. All hysterectomies were performed
by laparotomy until the introduction of robotic-assisted laparoscopic
hysterectomy in 2010 and conventional laparoscopy in 2013 for se-
lected patients (manageable comorbidity, no presumed extrauterine
disease, and para-aortic lymphadenectomy not planned for). In the pal-
liative setting, treatment options included debulking, hysterectomy for
symptom control, or primary non-surgical therapy (chemotherapy, ra-
diotherapy, or hormonal therapy). Treatment decisions were made at
tumor board meetings including specialists in gynecological oncology,
oncology, radiology, and pathology.
2.4. Indications for lymphadenectomy
Indications for lymphadenectomy changed during the observation
period from a general pelvic sampling policy (sampling pelvic nodes
at the surgeon's discretion unless deemed not tolerable or restricted ac-
cess perioperatively) to a selective policy based on preoperative risk as-
sessment. Preoperative low-, intermediate-, and high-risk groups were
defined by histological assessment of curettage/endometrial biopsy
and radiological findings according to the European Society of Medical
Oncology (ESMO) guideline [11]. Low risk was defined as endometrioid
endometrial cancers grade 1–2 with <50% myometrial invasion (MI)
assessed by MRI, intermediate risk as endometrioid grade 1–2 with
MI > 50%, or grade 3 endometrioid with MI <50%. Endometrioid
grade 3 tumors with MI > 50% and all non-endometrioid cancers were
classified as high risk. The evaluation of myometrial invasion was non-
systematically performed by CT or ultrasound prior to the implementa-
tion of MRI in 2009, after which all patients were systematically
grouped. Pelvic lymphadenectomy was gradually restricted (2010
−2012) to the intermediate-risk group while pelvic and para-aortic
lymphadenectomy was performed for the high-risk group. In 2011,
PET/CT was introduced for preoperative evaluation. Any patient with
PET-positive pelvic or para-aortic lymph nodes underwent lymphade-
nectomy, unless intolerable or complete debulking was deemed
unattainable. In October 2015, preoperative immunohistochemical
expression of PR and ER was included as part of a phase 4 implementa-
tion study (MoMaTEC2); in low- and intermediate-risk cases, lymphad-
enectomy was omitted when ER and PR expression was positive. In
addition to preoperative assessment, perioperative findings (e.g. en-
larged lymph nodes) could prompt lymphadenectomy. Supplementary
Table 1 shows the current algorithm for extent of surgery.
2.5. Adjuvant treatment
Patients were postoperatively reclassified based on histopathologi-
cal examination of the hysterectomy specimen and final FIGO stage
into low-, intermediate-, or high-risk groups (endometrioid grade 3
stage IB, any stage II-IV tumors and any non-endometrioid tumors), in
line with the ESMO classification [11,12]. At Haukeland University Hos-
pital, lymphovascular space invasion status was added to the pathology
report in 2018, but did not affect treatment, and is not included in our
analyses. Standard adjuvant treatment in 2001–2009 was adjuvant ra-
diotherapy (external beam+/− brachytherapy) or platinum based ad-
juvant chemotherapy (standard being carboplatin plus paclitaxel for six
cycles) for high-risk tumors. The contemporary guidelines contained no
specification for choice of modality, except for a preference for chemo-
therapy in serous or clear-cell tumors. From 2009, national guidelines
no longer recommended adjuvant radiotherapy except for stage II pa-
tients with incomplete surgical margins. Instead, adjuvant chemother-
apy was advocated for all high-risk tumors, with six cycles of
carboplatin plus paclitaxel as standard treatment.
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2.6. Statistical analysis
All statistical analyseswere performed in SPSS 25.0 (IBM, NewYork)
or R v3.6.1 (R Core Team 2019). Year-to-year time trendswere assessed
by linear regression for continuous variables and the Chi-square test for
trend for proportions. Categorical variables were compared by
Chi-square test or Fischer's exact test, and differences in distributions
of continuous variables were assessed by the Mann-Whitney U test. To
explore the influence of clinicopathologic variables over the observation
period, a multivariable cox regression survival model was built using
enter method. Age, BMI, parity, MI, histological type and grade, FIGO
stage, year of treatment and adjuvant treatment modalities were ana-
lyzed in univariable analysis. Variables with hazard ratios with p < 0.1
were included in the adjusted multivariable analysis.
To compare different adjuvant treatment strategies the cohort was
divided at 01 Jan 2010, based on the time point for national guideline
change in 2009. For analysis of outcomes related to the systematic re-
duction in the rate of patients undergoing lymphadenectomy, 01 Jan
2013 was chosen, based on the time point where patient surgical files
started containing explicit rationale for performing lymphadenectomy
(gradual increase over 2010–2012).
Overall survival (OS) was defined as time from treatment to death
from any cause. Disease specific survival (DSS) was defined as time
from treatment to death from endometrial cancer. Recurrence-free Sur-
vival (RFS)was defined as time from surgery tofirst verified recurrence,
and only included patients with completely resected tumors (macro-
scopically tumor-free). To account for differences in follow-up times
due to sampling groups from different time periods, OS and DSS were
reported at 5 years after primary treatment longer follow-up was
blinded. RFS was analyzed at 3 years and follow-up was blinded at 3
years, as more than 70% of recurrences occur within 3 years, allowing
earlier reliable assessment of RFS than OS and DSS [13]. The Kaplan-
Meier method was used to visualize differences in survival between
groups, using the log-rank test for comparisons between groups. For
all statistical analyses, differences were considered significant at
p < 0.05 (two-sided).
3. Results
3.1. Increasing age, BMI and serous histology over time
A total of 1308 patients were included in the study (Table 1), with a
median follow-up time of 49 months (range 0–212). The number of
treated patients showed an increasing trend over 2001–2019, mirroring
the Norwegian increase in endometrial cancer incidence (Fig. 1A, Sup-
plementary Table 2). Median age at primary treatment was 66 years
(interquartile range 15), with an average 2 months/year increase
(p = 0.008, Fig. 1B). Median BMI was 27.3 kg/m2 (interquartile range
8), also with a slightly increasing trend over time (0.08 kg/m2/year,
p = 0.037, Fig. 1C). The distribution of FIGO stages showed some year-
to-year variation, but no time-dependent trend was observed
(Fig. 1D). The proportion of endometrioid endometrial cancer at post-
operative histopathological diagnosis was stable, as well as histological
grade within the endometrioid subtype (Fig. 1E and F). Distribution of
non-endometrioid histological typeswas constant, apart from a statisti-
cally significant increasing trend in the proportion of serous endome-
trial cancer (p = 0.004, Fig. 1E). The proportion of serous tumors in
2010–2019 was 13%, compared to 9% in 2001–2009 (Fig. 1F).
In a Cox regression model (Supplementary Table 3), increasing age,
stage III-IV, high grade EEC, NEEC, and deep myometrial invasion were
all significant predictors of poor survival in both unadjusted analysis
and after adjusting for all other variables (p = 0.031 for grade 3 EEC,
p<0.001 for the rest,). Year of primary treatment did not affect survival
outcome. Any adjuvant treatment was associated with higher hazard
ratio (for disease specific death) compared to no adjuvant treatment,
howeverwhen adjusting for the other variables, radiotherapy remained
significant with an adjusted hazard ratio of 1.9 (95% CI 1.1–3.4, p =
0.035), whereas chemotherapy did not (1.2, 95% CI 0.8–1.9, p = 0.47).
3.2. Reduction of lymphadenectomy with maintained rate of stage IIIC
patients
MRI and PET/CT were implemented in diagnostics during the study
period (Fig. 1G), peaking in 2015–2019with>85% of patients subjected
to both examinations. The rate of lymphadenectomy decreased, with a
pronounced decline in 2012–2013, and flattening out to 50–60% on-
wards (Fig. 1H). Thus, a significantly smaller proportion of patients
underwent lymphadenectomy in 2013–2019 compared to 2001–2012
(53% versus 78%, p < 0.001). The rate of para-aortic procedures in-
creased (5% to 20% of all patients, p < 0.001) (Table 2). The rate of pa-
tients with verified lymph node metastases was stable across the two
time periods (8% vs 9%, p = 0.576), including para-aortic metastases
(Stage IIIC2; 2% vs 2%).
The group of patients not undergoing lymphadenectomy in
2013–2019 largely consisted of low- and intermediate-risk patients
(based on preoperative histology and MI) without additional risk
Table 1
Clinical and pathological characteristics of the cohort (n = 1308).
Median Interquartile range
Age at treatment 66 15






Para 0 208 16.1%
Para 1+ 1086 83.9%
Primary treatment
Hysterectomy 1241 94.9%
Tumor reduction 8 0.6%
Curettage 59 4.5%
Mode of surgery (hysterectomy)
Laparotomy 972 78.3%
Laparoscopy 92 7.4%
Robot-assisted laparoscopy 177 14.3%
Lymph node sampling
Not performed 422 32.3%
Pelvic 742 56.7%










Endometrioid (EEC) 1016 77.7%
Non-endometrioid 292 22.3%
Clear cell 50 3.8%
Serous papillary 148 11.3%
Carcinosarcoma 58 4.4%
Undifferentiated/other 36 2.8%
Histological Grade (EEC only)
Grade 1–2 826 82.8%
Grade 3 172 17.2%
Adjuvant treatment
None 863 66.0%
External radiation 81 6.2%
Brachytherapy 7 0.5%
Chemotherapy 325 24.8%
Chemotherapy + radiation 10 0.8%
Hormonal treatment 22 1.7%
FIGO International Federation of Gynecology and Obstetrics.
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factors (lymphadenopathy on imaging, loss of ER/PR or clinical
upstaging) (Fig. 2A). Interestingly, among patients undergoing lymph-
adenectomy in this period, no patients had verified lymph node metas-
tases in the low- and intermediate-risk groups unless having additional
risk factors. Among non-lymphadenectomized low-risk patients, five
out of 79 (6%) experienced recurrence within 3 years, compared to
one of 25 (4%) of patients undergoing lymphadenectomy in spite of
not having any apparent risk factors. Corresponding percentages for
intermediate-risk patients without additional risk factors were four re-
currences in 41 node negative patients (10%) and three recurrences in
43 non-lymphadenectomized patients (7%).
Survival data was available for 778 patients treated between 2001
and 2012 with a median follow-up of 71 months (range 0–212) and
for 530 patients treated between 2013 and 2019 in with a median
follow-up of 25 months (range 0–70). Although the proportion of
stage I patients not undergoing lymphadenectomy increased from 17%
to 51%, 3-year RFS was maintained in this group (0.91 (95% CI
0.86–0.96) for 2013–2019 compared to 0.88 (95% CI 0.82–0.95), p =
0.46, Fig. 2B). For the whole cohort comparing 2001–2012 to
2013–2019, 3-year RFS was 0.84 (95% CI 0.81–0.87) vs 0.85 (95% CI
0.81–0.89, p = 0.56).
3.3. Changes in adjuvant treatment with discontinuation of radiotherapy
Administration of adjuvant radiotherapy was reduced from 12% of
all patients in 2001–2009 to 1% in 2010–2019 (p < 0.001, Fig. 3A),
while the proportion of patients receiving adjuvant chemotherapy in-
creased from 10% to 31% (p < 0.001). In stage I high-risk patients, 79%
received chemotherapy in 2010–2019 compared to 28% in 2001–2009
(p < 0.001), representing the main contribution to the overall increase
in use of adjuvant therapy (Fig. 3B). For (postoperative) low- and
intermediate-risk patients in stage I, adjuvant therapy rates were low
and stable. In stage II patients, the reduction in radiotherapy was com-
parable to the increase in chemotherapy, thus with a stable overall
rate of adjuvant treatment in this group (62% to 58%, p=0.7). The pro-
portion of patientswith stage III (macroscopically tumor-free) receiving
adjuvant chemotherapy increased significantly from 27% to 95%
(p < 0.001). The proportion not receiving any adjuvant treatment in
this group decreased from 16% to 5% (p < 0.05).
The median follow-up time was 73 months (range 0–212) for the
2001–2009 group and 35 months (range 0–95) for the 2010–2019
group. No differences in 5-year OS or DSS between groups were
found, nor for 3-year RFS (Fig. 4A). In subgroup analysis, 5-year OS im-
proved significantly in completely resected stage III patients from 0.49
(95% CI: 0.37–0.65) to 0.61 (0.45–0.83, p = 0.04, Fig. 4B). RFS at
3 years in stage III was also significantly better in 2010–2019 (0.71
(95% CI: 0.39–0.68)) compared to the 2001–2009 group (0.51
(0.39–0.68, p=0.03)). OS, DSS and RFS in stage I and II were similar be-
fore and after 2009. Outcome was also stable for stage I high-risk pa-
tients in spite of a substantial increase in adjuvant chemotherapy in
this group (Supplementary Fig. 1). The 3-year recurrence rate for all pa-
tients for the whole observation period was 17%, with distant recur-
rences in 9%, pelvic in 2% and vaginal recurrences in 6% (Fig. 4C). In
completely resected stage III patients the rate of distant recurrences de-
creased from 38% in 2001–2009 to 28% in 2010–2019, vaginal recur-
rences from 9% to 3% and pelvic recurrences increased from 5% to 8%,
but the changes were not statistically significant.
4. Discussion
Major research efforts are being deployed into uncovering the opti-
mal ways to stage and treat endometrial cancer. Main points of contro-
versy are the role of lymphadenectomy andmatching optimal adjuvant
therapy regimes to subgroups.We have performed a broad analysis in a
population based Norwegian cohort to retrospectively assess the effects
of national and local changes to optimize the rate of patients undergoing
lymphadenectomyon onehand, and the discontinuation of adjuvant ra-
diotherapy on the other. We describe a successful reduction of the rate
of endometrial cancer patients undergoing lymphadenectomy, with
maintained identification rates of stage IIIC patients and consistent
low recurrence rates in unstaged patients. In addition,we have analyzed
outcome after discontinuing radiotherapy as an adjuvant option and
implementing adjuvant chemotherapy alone as standard treatment in
high-risk patients, and find maintained overall survival outcome and
improved survival in stage III patients.
Sentinel node (SN)mapping is on the rise in endometrial cancer, due
to high sensitivity and negative predictive value [14]. Nevertheless, in a
recent survey, 50% of gynecological oncologists in Europe and USA did
not use this technique, implying that for many institutions a better
risk-stratification of patients prior to surgical staging is still an impor-
tant issue [15]. At our institution, where sentinel node mapping is not
implemented, the rate of patients undergoing lymphadenectomy has
decreased over the last 6–7 years. This is due to a shift from universal
sampling to selective lymphadenectomy, following an incorporation of
imaging and molecular biomarkers into the diagnostic work-up. We
show that in spite of a marked reduction in lymphadenectomies, we
still identifymetastatic nodes at the same rate, and there is no indication
of increased recurrence rates in the non-staged patients. For institutions
using sentinel node techniques, these results may also be of interest, es-
pecially when failed mapping mandates a full- or hemipelvic lymphad-
enectomy [16]. Even when successful, sentinel node procedures add
significant time and cost to surgery compared to no lymph node re-
moval, and should be omitted when unnecessary [17].
Fig. 1. Time trends in clinicopathological characteristics 2001–2019. A)Number of endometrial cancer patients receiving primary treatment atHaukelandUniversity Hospital. The stippled
lines show the incidence in Norway divided by 10 and the Norwegian age-standardized rate per 100,000 person years (ASR) based on 2014 age weights [2]. Full numerical data in Sup-
plementary Table 1. B) Age at primary treatment, median and inter-quartile range with linear regression y = Bx + k. C) Body mass index, median and inter-quartile range with linear
regression y= Bx+ k. D) Trend in distribution of FIGO stages. Trends analyzedwith chi-square test for trend. E) Trend in distribution of histopathological subtypes in final surgical spec-
imen. Trends analyzed with chi-square test for trend. F) Distribution of histologic types in final surgical specimen split by decade. Other includes undifferentiated and rare histological
subtypes. G) Changes in the use ofmagnetic resonance imaging (MRI) and positron emission tomography/computerized tomography (PET/CT). MRI was included in routinemanagement
from 2009, PET/CT from 2011. H) Changes in rates of lymphadenectomy, and extent of procedure.
Table 2
Comparison of extent of disease and extent and outcome of lymphadenectomy before and
after 1 Jan 2013.
2001–2012 2013–2019 p (chi-square)
(n = 778) (n = 530)
n (%) n (%)
FIGO Stage 0.899
I 581 (75) 384 (73)
II 60 (8) 41 (8)
III 91 (12) 66 (13)
IIIc1 49 (6) 30 (6)
IIIc2 14 (2) 9 (2)
IV 46 (6) 35 (7)
Lymphadenectomy (LA) <0.001
Not performed 171 (22) 251 (47)
Pelvic 567 (73) 175 (33)
Para-aortic and pelvic 40 (5) 104 (20)
Lymph node metastasis 0.576
Negative + unknown 708 (91) 487 (92)
Positive 70 (9) 43 (8)
FIGO: International Federation of Obstetrics and Gynecology.
Numbers in bold signify p-values < 0.05.
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We report an increase in use of adjuvant chemotherapy in high-risk
patients (stage I high-risk + stage II and III), and a concomitant cessation
of adjuvant radiotherapy. Although adjuvant therapy for high-risk pa-
tients is in line with current international recommendations, the optimal
treatment algorithm is under debate, especially concerning the respective
roles of radiotherapy and systemic chemotherapy. The ESMO consensus
favors external beam radiation therapy for stage I high-risk patients
when staged and node negative, and supports consideration of brachy-
therapy, but states that the role of systemic chemotherapy is insufficiently
investigated [12]. In trials with stage I high-risk patients where chemo-
therapy alone has been compared with radiotherapy, no differences in
OS or RFS have been shown, although pelvic recurrence rates were
lower after radiotherapy and distant recurrences lower after chemother-
apy [18,19]. Our study shows that omitting radiotherapy in stage I
patients has not produced poorer outcome, when substituted with che-
motherapy. Advantages with this approach is avoidance of radiotherapy
related side effects and saving radiotherapy for salvage treatment of vag-
inal and small pelvic recurrences in patients if they do occur. We report a
vaginal recurrence rate of 6% in thewhole population-based series, which
seems comparable to 5–10% in previously published chemotherapy only-
studies reporting high-risk cases [18–20].We do note that the substantial
increase in adjuvant chemotherapy in stage I patients does not seem to
improve outcome. The ongoing ENGOT-EN2-DGCG/EORTC55102 study
(clingov ID NCT01244789), comparing adjuvant chemotherapy with ob-
servation for low-stage high-risk patients will hopefully provide addi-
tional data to optimize treatment strategies for this group. Molecular
subtyping provides prognostic information independent of classical histo-
pathological stratification and could improve tailoring of treatment [21].
Fig. 2. A) Preoperative characterization of hysterectomized patients, before and after 01 Jan 2013, with a preoperative endometrial cancer assessment (excluding incidental findings after
benign diagnosis and surgery for presumed ovarian cancer). Inner circle displays risk groups based on histologic assessment of preoperative biopsy/curettage and imaging: Low:
endometrioid grade 1–2 with <50% myometrial invasion (MI) or MI unknown. Intermediate: endometrioid grade 1–2 with >50% MI or grade 3 with <50% MI. High: endometrioid
grade 3 with >50% MI or MI unknown and all non-endometrioid cancers. Patients missing preoperative histological info were excluded (n = 31). Second circle displays the additional
risk factor most important for explaining whether patients underwent LA, based on patient file review. Third circle displays prevalence of metastatic lymph nodes where LA was
performed. Outer circle displays recurrences or progression occurring within 3 years. All sectors correspond to proportions of patients included. ER Estrogen Receptor, PR Progesterone
Receptor, pre/perioperatively upstaged signifies imaging or clinical findings corresponding to stage>I (other than lymphadenopathy), technical signifies perioperative technical issues
due to adhesions, bleeding, also including patient's wish. B) Kaplan-Meier survival curve showing 3-year recurrence free survival before and after reduction of lymphadenectomies in
2013. FIGO: International Federation of Gynecology and Obstetrics.
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As of yet, no published prospective data regarding management of endo-
metrial cancer by molecular subtype is available.
Unlike early stage endometrial cancer, for advanced endometrial
cancer patients there is strong evidence in favor of adjuvant chemother-
apy. In the GOG-122 trial, chemotherapy demonstrated superior OS and
progression-free survival to radiotherapy for stage III-IV patients, and
was non-inferior to the combination of chemotherapy and radiotherapy
in GOG-258, although the pelvic recurrence rate was higher for chemo-
therapy alone [7,22]. In the present study, improvement in OS and RFS
for stage III patients was observed, coinciding with an overall increase
in adjuvant treatment, and at the same time a cessation of radiotherapy.
Similar survival and recurrence rates have been demonstrated in a sep-
arate Norwegian high-risk cohort [20]. The low rate of vaginal recur-
rences in stage III patients is interesting. However, a low number of
stage III patients could affect this result, and the drop from 9% to 3%
was not statistically significant. Preoperative MRI and PET/CT could in-
crease the proportion of stage IIIC patients with limited uterine disease,
and thus lower the risk for local recurrence as observed in our study, but
this needs to be confirmed in future studies. The PORTEC-3 trial recently
demonstrated improved OS and failure-free survival when combining
chemotherapy and radiotherapy compared to radiotherapy alone in
high-risk patients, mainly driven by improved results in stage III
patients and with an increased rate of adverse events and persisting
morbidity [23]. Adjuvant chemotherapy alone was not explored in
PORTEC-3, thus the available evidence today does not support a benefit
of adding radiotherapy when adjuvant chemotherapy constitutes the
management strategy for advanced stage endometrial cancer, again
reflected in the analysis of the present population based series.
Our retrospective study is limited in its inability to establish clear
cause-effect relationships, especially in evaluating contributions of dif-
ferent diagnostic methods towards a reduction of the overall rate of pa-
tients undergoing lymphadenectomy. We are however, at this time
satisfied to point out that the rate of lymphadenectomy can be reduced,
and that in our setting, no apparent detrimental effect is seen. Preoper-
ative risk grouping to tailor surgery depends on a high concordance be-
tween the diagnostic workup and final diagnosis. We have previously
shown that there is histological discordance between biopsy and hys-
terectomy specimen in 16%, and that theMRI diagnosis of cervical inva-
sion and deep myometrial invasion have an accuracy of 79%–89% and
61–68% respectively, and thus additional parameters are necessary to
optimize a selective lymphadenectomy algorithm [24,25]. Availability
of imaging modalities including MRI and PET differs between institu-
tions and they are not standard of care in many countries. Immunohis-
tochemical analysis of ER and PR however, carries little extra cost and is
potentially beneficial for clinics without access to advanced imaging.
Improvement of the selective lymphadenectomy algorithm with focus
on cost effectiveness is an important aim for future research.
Another potential bias is the shorter follow-up time for the patients
treated in the most recent time period. We have attempted to compen-
sate for this by choosing appropriate outcome for comparison. This is es-
pecially relevant for lymphadenectomy frequencies, where the most
recent group has a median follow-up time of 25 months. Data matura-
tion will enable a better estimate of the recurrence rate and survival of
low-stage patients not undergoing lymphadenectomy, and will be re-
ported when finalizing theMoMaTEC2 study. We were unable to retro-
spectively quantify treatment related complications in our study, as
Fig. 3. A) Changes in administration of adjuvant treatment between 2001 and 2009 and 2010–2019. Hysterectomized patients with macroscopically resectable tumors included. Other
includes hormonal treatment (n = 5), brachytherapy alone (n = 2) and chemoradiation (n = 1). Statistical comparison between use of chemotherapy/radiotherapy in the different
time periods by Chi-square or Fischer's exact test (2-sided) where appropriate. B) Stage I risk groups based on histologic assessment of preoperative biopsy/curettage: low;
endometrioid grade 1–2 with <50% myometrial invasion (MI) or MI unknown, intermediate; endometrioid grade 1–2 with >50% MI on imaging or grade 3 with <50% MI, and high;
endometrioid grade 3 with >50% MI or MI unknown and all non-endometrioid cancers. FIGO: International Federation of Gynecology and Obstetrics.
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Fig. 4. Kaplan-Meier survival curves showing survival outcome before and after omitting radiotherapy as adjuvant treatment for A) all patients. B) completely resected FIGO stage III
patients. C) Recurrence rate by site at 3 years in completely resected patients. Patients censored before 3 years not included. Statistical comparison of groups with chi-square. FIGO:
International Federation of Gynecology and Obstetrics.
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these have not been systematically registered clinically. There is a need
for prospective data on patient reported outcomes for different treat-
ment modalities, to better understand tolerability in short and
long term.
In conclusion, we present data from a population based endometrial
cancer cohort over the span of twodecades, and show that changing to a
strategy of individualized risk-based stratification for lymphadenec-
tomy does not affect survival outcomes negatively, when compared to
the previous practice based onmore frequent lymphadenectomy. Addi-
tionally, our data supports that adjuvant treatment without radiother-
apy is feasible with maintained survival and was even associated to
improved survival for stage III patients.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2020.12.002.
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Supplementary Fig. 1. Kaplan–Meier curves for FIGO stage I high-risk patients. 
FIGO: International Federation of Gynecology and Obstetrics. 
 
Supplementary table 1. Treatment algorithm at Haukeland University Hospital (2019)  
Presumed 
FIGO Stage I Type Grade MI SIZE>5cm ER/PR LNM Treatment 
Low risk EEC 1-2 <50% - - - Hysterectomy 
 
  
 +   + pelvic LA 
 
  
  +  + pelvic LA 
            + + pelvic (±para-aortic LA) 
 
  
     
Intermediate 
risk 
EEC 1-2 ≥50% - - - 
Hysterectomy 
EEC 3 <50% - - - 
 
  
 +   + pelvic LA 
 
  
  +  + pelvic LA 
            + + pelvic (±para-aortic LA) 
 
  
     
High risk 
EEC 3 ≥50% 
+/- +/- +/- 
Hysterectomy + pelvic and para-
aortic LA 
NEEC   any +/- +/- +/- 
Hysterectomy + pelvic and para-
aortic LA + omentectomy 
FIGO Stage 
II-III 
    
          
Cervical stromal infiltration 
(FIGO Stage II) 
    
Wertheim-Meigs (radical) 




    
        
Hysterectomy + pelvic and para-
aortic LA 
Palliative intent (advanced cancer or patient 
issues)     
Hysterectomy/tumor reduction/non-
surgical treatment 
FIGO International federation of gynecology and obstetrics, ER/PR loss of expression of 
estrogen/progesterone receptor in curettage/biopsy (<30% nuclei positive for either ER or PR), MI 
Myometrial infiltration (CT/MRI), SIZE maximum tumor diameter (imaging), LNM lymphadenopathy on 




Supplementary table 2. The study cohort compared to endometrial cancer statistics drawn from the 
Norwegian Cancer Registry. 
 Norway  
Hordaland (primary 
uptake area)  Study cohort  
Year Cases Rate¹ ASR²  Cases Rate¹ ASR²  Total Local Referred % 
2001 589 25.9 26.0  62 28.1 29.5  50 47 3 6 % 
2002 589 25.7 25.9  59 26.7 27.8  58 50 8 14 % 
2003 633 27.5 27.8  78 35.0 37.9  64 57 7 11 % 
2004 682 29.5 29.4  52 23.2 24.9  53 49 4 8 % 
2005 678 29.1 28.8  78 34.5 35.9  73 65 8 11 % 
2006 661 28.2 27.7  54 23.7 24.4  51 48 3 6 % 
2007 673 28.4 28.2  65 28.2 30.4  71 62 9 13 % 
2008 718 30.0 29.9  63 27.1 28.1  77 66 11 14 % 
2009 714 29.5 29.1  54 22.9 23.3  53 45 8 15 % 
2010 758 31.0 30.3  68 28.4 28.7  67 57 10 16 % 
2011 749 30.3 29.3  86 35.5 35.4  88 73 15 17 % 
2012 652 26.1 25.1  67 27.3 27.3  73 54 19 26 % 
2013 766 30.3 29.2  86 34.6 34.9  99 78 21 22 % 
2014 733 28.7 27.3  69 27.5 27.4  88 71 17 19 % 
2015 785 30.5 28.9  61 24.0 23.9  74 53 21 29 % 
2016 785 30.2 28.0  67 26.2 25.7  57 48 9 16 % 
2017 708 27.0 24.9  74 28.8 27.9  81 69 12 15 % 
2018 797 30.2 27.7  78 30.2 29.1  62 50 12 19 % 
Average/year 704 28.8 27.9   68 28.4 29.0   69 58 18 15 % 
¹ Cases/100 000 person years, source (https://sb.kreftregisteret.no/insidens/) 
² Age standardized rates as computed by Norwegian cancer registry (weights based on 2014 age 
distribution) 
Local; patients within primary district for Haukeland University Hospital 
Referred; patients referred from neighboring counties with low risk endometrial cancer surgery. 
% Referred of total in study cohort          
 
  
Supplementary table 3. Survival analysis by Cox proportional hazards regression model. N = 1167, 
events (disease specific death<5y n = 147). Patients missing data for any variable are excluded. 
Variable n 
Unadjusted HR 
[95% CI] p 
Adjusted HR  
[95% CI] p 
Year of primary treatment 1167 1.00 [0.96-1.04] 0.53    
Age¹ 1167 1.06 [1.04-1.07] <0.001 1.03 [1.01-1.05] 0.001 
BMI¹ 1167 0.97 [0.95-1] 0.056 1.01 [0.98-1.03] 0.717 
Parity        
0 187 1.00      
1+ 980 0.84 [0.55-1.27] 0.40    
Histologic type/grade¹        
EEC grade 1-2 765 1.00   1.00   
EEC grade 3 156 3.73 [2.25-6.18] <0.001 1.79 [1.06-3.04] 0.031 
Non- EEC 246 9.85 [6.66-14.56] <0.001 5.17 [3.26-8.21] <0.001 
FIGO Stage¹        
I-II 973 1.00   1.00   
III-IV 194 10.51 [7.54-14.65] <0.001 3.74 [2.49-5.62] <0.001 
Myometrial invasion¹        
<50% 701 1.00   1.00   
>50% 466 5.77 [3.96-8.4] <0.001 2.39 [1.55-3.69] <0.001 
Adjuvant treatment¹        
None 788 1.00   1.00   
Radiotherapy 67 5.47 [3.25-9.22] <0.001 1.89 [1.05-3.43] 0.035 
Chemotherapy 295 6.19 [4.25-9.02] <0.001 1.18 [0.75-1.87] 0.47 
Other² 17 10.75 [5.05-22.89] <0.001 2.73 [1.2-6.2] 0.017 
¹ Variables included in multivariable model      
² Including brachytherapy (n= 6), radiotherapy+chemotherapy (n=4), hormonal therapy (n=7) 
HR: hazard ratio, CI: confidence interval      
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ABSTRACT 
Background: Most endometrial cancer patients with localized disease are effectively treated 
and survive for a long time. Primary treatment is hysterectomy, to which surgical staging 
procedures may be added to assess the need for adjuvant therapy. Longitudinal data on patient-
reported outcomes comparing different levels of primary treatment is lacking, especially when 
adjuvant radiotherapy is omitted. 
  
Objectives: We assessed the impact of lymphadenectomy and adjuvant chemotherapy on 
patient-reported symptoms, function and quality of life. We hypothesized that these treatment 
modalities would substantially affect patient-reported outcome at follow-up. 
 
Study design: We prospectively included endometrial cancer patients enrolled in the ongoing 
MoMaTEC2 study (clingov id NCT02543710). Patients were asked to complete the patient-
reported outcome questionnaires EORTC-QLQ-C30 and EORTC-EN24 preoperatively and at 
1 and 2 years of follow-up. Functional domains and symptoms were analyzed for the whole 
cohort and by treatment received. To assess the effect of the individual treatment modifications 
we used  mixed regression models. 
 
Results: Of 448 included patients at baseline, 339 and 219 had reached one- and two-year 
follow-up. Overall, patients reported improved global health status/quality of life (+9 units, P 
< 0.001), increased emotional and social functioning and increased sexual interest and activity 
(P < 0.001 for all) from baseline to year one, and these remained stable at year two. Means of 
functional scales and quality of life were similar to an age- and sex-weighted reference cohort. 
Mean tingling/numbness and lymphedema increased after treatment. Compared to the group 
treated with hysterectomy and salpingo-oophorectomy only, the group who received adjuvant 
chemotherapy had a larger mean reduction in physical functioning (-6 versus +2, P = 0.002) at 
year 1, more neuropathy (+30 versus +5, P < 0.001, year 1) at year 1 and 2, and more 
lymphedema at year 1 (+11 versus +2, P = 0.007). In patients not receiving adjuvant 
chemotherapy, patient-reported outcomes were similar regardless of lymph node staging 
procedures. Adjuvant chemotherapy independently increased fatigue, lymphedema, and 
neuropathy in mixed regression models. 
Conclusion: Endometrial cancer patients receiving adjuvant chemotherapy report significantly 
reduced functioning and more symptoms up to two years after treatment. For patients treated 
by surgery alone, surgical staging does not appear to affect quality of life or symptoms to a 
measurable degree at follow-up. Subjecting patients to lymph node removal to tailor adjuvant 
therapy therefore seems justified from the patient’s viewpoint, while efforts should increase to 
find alternatives to traditional chemotherapy. 
  
INTRODUCTION 
Endometrial cancer is the sixth most common cancer in women, with a lifetime risk reaching 
2-3% in many industrialized countries.1  Surgery is the cornerstone of treatment, consisting of 
hysterectomy and bilateral salpingo-oophorectomy, with the addition of lymph node staging 
(LNS) to assess the extent of spread and adjuvant radiation or chemotherapy for patients at a 
high risk of recurrence.2 With an excellent 5-year survival at >90% for localized disease, 
treatment-related complications and post-treatment health-related quality of life (HRQL) are 
gaining attention. Patient-reported outcome (PRO) data regarding these issues is still scarce, 
but suggests benefits for minimally invasive surgery over laparotomy3, 4, sentinel node biopsy 
over lymphadenectomy5, 6, and potential long-term gastrointestinal symptoms for patients 
undergoing adjuvant radiotherapy7-9. Less is known about the effects of adjuvant chemotherapy 
on endometrial cancer survivors, in particular beyond the initial treatment period. Many 
institutions, especially in the Nordic countries, have discontinued the use of adjuvant 
radiotherapy in favor of chemotherapy, based on data suggesting equal or better survival10-12, 
and the possibility of reserving radiotherapy for salvage treatment. PRO data for patients 
undergoing these types of treatment algorithms may be helpful in identifying and quantifying 
treatment-related problems and contribute to better information to patients and prioritization of 
clinical efforts and research but are not yet available. 
We evaluated prospectively registered PROs in treatment groups defined by the Norwegian 
national guidelines for treatment of endometrial cancer, comprising selective 
lymphadenectomy or sentinel node biopsy and adjuvant chemotherapy for high-risk cases. We 
hypothesized that undergoing lymphadenectomy and/or adjuvant chemotherapy would have 
significant health effects that could be detected by self-reported outcome measurements. 
METHODS 
Ethical considerations 
The study has been approved according to Norwegian legislation by the Western Regional 
Committee for medical and health Research Ethics (REK2015/0548). All included patients 
gave written informed consent. 
 
Patient series 
MoMaTEC2 is an ongoing international multicenter phase 4 study (clinicaltrials.gov ID 
NCT02543710), for the implementation of preoperative assessment of hormone receptors as 
biomarkers to guide treatment in endometrial cancer. PROs are collected as secondary 
endpoints. All patients treated at Norwegian participating centers undergoing hysterectomy 
between 15 October 2015 and 11 November 2020 were eligible for this study. 
Clinicopathological characteristics and treatment information were collected at baseline. 
Patients with advanced disease (not completely resected at primary treatment) and patients 
receiving adjuvant treatment other than chemotherapy or additional second-line treatment due 
to recurrence were excluded (Figure 1). Treatment details for included patients are listed in 
Table 1 and treatment principles are outlined in detail in Appendix A.  
Separate consent for PRO follow-up was obtained at inclusion, with 467 patients consenting to 
participate (participation rate 71%). PRO respondents and non-respondents had largely similar 
clinical profile (Supplementary table 1).  
Included patients were grouped based on treatment received: Hysterectomy and bilateral 
salpingo-ooforectomy (BSO) alone (Hyst group), hysterectomy with BSO and lymph node 
staging (LNS group), and hysterectomy and BSO with adjuvant chemotherapy, with or without 
LNS (Chemo group) (Figure 1). 
 
Patient-reported outcome  
The general European Organisation for Research and Treatment of Cancer – Quality of Life 
Questionnaire C30 (EORTC-QLQ-C30) version 3 and endometrial cancer specific EORTC-
QLQ-EN24 questionnaires were completed pre-operatively (baseline) and annually post-
treatment. These questionnaires are validated to describe different/complementing dimensions 
of function and symptoms for endometrial cancer patients and are available in Norwegian13, 14. 
Norwegian reference data from EORTC-QLQ-C30 were extracted from a previous survey in 
an unselected Norwegian population and adjusted by age and gender to reflect the study 
cohort15. 
Function and symptom scales were derived according to the EORTC scoring manual16 for 
scales that were considered relevant for our patient group. For functional scales, a positive 
change signifies improved function, whereas for symptomatic scales a positive change signifies 
increased amount of symptom, i.e., a deterioration. Response rates for most analyzed scales 
were found to be consistently high (97-100%) at each time point (Supplementary table 2). 
Exceptions were sexual interest and sexual activity with response rates of 93% and 94% at 
baseline.  
To evaluate the clinical impact of changes for EORTC scales, Cohen’s d was used to represent 
effect size (ES), defined as the change in means divided by the pooled standard deviation.17 We 
established cutoffs for our cohort by using the standard deviation of baseline values. Changes 
were interpreted according to Cohens general criteria as <0.2 – trivial, 0.2-0.5 small, 0.5-0.8 
moderate, >0.8 large. These values are arbitrary, however the 0.5 cutoff has been shown to be 
valid as a surrogate for a clinically relevant difference in HRQL assessment.18 We compared 
these effect sizes to previously published anchor based cutoffs19 and found little deviation 
(Supplementary table 3).  
To explore the development of relevant symptoms over time, a case-wise analysis of the 
EORTC-QLQ-EN24 items regarding lymphedema and neuropathy (tingling/numbness) was 
performed in patients with completed 2 years follow-up. For this purpose, item responses were 
dichotomized into "no/light symptoms” (“None” or “A little”) and “moderate/severe 
symptoms” (“Quite a bit” or “Very much”). For lymphedema, the most severe of the two 
corresponding item responses was selected. 
 
Statistical Analysis 
All statistical analyses were performed in R version 4.0.2 (R Core Team 2020) R Foundation 
for Statistical Computing, Vienna Austria).  
Missing entries were analyzed for non-randomness using the R package ‘Finalfit’. Imputation 
was performed according to the EORTC scoring manual to compute scales in spite of missing 
items if < 50% of relevant items were missing.16 Missing questionnaires due to short follow-up 
were perceived as missing completely at random. Missing scale scores were perceived as 
missing at random related to treatment variables and dropped. This resulted in complete case 
analysis for statistical analyses comparing year to year changes except linear mixed models 
which can handle missing at random data points in longitudinal analysis through maximum 
likelihood modelling.  
Categorical variables were compared by Chi-square test or Fischer’s exact test where 
appropriate, and differences in distributions of continuous variables were assessed by Mann-
Whitney test for two groups or Kruskal-Wallis test for multiple group comparisons.  
To assess changes in PRO scales over time for the entire cohort, Wilcoxon signed-rank test was 
used to compare changes in means from baseline to year one and two. To assess differences 
between treatment groups at specific time points, the Mann-Whitney test was used.  
To explore how different treatment modalities independently affected PROs, effect magnitudes 
of EORTC scale changes were assessed, as described by the SISAQOL consortium.20 For each 
scale, a linear mixed model (R packages ‘lme4’, ‘lmerTest’) was fitted with the scale score as 
dependent variable, a subject level random intercept, time and treatment factors as independent 
variables, and a baseline score covariate. Included treatment effects were surgical modality 
(laparoscopy or laparotomy), any LNS procedure including sentinel node biopsy and pelvic +/- 
paraaortic lymphadenectomy, and adjuvant chemotherapy (yes/no). Interaction terms between 
time and LNS and time and adjuvant chemotherapy were included to account for differences 
between year 1 and 2 of follow-up. In addition, separate models were explored where patients 
who underwent sentinel node biopsy with removal of ≤4 nodes were grouped with patients 
without any lymph node sampling. Effect estimates (regression coefficients) with 95% 
confidence intervals and p-values were reported for all mixed models. P-values < 0.05 were 
considered statistically significant in all analyses. 
 
RESULTS 
At baseline, 448 patients had consented to participate in the PRO follow-up, of which 339 and 
219 patients had completed follow-up at year 1 and year 2, respectively (Figure 1). LNS had 
been performed in 56% of participating patients, and 32% had received adjuvant chemotherapy 
(Table 1). The treatment groups had similar age and body mass index distribution but differed 
in treatment- and histopathological characteristics (Table 1). Patients in the Chemo group more 
often had undergone laparotomy (69% compared to 32% in the LNS group and 9% in the Hyst 
group (P < 0.001, Table 1). Among patients in the Chemo group 39% had undergone a para-
aortal dissection compared to 10% in the LNS group. Only 14% of the Chemo group had not 
undergone any LNS. The Chemo group had significantly higher FIGO stage and more 
aggressive histological subtypes (P < 0.001 for both). The rate of recurrences at 2 years was 
higher in the Chemo group (9.4% versus 4.5% and 2.8% for LNS and Hyst groups, P = 0.039). 
 
Patient-reported functioning 
In the overall cohort, global health status/quality of life increased from baseline to year 1 (+9 
units, P < 0.001) and remained stable at year 2 (Table 2). Emotional function increased 
moderately from mean score 75 to 87 at year 1 and was stable at year 2, (P < 0.001). Baseline 
average scores for these estimates were close to or slightly below the general population 
reference values, whereas the higher year 1 values were slightly above reference values. Sexual 
functioning and sexual activity likewise increased after treatment and remained stable at year 
2.  
There was a small deterioration in physical functioning (-6 units at year 1 and -8 units at year 
2) in the Chemo group compared to baseline, whereas changes were trivial in the other two 
groups (Figure 2, Supplementary table 4). Emotional function improved significantly more in 
the LNS group than in the Hyst group (P = 0.005 at year 1, P = 0.017 at year 2).  
 
Patient-reported symptoms 
Mean scores for lymphedema, tingling/numbness and muscular pain increased significantly for 
the whole cohort from baseline to year one and remained elevated at year 2 (Table 2). The 
Chemo group had a large mean increase in tingling/numbness at year 1 and 2 (30-32 units), 
significantly larger than the increase in the Hyst group (5-6 units, P < 0.001 between groups at 
year 1 and 2) (Figure 2, Supplementary table 4). Significant between-group differences were 
also found for lymphedema at year 1, with a moderate increase of 11 units in the Chemo group 
compared to 2 (trivial) in the Hyst group (P = 0.007). There were no between-group differences 
in symptom scales between the Hyst group and the LNS group.  
Development of treatment-related symptoms 
Overall, 76% of patients reported no moderate/severe lymphedema symptoms at any timepoint 
(Figure 3A). Preoperatively, 10% of patients reported moderate/severe lymphedema symptoms, 
while an additional 13% reported moderate/severe symptoms that debuted post-operatively. Of 
27 patients reporting moderate/severe lymphedema symptoms at year 1, 12 had reported 
moderate/severe symptoms at baseline (Figure 3B). Debut of moderate/severe lymphedema 
symptoms at year 1 were reduced/resolved in a third of patients at year 2. At year two, 12/28 of 
patients reporting lymphedema had  previously reported no/light symptoms.  
At baseline 7% of all patients reported moderate/severe tingling/numbness, while 19% of 
patients reported debut at year 1 and/or year 2 (Figure 3C). At year 1, 27 of 30 patients reporting 
moderate/severe tingling/numbness symptoms had reported no/light symptoms at baseline 
(Figure 3D). Of these 27, 16 reported persisting moderate/severe symptoms at year 2, the 
majority (14) being from the Chemo group.  
 
 
Treatment-specific effect on patient-reported outcome 
In linear mixed regression models (Figure 4, Full data in Supplementary table 5) adjuvant 
chemotherapy had an independent negative effect on physical function (regression coefficient 
-7.5, 95% CI -11.6 to -3.4, P < 0.001) and social function (-9.3, 95% CI -14.7 to -3.8, P = 0.002; 
Figure 4A). 
For symptom scales (Figure 4B), adjuvant chemotherapy had a large increasing (detrimental) 
effect on tingling/numbness (regression coefficient 27.1, 95% CI 20.1-34.2, P < 0.001) and 
smaller increasing effects on fatigue (6.9, 95% CI 0.9-12.9, P = 0.025), lymphedema (8.9, 95% 
CI 3.6-14.2, P = 0.001) and taste change (5.0, 95% CI 0.7-9.3, P = 0.024). No effects of LNS 
or surgical modality were identified in the models. There were no relevant time-treatment 
interactions between year 1 and 2 post-treatment, thus effects of treatment were considered 
stable over this period (Supplementary table 5).  
As it may be argued that patients undergoing sentinel node biopsy have a risk of morbidity 
more similar to non-lymphadenectomized patients than to those undergoing lymphadenectomy, 
this was explored in separate models. Grouping unstaged patients with those who had 
undergone sentinel node biopsy and comparing these with patients undergoing 
lymphadenectomy, did not identify any significant effect on lymphedema score or alter 





We present, to our knowledge, the largest study prospectively investigating PROs in patients 
treated with no LNS for low-risk disease and adjuvant chemotherapy for high-risk disease, 
largely omitting adjuvant radiotherapy. Overall, endometrial cancer patients had good post-
treatment quality of life, functioned well and expressed few symptoms, but increases in 
tingling/numbness and lymphedema were identified at the cohort level. We found that patients 
undergoing adjuvant chemotherapy more often reported long-term neuropathy, lymphedema, 
and fatigue as well as inferior physical function. In contrast, among patients not undergoing 
chemotherapy, we found no differences between those undergoing LNS and those treated by 
hysterectomy and BSO alone. 
 
Results in context of what is known 
We demonstrate that endometrial cancer patients overall have good self-reported quality of life 
and functioning at one and two years post-treatment. At baseline, global health status/quality 
of life and emotional function were below the average population reference but increased with 
time in all treatment groups. These findings harmonize with previous prospective studies in 
endometrial cancer populations.21-23 The observed mean increase of quality of life and 
functional scales could potentially be explained by low baseline scores due to a newly received 
cancer diagnosis with associated symptoms, anxiety and affection of quality-of-life domains.  
Our study did not demonstrate a clear link between lymphedema and LNS. Increased 
lymphedema score was reported for the Chemo group, but not for the group treated with LNS 
without adjuvant chemotherapy. Although the proportion of sentinel node biopsy was higher in 
the LNS group, and the proportion of para-aortic lymphadenectomy was higher in the Chemo 
group, the total lymphadenectomy rates excluding sentinel node biopsy were similar for the two 
groups (73% vs 75%). Cross-sectional studies have reported significant mean increases in self-
reported lymphedema scores in patients with lymphadenectomy compared to those without.24, 
25 Importantly, other conditions than lymph tissue removal can result in lymphedema, and likely 
have increasing impact at longer follow-up times, especially in an endometrial cancer 
population with high age and comorbidity burden. These factors, combined with specified time 
points for follow-up, correction for baseline values and avoidance of recall-bias could explain 
why results from longitudinal and cross-sectional studies may differ.  Adjuvant chemotherapy 
is not an acknowledged risk factor for lymphedema in endometrial cancer patients. 
Interestingly, in experimental models, paclitaxel inhibits neolymphangiogenesis, implying 
possible interference in the post-operative healing process.26 In addition, adjuvant taxane-based 
chemotherapy has been implicated as a risk factor for arm lymphedema after breast cancer 
surgery with axillar node dissection, but clinical data is conflicting.27, 28 
 
The increase in self-reported neuropathy after receiving adjuvant chemotherapy harmonizes 
with longitudinal studies on endometrial cancer patients receiving radiochemotherapy 
compared to either adjuvant modality alone.22, 29 Our results further confirm this effect and 
provide novel data on the evolution of these symptoms over the first two postoperative years, 
with late debut of symptoms in some patients, and a substantial proportion of patients reporting 
unresolved symptoms at year two.  
 
Clinical implications 
We have identified treatment-specific changes in self-reported outcomes that are useful when 
counselling patients on adjuvant treatment, as this is a group with a high comorbidity load and 
varying life-expectancy. The main alternative approach for high-risk patients, adjuvant external 
beam radiotherapy, is not likely to cause neurological symptoms but instead causes long-term 
bowel symptoms, with remaining problems at follow-up after 10-15 years7-9, thus the most 
promising approach to improving quality of life in endometrial cancer survivors is likely a 
further individualization of adjuvant treatment. We have recently reported that despite a 
substantial increase over time of adjuvant chemotherapy to early-stage/high-risk patients in a 
Norwegian tertiary hospital, survival and recurrence rates were unchanged for this group.30 
Further reduction of patients undergoing adjuvant chemotherapy may be achieved through 
better stratification, ideally by implementing new classifiers such as imaging biomarkers or 
molecular subgroups (e.g. TCGA/ProMisE) in treatment planning for these patients31, 32, as well 
as developing and making available novel therapeutic agents to replace traditional 
chemotherapy where possible.  
 
Research implications 
Self-assessed lymphedema did not associate to LNS in our study. Whether this is attributable 
to measurement tool issues, prompt and effective treatment of lymphedema, patient adaptation, 
or cultural differences in reporting symptoms would be interesting to explore in future studies. 
Due to insufficient data, we were unable to explore the effect of SNL subgroups on PROs, and 
data on this is still mainly lacking.33 Finalizing inclusion and maturation of MoMaTEC2 data 
will provide better insight into the effect of different LNS techniques and long-term evolution 
of associated symptoms.   
Strengths and limitations  
Our study has several strengths. The importance of prospective registration for PROs should be 
stressed, as the baseline values areimportant determinators for long-term PROs. Previous 
studies have identified age, body mass index, comorbidity, tumour stage and marital and 
socioeconomic status to be important predictors of PROs in endometrial cancer21, 23, 34, and 
these can be approximated by including baseline PRO values. We also limited our analyses to 
non-relapsing survivors thereby excluding bias introduced by successive treatments and 
changes in prognosis. PROs for patients with progressive and recurrent disease is likely to differ 
from the results of our study, and research questions and assessment approaches should be 
different for these groups.  
Our results may be biased by the fact that treatment is not randomized but based on risk-
assessment, leading to unbalanced clustering of treatment modalities such as more 
comprehensive lymphadenectomy performed in patients receiving chemotherapy. We have 
attempted to handle this through mixed model analysis, but few included patients receiving 
chemotherapy without LNS may to some degree influence the isolated PRO effects when 
comparing chemotherapy and lymph surgery.  
 
Conclusions 
We find that endometrial cancer patients undergoing LNS without receiving chemotherapy are 
comparable to those not undergoing LNS and do not experience any significant deterioration 
from baseline to year 1 and 2, whereas patients receiving adjuvant chemotherapy have a higher 
risk of experiencing long-term neuropathy, lymphedema, and fatigue as well as inferior physical 
function. Considering these data, further striving to individualize adjuvant treatment is more 
pressing than adopting new surgical staging techniques. 
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Table 1. Clinical and pathological characteristics of included patients  





Included (n) 176 132 138  
Age at treatment 
(median/IQR) 67 (14) 66 (13) 69 (11) 0.129 
Body mass index 
(median/IQR) 28.3 (8) 28.3 (7) 27.4 (7) 0.219 
  n (%) n (%) n (%) 
p (Fischer 
exact test) 
Mode of surgery 
(hysterectomy)    <0.001 
Laparotomy 16 (9) 40 (32) 88 (69)  
Robot-assisted laparoscopy 64 (37) 82 (66) 37 (29)  
Conventional laparoscopy 91 (53) 2 (2) 3 (2)  
Lymph node staging    <0.001 
Not performed  177 (100) 0 (0) 20 (14)  
Sentinel node mapping 0 (0) 34 (26) 17 (12)  
Pelvic lymphadenectomy 0 (0) 86 (65) 47 (34)  
Para-aortic and pelvic 0 (0) 13 (10) 54 (39)  
Lymph node metastasis    <0.001 
Not investigated 177 (100) 0 (0) 20 (14)  
Positive 0 (0) 0 (0) 30 (22)  
Negative 0 (0) 133 (100) 88 (64)  
FIGO stage    <0.001 
I 172 (98) 133 (100) 72 (52)  
II 3 (2) 0 (0) 22 (16)  
III 1 (1) 0 (0) 40 (29)  
IV 0 (0) 0 (0) 4 (3)  
Histological group    <0.001 
EEC Grade 1 110 (65) 72 (54) 12 (9)  
EEC Grade 2 50 (29) 52 (39) 26 (19)  
EEC Grade 3 5 (3) 5 (4) 32 (23)  
Non-endometrioid 5 (3) 4 (3) 68 (49)  
Recurrence within 2 years    0.039 
Yes 5 (3) 6 (5) 13 (9)  
No 172 (97) 127 (95) 125 (91)   
Hyst group, Hysterectomy alone; LNS group, Hysterectomy with lymph node staging procedure;  
Chemo group: Hysterectomy with adjuvant chemotherapy, +/- LNS 
IQR, Interquartile range; FIGO, International Federation of Gynecology and Obstetrics; EEC, 
Endometrioid endometrial cancer 
 
    
 
  
Table 2. Overall cohort changes in EORTC scale means over time.  
  Refa  Baseline  Year 1   Year 2 
Functional scalesb     
mean 
(sd)   
mean 
(sd) ES p   
mean 
(sd) ES p 
Global health 
status/QoL 72  69 (22)  78 (20) Small <0.001  76 (23) Small 0.002 
Physical Function 80  87 (17)  86 (16) Trivial 0.279  85 (19) Trivial 0.115 
Emotional Function 83  75 (21)  87 (18) Moderate <0.001  86 (18) Moderate <0.001 
Cognitive Function 85  86 (19)  87 (18) Trivial 0.686  86 (19) Trivial 0.282 
Social Function 85  82 (22)  89 (20) Small <0.001  88 (21) Small 0.011 
Sexual interest -  13 (22)  19 (26) Small <0.001  20 (25) Small <0.001 
Sexual activity -  9 (19)  15 (24) Small <0.001  14 (23) Small <0.001 
Sexual enjoyment -  65 (22)  57 (28) Small 0.514  55 (27) Small 0.303 
Symptomatic 
scalesc            
Fatigue 29  26 (23)  24 (23) Trivial 0.162  25 (26) Trivial 0.862 
Lymphoedema -  10 (18)  15 (22) Small <0.001  14 (20) Small 0.003 
Urological 
symptoms -  17 (19)  16 (18) Trivial 0.715  15 (16) Trivial 0.606 
Gastrointestinal 
symptoms -  16 (16)  14 (15) Trivial 0.232  14 (15) Trivial 0.503 
Poor body image -  9 (18)  8 (16) Trivial 0.211  9 (19) Trivial 0.655 
Sexual/vaginal 
problems -  16 (21)  20 (21) Small 0.124  24 (24) Small 0.054 
Pain in back and 
pelvis -  27 (29)  23 (28) Trivial 0.014  23 (29) Trivial 0.132 
Tingeling/numbness -  11 (22)  24 (30) Moderate <0.001  24 (29) Moderate <0.001 
Muscular pain -  26 (30)  30 (30) Trivial 0.026  31 (30) Trivial 0.004 
Hair loss -  9 (20)  6 (18) Trivial 0.173  8 (19) Trivial 0.338 
Taste change -   5 (14)   4 (15) Trivial 0.611   6 (18) Trivial 0.283 
Wilcoxon signed rank analysis of difference in means between each follow-up time point and baseline. P-values 
<0.05 in bold. 
EORTC, European Organisation for Research and Treatment of Cancer; QoL, Quality of life 
ES: Effect size based on Cohen's d (Supl. Table 3) 
a References are sex-specific, age-weighted means from an unselected Norwegian population (Fossa et al. 2007) 
b Increasing means signify increased function 





Norwegian patients enrolled in MoMaTEC2
Excluded
Decline participation in PRO, n = 191 (29%)
<1 years since inclusion, n = 81
n = 448
Dead or Recurrence < 1 years n = 9
Formally withdrawn < 1 years n = 10 
Completed Year 1 follow-up
n = 658
PRO participants from inclusion
Missed year 1 
followup n = 9
Advanced disease (non-resectable), n = 13
Completed Year 2 follow-up
Dead or recurrence 1-2 years n = 7 
Formally withdrawn 1-2 years n = 4
Missed year 2 
followup n = 16
<2 years since inclusion, n = 102










Hysterectomy + LNS procedure
Hysterectomy + adjuvant chemotherapy
+/- LNS procedure
Treatment group
Figure 1. Patients assessed for eligibility and included in study at each follow-up 
time point. PRO – patient-reported outcomes, LNS -  lymph node staging.
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Baseline Year 1 Year 2
p = 0.572 p = 0.577 
p = 0.079 p = 0.090 
LNS vs Hyst
Chemo vs Hyst
Baseline Year 1 Year 2
p = 0.901 p = 0.256 
p = 0.007 p = 0.078 
LNS vs Hyst
Chemo vs Hyst
Baseline Year 1 Year 2
p = 0.141 p = 0.197 
p < 0.001 p < 0.001 
LNS vs Hyst
Chemo vs Hyst
Figure 2. Patient reported mean EORTC scale scores with 95% confidence intervals. Increases in functional scales 
signify an increase in function, increases in symptom scales signify increase of symptom. Reference values (black 
lines) are age- and sex weighted means from a Norwegian general population survey (Available for EORTC QLQ-
C30, Fossa et al. 2007). P-values are derived from Mann-Whitney test of change from baseline compared to Hyst 
group. Values of all analysed EORTC scales can be seen in supplementary table 4.
Hysterectomy only Hysterectomy + LNS procedure Hysterectomy + adjuvant chemotherapy
+/- LNS procedure
Treatment group

























Patients reporting Tingling/numbness at any timepoint
























































































































































































































Figure 3. Case-wise analysis of treatment related symptoms in patients with complete 2 year follow-up data. A) 
Lymphedema symptoms defined as answering “quite a bit” or “very much” to either of the lymphedema associated 
items at any timepoint, in all patients (n=204). B) Case-wise evolution of lymphedema symptoms over time, by 
treatment received, only patients reporting symptoms are shown. C) Neuropathy symptoms defined as answering 
“quite a bit” or “very much” to the tingling/numbness item at any timepoint, in all patients (n=203).  D) Case-wise 



























































































































































































































































































































































































































































































Included (n) 467 191
Age at treatment (median/IQR) 68 (14) 68 (16)
Body mass index (median/IQR) 28 (8) 28 (7)
n (%) n (%)
Mode of surgery (hysterectomy)
Laparotomy 152 (35) 77 (48)
Laparoscopy 185 (42) 41 (26)
Robot-assisted laparoscopy 101 (23) 43 (27)
Lymph node staging
Not performed 203 (44) 102 (53)
Sentinel node mapping 52 (11) 5 (3)
Pelvic lymphadenectomy 140 (30) 56 (29)
Para-aortic and pelvic 70 (15) 28 (15)
Lymph node metastasis
Not investigated 203 (44) 102 (53)
Positive 37 (8) 16 (8)
Negative 226 (49) 73 (38)
FIGO stage
I 381 (82) 134 (75)
II 27 (6) 12 (7)
III 45 (10) 22 (12)
IV 12 (3) 11 (6)
Histology
EEC Grade 1 197 (43) 72 (40)
EEC Grade 2 130 (28) 50 (28)
EEC Grade 3 46 (10) 20 (11)
Non-EEC 86 (19) 36 (20)
Adjuvant treatment
None 313 (67) 113 (59)
External radiation 1 (0) 3 (2)
Brachytherapy 1 (0) 1 (1)
Chemotherapy 147 (32) 67 (35)
Hormonal treatment 3 (1) 3 (2)
Chemotherapy + radiation 1 (0) 2 (1)
Recurrence within 2 years
Yes 25 (5) 16 (8)
No 429 (92) 151 (79)
Not completely resected at primary 
surgery 13 (3) 24 (13)
IQR: Interquartile range
FIGO: International Federation of Gynecology and Obstetrics
EEC: endometrioid endometrial cancer
Supplementary table 1. Clinical and pathological characteristics of the studied cohort 
compared to patients declining participation in patient reported outcome registration.
Baseline Year 1 Year 2
n (%) n (%) n (%)
Eligible patients 448 367 237
Missing assessments 0 (0) 28 (8) 18 (8)
Respondents 448 (100%) 339 (92) 219 (92)
EORTC scales
Global health status/ Quality of 
life 443 (99%) 338 (100%) 219 (100%)
Physical Function 447 (100%) 339 (100%) 219 (100%)
Emotional Function 443 (99%) 338 (100%) 219 (100%)
Cognitive Function 444 (99%) 338 (100%) 219 (100%)
Social Function 444 (99%) 338 (100%) 219 (100%)
Sexual interest 418 (93%) 333 (98%) 211 (96%)
Sexual activity 421 (94%) 333 (98%) 211 (96%)
Sexual enjoyment* 80 (18%) 109 (32%) 68 (31%)
Fatigue 446 (100%) 339 (100%) 219 (100%)
Lymphoedema 444 (99%) 336 (99%) 216 (99%)
Urological symptoms 444 (99%) 336 (99%) 216 (99%)
Gastrointestinal symptoms 443 (99%) 336 (99%) 216 (99%)
Poor body image 436 (97%) 334 (99%) 216 (99%)
Sexual/vaginal problems* 81 (18%) 110 (32%) 68 (31%)
Pain in back and pelvis 442 (99%) 335 (99%) 216 (99%)
Tingeling/numbness 443 (99%) 335 (99%) 216 (99%)
Muscular pain 441 (98%) 336 (99%) 215 (98%)
Hair loss 443 (99%) 335 (99%) 215 (98%)
Taste change 443 (99%) 336 (99%) 215 (98%)
EORTC: European Organisation for Research and Treatment of Cancer
Supplementary table 2. Number of responses per EORTC scale at each assessment time point 





































































































































































































































































etrial cancer questionnaire - 24 item
s
¹ Increasing m
eans signify increased function
² Increasing m









entary table 3. C





 scales as calculated based the study population baseline scores and 
com









































































































































































































































































































































































































































eans signify increased function
² increasing m







ohen's d):  T


















eans at year one and tw
o com
pared to baseline m
ean score by treatm
ent subgroup. M
agnitude of changes assessed 
by effect size of the change (C
ohen's d). Statistical com
parison of change from
 baseline in treatm
ent group com
pared to hysterectom






















































































































































































































































































































































































































































































































































































ph node staging (including sentinel node biopsy)
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Treatment in MoMaTEC2 
Standard treatment was hysterectomy with bilateral salpingo-oophorectomy (BSO). In 
algorithm-adhering centers, lymphadenectomy was omitted in patients with low-risk disease 
(endometrioid histology grade 1-2 in preoperative biopsy and grade 3 if less than 50% 
myometrial invasion on imaging) with immunohistochemical estrogen and progesterone 
receptor (ER/PR) positive expression in the preoperative endometrial sample. In the case of 
ER/PR negativity in otherwise low-risk patients a pelvic lymphadenectomy was performed. The 
level of immunohistochemical expression was revised in 2019 following an interim analysis 
comparing research-derived expression levels to routinely reported levels. The original cutoff 
<1% for ER and <10% for PR was changed to <30% for both, after consulting the MoMaTEC2 
advisory board and participating centers. 
Pelvic and para-aortic lymphadenectomy was routinely performed in high-risk patients: 
Endometrioid grade 3 with deep myometrial infiltration, any non-endometrioid histology or 
suspicion of FIGO stage >I (Imaging, preoperative clinical status, perioperative findings). 
Omentectomy was performed in patients with serous and clear cell histology. In control centers, 
sentinel node biopsy was performed for all risk groups, with hemipelvic lymphadenectomy in 
case of failed mapping. Mode of surgery (laparotomy, laparoscopy or robot-assisted 
laparoscopy) varied within and between centers.  
Adjuvant treatment 
MoMaTEC2 does not require a certain adjuvant therapy policy to be followed. Adjuvant 
treatment policy is however conform in Norway and advocates use of chemotherapy rather than 
radiotherapy. According to national guidelines, no adjuvant treatment is given to patients with 
endometrioid histology tumors and final FIGO I except IB with grade 3 differentiation. For 
patients deemed at high risk postoperatively (FIGO IB endometrioid grade 3, any non-
endometrioid histology, or any FIGO stage > I), standard treatment is 6 rounds of carboplatin 
plus paclitaxel at 3-week intervals. The regimen could be shortened/altered due to patient status 
at the treating physician’s discretion. For FIGO II with possible non-free resection margins 
brachytherapy can be considered. 
Appendix A 
Specimens of the European Organisation for research and treatment of cancer 
(EORTC) questionnaires used in this thesis. Reprinted with permission from the 
EORTC Quality of Life group. 
 
For the validation paper for the EORTC-C30, see 
Aaronson, N. K., et al. (1993). "The European Organization for Research and 
Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in 
international clinical trials in oncology." J Natl Cancer Inst 85(5): 365-376. 
 
For using questionnaires in research, please contact EORTC, Quality of Life 










EORTC  QLQ – EN24 
 
Patients sometimes report that they have the following symptoms or problems. Please indicate the extent to 
which you have experienced these symptoms or problems. 
 
 










31. Have you had swelling in one or both legs? 1 2 3 4 
32. Have you felt heaviness in one or both legs? 1 2 3 4 
33. Have you had pain in your lower back and / or pelvis? 1 2 3 4 
34. When you felt the urge to pass urine, did you have to hurry to get to 
the toilet? 
1 2 3 4 
35. Have you passed urine frequently? 1 2 3 4 
36. Have you had leaking of urine? 1 2 3 4 
37. Have you had pain or a burning feeling when passing urine? 1 2 3 4 
38. When you felt the urge to move your bowels, did you have to hurry 
to get to the toilet? 
1 2 3 4 
39. Have you had any leakage of stools? 1 2 3 4 
40. Have you been troubled by passing wind? 1 2 3 4 
41. Have you had cramps in your abdomen? 1 2 3 4 
42. Have you had a bloated feeling in your abdomen? 1 2 3 4 
43. Have you had tingling or numbness in your hands or feet? 1 2 3 4 
44. Have you had aches or pains in your muscles or joints? 1 2 3 4 
45.  Have you lost hair? 1 2 3 4 
46. Has food and drink tasted differently from usual? 1 2 3 4 
      
Please go on to the next page 
ENGLISH 
 QLQ-EN24 Copyright 2010 EORTC Quality of life Group. All rights reserved. 
 
 










47. Have you felt physically less attractive as a result of your disease or 
treatment? 
1 2 3 4 
48. Have you felt less feminine as a result of your disease or treatment? 1 2 3 4 
      
  










49. To what extent were you interested in sex? 1 2 3 4 
50. To what extent were you sexually active? 1 2 3 4 
  
Answer these questions only if you have been  
sexually active during the past 4 weeks: 
 
    
51. Has your vagina felt dry during sexual activity? 1 2 3 4 
52. Has your vagina felt short and / or tight? 1 2 3 4 
53. Have you had pain during sexual intercourse or other sexual 
activity? 
1 2 3 4 





EORTC QLQ-C30 (version 3)  
 
We are interested in some things about you and your health. Please answer all of the questions yourself by circling the 
number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will 
remain strictly confidential. 
 
Please fill in your initials:  
Your birthdate (Day, Month, Year):  
Today's date (Day, Month, Year):  31  
__________________________________________________________________________________________ 
  Not at A Quite Very 
  All Little a Bit Much 
1. Do you have any trouble doing strenuous activities,  
 like carrying a heavy shopping bag or a suitcase? 1 2 3 4 
 
2. Do you have any trouble taking a long walk? 1 2 3 4 
 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4  
 
5. Do you need help with eating, dressing, washing  
 yourself or using the toilet? 1 2 3 4 
 
 
During the past week:  Not at A Quite Very 
  All Little a Bit Much 
 
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
 
7. Were you limited in pursuing your hobbies or other 
 leisure time activities? 1 2 3 4 
 
8. Were you short of breath? 1 2 3 4 
 
9. Have you had pain? 1 2 3 4 
 
10. Did you need to rest? 1 2 3 4 
 
11. Have you had trouble sleeping? 1 2 3 4 
 
12. Have you felt weak? 1 2 3 4 
 
13. Have you lacked appetite? 1 2 3 4 
 
14. Have you felt nauseated? 1 2 3 4 
 
15. Have you vomited? 1 2 3 4 
 
16. Have you been constipated? 1 2 3 4 
 








During the past week:  Not at A Quite Very 
  All Little a Bit Much 
 
17. Have you had diarrhea? 1 2 3 4 
 
18. Were you tired? 1 2 3 4 
 
19. Did pain interfere with your daily activities? 1 2 3 4 
 
20. Have you had difficulty in concentrating on things, 
 like reading a newspaper or watching television? 1 2 3 4 
 
21. Did you feel tense? 1 2 3 4 
 
22. Did you worry? 1 2 3 4 
 
23. Did you feel irritable? 1 2 3 4 
 
24. Did you feel depressed? 1 2 3 4 
 
25. Have you had difficulty remembering things? 1 2 3 4 
 
26. Has your physical condition or medical treatment 
 interfered with your family life? 1 2 3 4 
 
27. Has your physical condition or medical treatment 
 interfered with your social activities? 1 2 3 4 
 
28. Has your physical condition or medical treatment 
 caused you financial difficulties? 1 2 3 4 
 
 
For the following questions please circle the number between 1 and 7 that  
best applies to you 
 
29. How would you rate your overall health during the past week? 
 
  1 2 3 4 5 6 7 
 
 Very poor      Excellent 
 
 
30. How would you rate your overall quality of life during the past week? 
 
  1 2 3 4 5 6 7 
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